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ABSTRACT 
The Food and Drug Administration (FDA) ’s Manufacturer and User Facility Device 
Experience (MAUDE) spontaneous reporting systems (SRS) database provides information 
about product-related adverse events and problems.  In the last decade, MAUDE reports 
and recalls of medical devices that pose a significant risk of serious injury or death have 
increased dramatically.  With over 70,000 text-based MAUDE reports submitted per month, 
new computational approaches are needed to aid in the earlier identification of possible 
product problems.   
This retrospective cohort study utilized a novel, sequential combination of text and 
data mining methodologies to evaluate the primary hypothesis that information in MAUDE 
adverse event text descriptions provides an early signal of product problems in advance of 
Class I implantable cardioverter-defibrillator (ICD) lead recalls.  Secondary hypotheses 
explored the model's predictive ability for: 1) recalled medical devices that are increasingly 
differentiated from ICD leads; 2) forecasting less serious ICD lead recalls.  Sensitivity 
analyses examined the influence of reports for particular ICD lead brands and the effect of 
using cumulative cohorts over time to build the text classification models.   
Early recognition of ICD lead problems could have a profound impact on patients 




to ICD lead failure.  Strong signals of the Riata and Riata ST lead recalls were observed 18 
months in advance of their recall and 6 months before their removal from distribution.  
Modest signals were detected 2.5 years prior to the Sprint Fidelis and 4 years in advance of 
the Riata/Riata ST recalls.  Signals were also observed 2.5 years before an FDA mandate 
placing two other non-recalled leads under additional surveillance.  The developed model 
was able to differentiate between more and less serious ICD lead recalls and showed good 
performance across a range of different devices.  Sensitivity analyses proved useful in 
identifying lead-specific patterns and may suggest the model’s responsiveness to different 
ICD lead failure modes.   
This work is likely the first research to use disproportionality analysis techniques to 
systematically assess temporal trends in SRS predictions made from a text classification 
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MDR:  Medical Device Reporting 
MedDRA: Medical Dictionary for Regulatory Activities  
MeSH (MH): Medical Subject Heading 
MFR:  Manufacturer 
MGPS:  Multi-item Gamma Poisson Shrinker 
MHRA: Medicines and Healthcare Products Regulatory Agency 
MoM THR: Metal-on-Metal Total Hip Replacement 
MRI:  Magnetic Resonance Imaging 
NLM:  Natural Library of Medicine 
NLP:   Natural Language Processing 
PhVidD: PharmacoVigilance signal Detection 
PMA:  Premarket Approval 
PRC:  Precision-Recall Curve 
PRIMO: Pharmacovigilance Report Intake and Managed Output 
PRR:  Proportional Reporting Ratio 
RBF:  Radial Basis Function 
ROC:  Receiver Operating Characteristic 




RRR:  Relative Reporting Rate 
SCD:  Sudden Cardiac Death 
SJM:  St. Jude Medical 
SMDA:  Safe Medical Devices Act 
SMO:  Sequential Minimal Optimization 
SMOTE: Synthetic Minority Over-sampling Technique 
SRS:  Spontaneous Reporting Systems 
SVM:  Support Vector Machine 
TN:  True Negative 
TP:  True Positive 
UDI:  Unique Device Identifier 
VAERS: FDA Vaccine Adverse Event Reporting System 
VaeTM: Vaccine Adverse Event Text Mining 




LIST OF DEFINITIONS 
 
Class I Medical Device:  a low-risk medical device, such as a tongue depressor, stethoscope 
or adhesive bandage. 
Class II Medical Device:  a medium-risk medical device, such as an intravenous catheter, 
powered wheelchair, contact lens, condom or home pregnancy test. 
Class III Medical Device:  a high-risk medical device typically defined as a product that 
sustains or supports life, is implanted, or that presents an unreasonable risk of illness or injury 
if it were to fail.  Examples include pacemakers/ICDs, breast implants, heart valves, and heart 
stents. 
Class I Recall:  a product withdrawal due to a reasonable probability of serious adverse health 
consequences or death with use or exposure to the product. 
Class II Recall:  a product withdrawal due to the risk of temporary or medically reversible or 
remotely occurring serious adverse health consequences with use of or exposure to a 
product. 
Class III Recall:  a product released in violation of FDA regulations, but posing no immediate 
or perceived danger of adverse health consequences. 
Data Mining:  statistical and computational techniques used to discover patterns in large 
datasets. 
Machine Learning:  the application of computer algorithms that iteratively learn from data. 
Natural Language Processing (NLP):  using computational techniques for analyzing natural 
texts for the purpose of achieving human-like language processing. 
Ontology:  a taxonomy representing the concepts and relationships of objects or expressions. 
RStudio:  open source statistical computing environment. 
SAS:  a suite of software programs used for data management and analysis. 
Signal:  a relationship between a product and adverse event that is strong enough to warrant 
further evaluation. 
Sudden Cardiac Death:  unexpected death due to malfunction of the electrical system to the 




Text Mining:  extracting information and patterns from unstructured (free form) text 
documents. 
Weka:  open source machine learning software written in Java and developed at the 









While most medical devices are safe and effective, an increasing number of products 
have been removed from the marketplace because they pose a risk of serious harm or 
death.  In addition to the rise in these medical device recalls, adverse event reports 
submitted to the United States Food and Drug Administration (FDA) have grown more than 
10-fold in the past decade to over 70,000 per month.  Spontaneous reporting systems (SRS) 
such as the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database, 
provide an important source of information about product-related adverse events and can 
reveal underlying problems with pharmaceutical, biological and medical device goods.  
Submissions to SRS contain structured and unstructured data, the latter including narrative 
descriptions of the adverse event.  While the data contained in these SRS reports can 
provide early signals of product problems, manual review of this information is time 
consuming, costly and incomplete, and the number of regulatory personnel available to 
review the growing volume of reports is not increasing. 
To facilitate the systematic and objective analysis of SRS, statistical techniques are 
routinely used to identify potential safety signals.  Most of this safety surveillance work has 
centered on applying data mining techniques to the structured data available in SRS 
databases.  These data mining efforts are typically used to detect patterns of harm by 
identifying drug or vaccine product-adverse event combinations that occur 




methodologies to inform safety surveillance of SRS databases is much more limited, but has 
been employed to identify medications, to extract features and events relating to vaccine 
usage, and to recognize health information technology (HIT)-related adverse events. 
This research built upon this prior safety surveillance work by utilizing a sequential 
combination of text and data mining methods to develop a data-driven early warning 
system predicting implantable cardioverter-defibrillator (ICD) lead recalls.  Text mining 
algorithms were used to create models predicting subsequent ICD lead recalls using 
information contained in unstructured MAUDE adverse event descriptions.  These recall 
predictions were then analyzed using disproportionality analysis (DPA) techniques to 
determine whether the text mining-based predictions provided an early signal of 
subsequent ICD lead recalls. 
This chapter identifies this study’s research hypotheses (Section 1.1), project 
background (Section 1.2), and the significance and innovation of this work (Section 1.3).  
Subsequent chapters provide a detailed discussion of the literature related to this proposal 
(Chapter 2) and introduce the text classification algorithms and the DPA signal detection 
methodologies used in this research (Chapter 3).  Chapter 4 describes the project’s specific 
research methods and analysis plans.  Chapters 5 and 6 detail the work necessary to create 
and prepare the analysis dataset.  Chapter 7 presents the results of text classification 
modeling, hypothesis testing and sensitivity analyses.  Chapter 8 concludes this work with a 





1.1 Research Hypotheses 
The central goal of this research was to develop a data-driven early warning system 
that predicted subsequent ICD lead recalls from MAUDE adverse event narrative 
(unstructured) reports.  This study investigated the primary hypothesis that information 
present in MAUDE adverse event text descriptions provides an early signal of product 
problems in advance of Class I (the most serious) ICD lead recalls.  This research also 
explored two secondary hypotheses: 1) the model's predictive ability will diminish for 
recalled medical devices that are increasingly differentiated from ICD leads; 2) the model's 
predictive ability will diminish when forecasting less serious (Class II or Class III) ICD lead 
recalls.  Finally, sensitivity analyses examined the influence of reports for particular ICD lead 
brands on the overall predictive ability of the model and the effect of using cumulative 
cohorts over time to build the text classification models, more closely resembling a real-
world application of this methodology. 
1.2 Background 
1.2.1 Medical Device Definition and Usage 
According to the FDA, a medical device is a product used to diagnose, treat, cure, 
mitigate, prevent or alter bodily functions. (1)  Medical devices encompass several thousand 
health products, ranging from simple tongue depressors and bandages, to complex medical 
lasers and magnetic resonance imaging (MRI) equipment.  They include products such as 
home pregnancy test kits and contact lenses used externally, and artificial knees and heart 
pacing devices that are internally implanted.  Medical devices also include machines such as 




or mechanical ventilators that are necessary to support or sustain life.  Although they may 
be combined with a drug as in the case of drug-eluting coronary stents, medical devices 
differ from pharmaceutical (drugs) or biological (blood, vaccine, gene or cellular) products in 
that they do not use metabolism, chemical or immunological means to achieve their 
primary intended purpose. 
There are over 5,700 medical device product types categorized by the FDA, 23,000 
medical device manufacturers and half a million medical device models. (2, 3)  It is 
estimated that over 8,000 new medical devices are marketed in the United States each 
year. (4)  Patient care increasingly relies on medical devices, driven by growing income, 
greater life expectancy, increased complexity of care, and technological advances that 
facilitate improvements in quality of life. (5, 6)  Given the lack of a universal medical device 
registry in the United States, the number of individuals using medical devices is unknown; 
however, findings from a National Center for Health Statistics Survey a quarter of a century 
ago estimated that more than 10 million people in the United States (4%) had at least one 
implanted medical device. (7)  David estimated that the average number of medical devices 
at a patient’s bedside has increased from 7 to 26 over the past two decades, (8) and Maisel 
has asserted that medical devices are utilized in most health care provider-patient 
interactions. (3) 
1.2.2 Medical Device Premarket Regulation 
For much of the twentieth century, medical devices were largely unregulated.  
However, in the 1970s a government report documented more than 10,000 injuries 




numerous maternal deaths, miscarriages, and infections. (3, 9)  In response, Congress 
passed the 1976 Medical Device Amendment (MDA) to the Federal Food, Drug, and 
Cosmetic Act (FDCA) in order to prevent the distribution of ineffective or dangerous 
products. (10) 
The MDA established three regulatory classes for medical devices based upon the 
potential risk the device poses to the patient or user.  Class I products, such as tongue 
depressors, stethoscopes and adhesive bandages, are low-risk devices having little potential 
for harm.  Class II is a medium-risk category that includes the majority of medical devices.  
Examples of Class II products include intravenous catheters, powered wheelchairs, contact 
lenses, condoms and home pregnancy test kits.  Class III is the highest-risk category, 
including medical devices that sustain or support life, are implanted, or present potential 
unreasonable risk of illness or injury if they were to fail.  Implantable pacemakers, ICD leads, 
breast implants, heart valves and coronary stents are examples of Class III devices. (3, 11-
13) 
As summarized in Table 1.1, the level of FDA review and oversight required before a 
medical device is allowed to enter the market is directly tied to its regulatory classification.  
All products are subject to general postmarket controls, including company and device 
registration and adherence to good manufacturing practices.  In addition to these general 
controls, the majority of Class II and Class III medical devices must also undergo either a 
premarket notification procedure, often referred to as a “510(k)” after the relevant section 




Table 1.1: Medical Device Regulatory Controls by Device Classification. 
This table provides the typical required regulatory controls by device classification.  Some 
devices may have lesser or greater requirements.  For example, certain Class I devices (e.g., 
accessories that attach to a medical examination light and assist in magnifying, clarifying, or 
enhancing the image being viewed) and Class III devices (e.g., automated external non-
wearable defibrillators) require a 510(k) notification instead of the regulatory control 
typically required for their device classification.  Percentages are from the U.S. Food and 
Drug Administration.  Learn if a Medical Device Has Been Cleared by FDA for Marketing 
Medical Devices, Resources for You, Consumers: FDA; 2009. (16) 
Medical Device 
Classification % Risk Level Examples Typical Regulatory Control 
I 47% Low Tongue depressor, 
Stethoscope, Adhesive 
bandage 
General only.  Mainly 
(95%) exempt from 
premarket notification 
II 43% Moderate Catheter, Wheelchair, 
Contact lens, Condom, 
Pregnancy test kit 
General plus premarket 
notification (510(k) 
clearance) 
III 10% High Pacemaker/ICD, Breast 
implant, Heart valve, 
Coronary stent 
General plus premarket 
review (PMA approval) 
 
Most medium-risk (Class II) medical devices are cleared through a 510(k) process.  
This pathway requires that a manufacturer establish that a new product is substantially 
equivalent to a “predicate” (previous) device by demonstrating that the new medical 
device’s intended use and technological characteristics are comparable to either a product 
on the market in 1976 when the MDA was passed or one that itself has been cleared 
through the 510(k) process. (3, 17)  The majority (92%) of Class II device applications do not 
require submission of clinical data, (4) and the product’s safety and effectiveness is 
indirectly established through the assumption that the new medical device is at least as safe 
and effective as its predicate.  However, this tautological argument that device “B” is safe 
and effective if device “B” is comparable to a device “A” already on the market has been 




medical devices that were cleared for market use through comparison to products that 
themselves were not required to show direct clinical evidence of their safety and 
effectiveness. (9, 11, 14, 15, 17-21) 
Other deficiencies in the review process have been noted.  Congress envisioned that 
most high-risk (Class III) devices would be required to undergo the more rigorous PMA 
process in which the company must directly establish the device’s safety and effectiveness, 
typically through one or more clinical trials. (3, 17)  However between 2003-2007, the U.S. 
Government Accountability Office (GAO) found that 25% of Class II devices cleared through 
the 510(k) process were in fact implantable, life-sustaining, or significant risk, and that 21% 
of Class III devices were processed through the less stringent 510(k) notification process. 
(22)  In total only 10% of all medical devices entering the market each year are required by 
the FDA to demonstrate the device’s safety and efficacy through clinical data. (4, 9, 18, 23) 
Even when clinical trials are conducted to assess a medical device’s safety and 
effectiveness, they are not expected to uncover all possible adverse events.  As noted by 
the American Medical Association, the World Health Organization and others, premarketing 
studies typically involve only small numbers of patients meeting narrow eligibility 
requirements followed for relatively brief periods of time. (12, 24-27)  Consequently, such 
studies are not designed to determine rare or delayed side effects or those that may result 
from long-term use of a product.  Further, increasing pressure to more rapidly release new 
medical devices means making approval decisions based on shorter follow-up durations. 




support new PMA-required cardiovascular devices, finding that the longest median follow-
up duration was only 365 days. (28) 
1.2.3 Medical Device Postmarket Surveillance 
Once a product is allowed to enter the market, product performance and safety is 
monitored through postmarket surveillance activities.  Postmarket surveillance consists of 
both active (systematic/proscribed) and passive (spontaneous/voluntary) reporting of 
medical device problems and has the ability to capture delayed side effects or those due to 
long-term product use.  Systematic postmarketing studies conducted in defined, 
representative real-world patient populations limit data problems and reporting biases and 
allows for the calculation of event rates.  However, these post-approval studies are 
generally limited to 36 months and mandated only for PMA-required medical devices and 
certain Class II and Class III products that meet at least one of the following (29): 
• Intended to be implanted for > 1 year; 
• Is a life-sustaining or life-supporting device used outside a user facility; 
• Projected to have significant use in pediatric populations; 
• Device failure would be reasonably likely to result in serious adverse health 
consequence. 
Given this narrow definition, in the United States compulsory, systematic 
postmarketing studies monitoring long-term performance of medical devices are fairly 
limited.  Instead SRS are used to monitor the safety of a variety of medical products.  These 




• FDA Adverse Event Reporting System (FAERS, formerly AERS) for drugs and 
biologics; 
• Vaccine Adverse Event Reporting System (VAERS) for vaccines; 
• Manufacturer and User Facility Device Experience (MAUDE) for medical 
devices. 
This research project utilized medical device adverse event and product problem 
data submitted to the FDA and made available through their MAUDE database.  The MAUDE 
database contains information required by the 1984 medical device reporting (MDR) 
regulation and the 1990 Safe Medical Devices Act (SMDA). (30, 31)  MAUDE includes 
mandatory reports of suspected device-associated deaths, serious injuries and 
malfunctions.  MAUDE data includes information submitted on MedWatch Form 3500 
(Appendix A) by user facilities since 1991, distributors since 1993 and manufacturers since 
1996.  MAUDE also contains voluntary reports (since 1993) from many different sources, 
including consumers and health care professionals.  The public-accessible portion of MAUDE 
encompasses the releasable (non patient-identifying) MDR information, including 
manufacturer, device, patient, and narrative adverse event information. 
As illustrated in Figure 1.1, the MAUDE database currently contains over three 
million adverse event reports, the vast majority of which have been submitted by 
manufacturers.  The exponential escalation of report submissions over the last decade is 
attributed to the growing complexity and sophistication of medical devices, an increasing 
number of medical device patients and users, and greater emphasis and awareness of 




performed by Donahoe, (35) it is unlikely that this increase simply reflects increase product 
usage.  Between 2003 and 2013 the number of MAUDE reports increased 7-fold, from 
72,868 to 573,842.  2011 marked the first time the average number of submissions topped 
one thousand reports per day; and just two years later, the number of submissions 
approached a daily average of two thousand reports. (36) 
 
 
Figure 1.1: Frequency of Adverse Event Reports Submitted to MAUDE by Year Received 
and Reporting Source. 
The number of medical device adverse event reports by year received and reporting source 
since MAUDE’s inception through 2013. 
 
Limitations inherent in passive reporting systems such as MAUDE include 




understand reports that limit the assessment of causality; inability to determine what 
proportion of the population was exposed and what percent experienced the adverse event 
due to the lack of denominator information; reporting bias due to an institution’s reporting 
practices or increased media attention; and insufficient information to accurately identify 
the product in question. (37-42)  Despite these limitations, SRS have played an important 
role in safety surveillance of medical products. (43, 44)  For example, fatal aplastic anemia 
and liver failure were found to be associated with felbamate, an anti-epileptic drug, based 
upon SRS reports (24); Bayer Healthcare voluntarily withdrew its statin drug cervastatin due 
to SRS reports of deaths caused by rahbdomyolysis and resulting renal failure; and SRS 
reports of sudden deaths associated with barium enema products proved to be an early 
signal of severe allergic reactions caused by the latex-tip used in the device. (45)  As noted 
by Redberg, (40) long-term surveillance is especially important for high-risk implanted 
cardiovascular devices that are permanently implanted.  This is particularly true of ICD leads 
for which removal of a faulty device often poses its own inherent risks. (46-49) 
1.2.4 Medical Device Recalls 
Once an adverse event report is received, reviewed, analyzed and assessed 
alongside other data, the FDA has several means to protect the public from a device that is 
defective or that poses a risk to health, including recalling the device from the marketplace. 
(50, 51)  Recalls are an important remedial action that can mitigate the risk of serious health 
consequences associated with defective or unsafe medical devices.  The FDA categorizes 
recalls based upon the relative degree of health hazard (risk) presented by use of the device 




Table 1.2: Medical Device Recall Classifications. 
 
Recall 
Classification Definition Risk Level Example 
I Reasonable probability that use of 
or exposure to a device will cause 
serious adverse health 
consequences or death 
High A defective artificial heart 
valve 
II Use of or exposure to a device may 
cause temporary or medically 
reversible adverse health 
consequences, or the probability of 
serious adverse health 
consequences is remote 
Medium A package defect that 
could compromise 
product sterility 
III Use of or exposure to a device 
violating FDA regulations that is not 
likely to cause adverse health 
consequences 
Low A package mislabeled as 
containing a different 
product size 
 
As shown in Figure 1.2, product and recall risk classifications are inversely related: 
higher risk products are denoted by higher numeric assignments, whereas higher risk recalls 
are signified by lower numeric classifications.  Class III recalls are independent of the 
medical device classification, whereas, Class I recalls almost always involve Class II or Class 
III medical devices. 
 
 
Figure 1.2: Association between Device and Recall Risk Classification. 
This figure shows the inverse association between regulatory device classification and recall 




Historically, cardiovascular device problems have comprised the greatest proportion 
of reports submitted to MAUDE (Figure 1.3).  Perhaps unsurprisingly given the life 
supporting nature of many cardiovascular devices, the largest proportion of Class I medical 
device recalls also concerned cardiovascular devices.  In three recent studies cardiovascular 
devices comprised 27-31% of all high-risk recalls. (19, 53, 54) 
 
 
Figure 1.3: Distribution of MAUDE Reports by Reported Product Area. 
The number of medical device adverse event reports received since MAUDE’s inception 
through 2013 by product area, defined using the FDA Review Panel assignment. (2)  “Other” 
includes Microbiology, Immunology, Clinical Toxicology, Pathology and reports associated 
with devices that do not fall into any of the specified groupings. 
 
1.2.5 ICD Lead Problems 
Sudden cardiac death (SCD) is defined as unexpected death due to malfunction of 




heart function (sudden cardiac arrest). (55)  It is estimated that SCD results in 180,000 to 
more than 450,000 deaths per year in the United States (56) and 4 to 5 million cases per 
year globally, (57) making SCD the leading cause of death worldwide. (58)  ICDs are small 
cardiovascular medical devices designed to prevent sudden cardiac death due to ventricular 
arrhythmias.  The ICD monitors a patient’s heart rhythm, and if an abnormal heart rhythm is 
detected the ICD delivers a pulse of energy to convert the irregular rhythm back to a normal 
heartbeat.  The wires that connect the ICD to the heart’s chamber(s) are referred to as 
“leads,” and these leads both sense the heart rhythm and deliver the electrical pulses 
needed to pace or defibrillate the heart. (59-61) 
ICDs were first used in humans in 1980 and are now a standard cardiac disease 
management tool with over 12,000 ICD devices and 26,000 ICD leads implanted per month 
in 2011. (62)  Modern ICDs are sophisticated devices that provide pacemaker capabilities, 
defibrillation, antitachycardia pacing and cardiac resynchronization therapy in ever smaller 
and lighter packages.  ICD leads (Figure 1.4) have evolved significantly over the past three 
decades and are described by Kalahasty as a medical device that is as “remarkable” and as 
critical as the ICD itself. (63)  The contemporary ICD lead includes conductors, defibrillation 
coils, pacing and sensing electrodes, fixation mechanism, yoke and lead connectors 
packaged in fluoropolymer, polyurethane or silicone rubber insulation.  To facilitate 
implantation, ICD leads have also become thinner, with the smallest ICD leads now 






Figure 1.4: Implantable Cardioverter Defibrillator and Lead. 
Blausen.com staff.  “Blausen gallery 2014”.  Wikiversity Journal of Medicine.  
DOI:10.15347/wjm/2014.010.  ISSN20019872. – Own work. (65) 
 
While ICDs offer an effective disease management strategy that has saved 
thousands of lives, (66-69) the systems have also been plagued with problems.  In 1996, 
Kawanishi noted that the history of pulse generators and leads had been “punctuated with 
distressing regularly by device failures at a systematic level,” (70) and more recently Maisel 
concluded from an analysis of FDA annual reports between 1990-2002 that ICD 
malfunctions have been increasing. (71, 72)  The ICD lead has been particularly problematic 
and is generally considered the “weakest” link of the system. (73-75)  Mechanical problems 
and failures of ICD leads “can compromise device function, cause inappropriate shocks, and, 
in rare cases, lead to loss of pacing, failure of defibrillation, or fatal proarrythmias.” (76)  




involving the Medtronic Sprint Fidelis lead (n=235,000) and the St. Jude Medical (SJM) 
Riata/Riata ST leads (n=128,000).  These recalls have sparked intense scientific investigation 
and discourse, and the SJM Riata and Riata ST lead recalls in November 2011 following the 
Medtronic Sprint Fidelis lead recall in June 2007 prompted Dr. Hauser to title a New England 
Journal of Medicine Perspective article “Here We Go Again – Another Failure of 
Postmarketing Device Surveillance” (77) due to the lack of “timely” and “scientifically valid” 
information. 
1.2.6 Use of Natural Language Processing, Data Mining and Text Mining to Identify 
Adverse Events 
Natural language processing (NLP), data mining and text mining have all been 
utilized to identify adverse events.  NLP uses computer systems to perform tasks involving 
human language (78, 79); data mining applies statistical techniques and computerized 
algorithms to reveal associations or “signals” in databases (80-82); and text mining - 
sometimes referred to as text data mining - intersects these two broader fields by utilizing 
NLP tools to delineate “at least some linguistic structures within the text” (78) and statistical 
algorithms to find patterns in the resulting data. (78, 83-85) 
There exists a rich body of literature dating back to the early 1990s (86, 87) using 
data mining techniques to identify adverse drug reactions (pharmacovigilance) in SRS 
databases.  To date, most of this safety surveillance is accomplished using DPA algorithms 
to establish product-adverse event combinations that occur more frequently than would be 
expected by chance. (81, 82, 88-92)  Until recently, use of data mining techniques to detect 




Literature Review section, recently two teams demonstrated the effective use of data 
mining techniques to detect the Sprint Fidelis ICD lead problems: Duggirala using DPA (93) 
within the MAUDE database, and Hauser using propensity matching of a three-center 
institutional database. (94) 
In healthcare, NLP has been used to automatically encode and extract adverse 
events from a variety of sources including radiographic reports, (95-100) discharge 
summaries, (101-103) and intensive care notes. (99, 104, 105)  Text mining has been used in 
a variety of life science areas, including the analysis of biological literature, the mining of 
genomic data, and the identification of drug names, adverse drug effects and hospital-
acquired infections in clinical and electronic health records. (106-109)  More recently, as 
discussed in Chapter 2, text mining has been applied to SRS surveillance data to classify 
vaccine adverse events, to predict drug label changes, to identify HIT incidents and to 
explore temporal relationships of late stent thrombosis adverse events. (110-113) 
1.3 Significance and Innovation 
Ensuring the safety and effectiveness of medical devices is a vital activity that 
underlies the entire product life-cycle from premarket approval to postmarket surveillance. 
(4)  Even the most rigorous clinical trials may not uncover all potential device problems, and 
thus postmarket surveillance and evaluation of adverse events and product problems 
submitted through SRS databases play a critical role in the monitoring of long-term device 
safety. 
This research utilized MAUDE medical device adverse event and product problem 




consumers.  These reports contain both structured and unstructured data, the latter which 
include narrative descriptions of the reported adverse event.  As shown in Figure 1.5, these 
descriptions range from a few characters to lengthy text descriptions.  Analysts at the FDA’s 
Center for Devices and Radiological Health (CDRH) review these medical device reports in 
order to identify potential patterns of harm.  With the exponential rise in the number of 
report submissions over the past decade, manual review is increasingly time consuming and 
costly, (51) and at the same time FDA CDRH funding and staffing levels have remained 
virtually flat. (114-116)  As a result, in a 2007 Institute of Medicine report, the National 
Research Council concluded that the FDA “lacks the resources needed to accomplish its 
large and complex mission today, let alone to position itself for an increasingly challenging 
future.” (117) 
But even with a sufficient pool of resources, given receipt of more than 70,000 new 
MAUDE reports each month spanning 5,000 product types and nineteen medical specialties, 
it would be difficult for even the most astute and experienced analyst to identify all possible 
device-related adverse event trends.  For example, questions such as “are there similarities 
between reports for a given medical device indicating an underlying product problem?” or 
“does the information in a report differ substantially from the body of previous reports for a 
medical device, potentially indicating emergence of new failure mechanism?” are 
particularly daunting given the need to identify issues amongst intermittent reports that 
may span years or even decades of a product’s history.  This task is even more complex if 







Figure 1.5: Histogram of MAUDE Adverse Event Narrative Descriptions. 
The distribution of character counts of MAUDE adverse event narrative descriptions in 
reports received since MAUDE’s inception through 2013.  The length of the narrative 
descriptions has gradually increased over the past fifteen years from 325 characters to 490 
characters. 
 
Given these challenges, the dramatic increase in report problem submissions and 
the flat staffing levels available to evaluate each report, it is critical to seek new 
technological approaches to the review of medical device adverse event information.  
Failure to do so could result in longer delays before unsafe products are removed from the 
market.  Arguably, given the discontinuous nature of adverse event reporting over time, 
computational methodologies provide a rapid, systematic and optimal approach to 
prioritizing those reports that should be escalated for further human review.  
Pharmacovigilance has demonstrated that analysis of SRS databases using data mining 




demonstrated the feasibility of using DPA data mining techniques to detect ICD lead 
problems, and text mining techniques have been successfully utilized to classify HIT-related 
events. 
Along with the exponential increase in medical device adverse event report 
submissions is a similar escalation in the rate of the most serious medical device recalls.  
There has been increasing pressure to enhance the assessment of medical device recalls “to 
better reduce the risk of serious health consequences from defective or unsafe devices”. 
(118)  Improving postmarket surveillance and recall implementation approaches have been 
among the top strategic priorities of the FDA’s CDRH in recent years. (119-123) 
Although the MAUDE database contains a wealth of adverse event and product 
problem data, the majority of these reports do not lead to a product recall; however, those 
that do are of particular concern to the public’s safety.  This dissertation research utilized a 
text mining framework to predict these most serious product problems, using ICD lead 
MAUDE reports and the two Class I ICD lead recalls occurring in the past decade to train text 
classification models.  DPA techniques were then used to systematically evaluate the 
predictions generated by the text classification models to determine whether signals of 
product problems were evident in advance of the ICD recalls.  While the serial combination 
of text mining and data mining techniques used in this research project was novel, the 
concepts were based upon a solid groundwork of prior work. 
1.4 Summary 
Early recognition of ICD lead problems could reduce the number of patients 




ICD lead failure.  This research utilized an innovative, sequential combination of text and 
data mining methodologies to develop an automated data-driven early warning system that 
predicted ICD lead recalls from text-based adverse event information in the MAUDE 
database.  As will be detailed in upcoming chapters, early signals of ICD lead product 
problems were found in the text-based adverse event report descriptions.  This work may 
help to identify future unsafe ICD leads and could provide a basis upon which to develop a 









The central goal of this research was to identify a data-driven early warning system 
that predicted subsequent ICD lead recalls using information mined from MAUDE adverse 
event narrative reports.  Although I was unable to find any published studies that used data 
or text mining methods to predict medical device recalls, there exists a large body of work 
pertaining to related topics.  This chapter summarizes this literature, concentrating on work 
in health-related fields, but also providing a brief synopsis of findings from other domains.  
Section 2.1 describes the methods used to conduct this literature review.  Subsequent 
sections then discuss the work reviewed in the following related domains of interest: 
• Literature referencing the MAUDE database (Section 2.2, Appendix Table B.1); 
• Literature relating to medical device recalls (Section 2.3, Appendix Table B.2); 
• Literature specific to data and text mining within SRS databases (Section 2.4, 
Appendix Tables B.3 and B.4); 
• Literature outside the medical domain that might guide or contribute to the 
work in this proposal (Section 2.5). 






2.1 Literature Search Methodology 
Due to the inclusion of recent and in-press articles, the primary literature search was 
performed using PubMed, a resource developed and maintained by the U.S. National 
Library of Medicine’s (NLM) National Center for Biotechnology Information. (124)  
Literature searches outside the medical domain were conducted using Elsevier’s 
ScienceDirect, (125) supplemented with the University of Colorado’s Health Sciences Library 
“FindIt” (126) search tool. 
Given the importance of the MAUDE database to this work, the literature search for 
this topic was not date restricted.  All other PubMed searches spanned 2004-2014.  Table 
2.1 provides a list of the search terms used to inform the discussions in Sections 2.2-2.4, 
along with a count of citations retrieved, abstracts examined and full-text articles reviewed.  
For the MAUDE PubMed search, the titles and abstracts for all retrieved citations were 
reviewed.  For the other searches, titles of the composite (filtered) search results were 
examined, and abstracts were reviewed unless an article title was clearly outside of the 
targeted domain.  In addition to the literature database searches, the bibliographies of 
reviewed articles were examined and additional articles were included in the discussion 
based upon their contribution to the key topic. 
All searches were restricted to English language articles.  The literature search 





Table 2.1: Literature Search Terms and Results. 
MH = MeSH Heading; FDA = Food and Drug Association; MAUDE = Manufacturer and User 
Device Experience; (F)AERS = (FDA) Adverse Event Reporting System; VAERS = Vaccine 
Adverse Event Reporting System; SRS = Spontaneous Reporting System.  When the title 
indicated the item was pertinent, the full text of citations not containing an abstract (e.g., 











MAUDE Literature Search (Appendix Table B.1) 
1. "manufacturer and user facility device experience" OR 
"manufacturer user facility device experience" OR 
"MAUDE database" OR “FDA MAUDE” or "food and drug 
administration MAUDE” 
126 118 17 
2. Search # 1 limited to “defibrillator” 9 9 9 
3. Search # 1 limited to “text” OR “narrative” 5 5 5 
 
Medical Device Recalls Literature Search (Appendix Table B.2) 
4. "safety-based medical device withdrawals"[MH] 29   
5. “medical device recalls"[MH] 84   
6. Search # 4 OR Search # 5 112 57 40 
7. Search # 6 limited to “defibrillator” 28 24 28 
8. Search # 7 limited to “text” OR “narrative” 0 0 0 
 
Data Mining Methods Used in SRS Databases Literature Search (Appendix Table B.3) 
9. “spontaneous reporting system” OR “AERS” OR “FAERS” 
OR “VAERS” OR “MAUDE” 
778 
  
10. “data mining” OR “disproportionality analysis” 6380   
11. Search # 9 AND # 10 103 102 20 
 
Text Mining Methods Used in SRS Databases Literature Search (Appendix Table B.4) 









2.2 MAUDE Database Literature 
As this dissertation was based upon the MAUDE database, a comprehensive, non-
date-restricted PubMed review of articles referencing the MAUDE database was performed 
using the terms (#1-#3) shown in Table 2.1.  One hundred and twenty-six citations were 
retrieved dating back to 2000.  These citations are tabularized in Appendix B, Table B.1.  
Removing eight commentary results, a total of 118 abstracts were reviewed and classified 
by product area as shown in Figure 2.1. 
  
 
Figure 2.1: Percentage of PubMED MAUDE Citations Classified by Product Area. 
PubMED citations are grouped based upon the review panel associated with the product 
code or codes related to the medical device(s) discussed in the article.  “Other” includes 
Clinical Chemistry (n=2), Dental (n=2), Physical Medicine (n=1) and Non-classified products 
(Tanning Bed, n=1).  “Not Product Specific” citations are divided between overview (n=4) 




As shown in Figure 2.1, the largest concentration of articles (26%) pertained to 
cardiovascular products, consistent with the majority representation of cardiovascular 
medical devices within the MAUDE database (see Figure 1.3).  The major focus of the 
cardiovascular MAUDE citations was related to ICD/ICD leads (n=9), stents (n=8) and 
catheters (n=7). 
The MAUDE database articles were further categorized by type as shown in Table 
2.2, defined for the purpose of this literature review as general overview, methodological, 
or adverse event summarization.  The majority (n=112) of MAUDE citations fell into this 
latter category, summarizing adverse events specific to a particular outcome, product or 
body system.  Within this group of 112 citations, twenty (18%) included only secondary 
mention of MAUDE.  The remaining 92 citations were evenly divided between those utilizing 
information contained solely in the MAUDE database (n=48, 43%) and those (n=44, 39%) in 
which information from the MAUDE database was aggregated with other sources 
(“Combo”).  Within the latter aggregate group, literature searches (66%) and/or 
institutional cases series (20%) constituted the main bodies used to supplement the 
information provided in MAUDE.  Table 2.2 highlights the 14 articles discussed in further 
detail below, including the entirety of the general overview and methodology references, as 





Table 2.2: MAUDE Citations by Product Area and Article Type. 
 
 
2.2.1 MAUDE General Overview Articles 
The three general overview MAUDE articles provide readers with an understanding 
of the FDA’s processes for ensuring safe medical devices.  While none of these articles 
present specific details about the MAUDE database, they do provide an introduction to the 
benefits and disadvantages of this SRS.  The American Society for Gastrointestinal 
Endoscopy Technology Committee (12) gives a comprehensive review of the role the FDA 






Adverse Event Summarization 
MAUDE 
Only Combo Secondary 
Cardiovascular  2 11 15 3 31 
ICD & Lead  1 4 4  9 
Stent  1 3 4  8 
Catheter   2 4 1 7 
Intravascular Filter   2 2 2 6 
Heart Valve    1  1 
General & Plastic 
Surgery 
  12 8 2 22 
Gastroenterology & 
Urology 
  2 5 6 13 
Obstetrics & 
Gynecology 
  6 7  13 
General Hospital   6  5 11 
Not Product Specific 3 1 3  1 8 
Other   2 4  6 
Ear, Nose, & Throat   2 1 1 4 
Orthopedic   3 1  4 
Anesthesiology   1 1 1 3 
Neurology    2 1 3 
Sub-total 3 3 48 44 20 




surveillance of released medical devices.  Gurtcheff (127) also provides a high-level 
summary of the premarket and postmarket processes, and delves into background 
information on the MAUDE database.  He discusses MAUDE’s utility to clinicians who, in 
considering the use of a new medical device, wish to gain an appreciation for potential 
issues that may not yet have appeared in peer-reviewed publications.  Gurtcheff also 
addresses limitations of MAUDE, including the lack of detail provided in some MAUDE 
reports and the inability to ascertain the relative or absolute risk of an event due to issues 
of underreporting and lack of denominator information.  Woo (128) extends the discussion 
of MAUDE strengths and limitations, including as assets the potential detection of rare 
events, the availability of broad versus center-specific data, and the ability to generate 
hypotheses from the reported information.  That information contained in MAUDE reports 
is not medically confirmed and analyses using the MAUDE database do not allow for the 
determination of causal associations are additional weaknesses that Woo raises. 
In summary, these articles highlight the utility of using the MAUDE database to 
investigate known issues, as well as to identify potential new product problems.  Thus, this 
dissertation research may benefit clinicians by summarizing a vast amount of information 
that “often requires inordinate amounts of sifting-through when accessing MAUDE on-line.” 
(127)  The results of this research, while not suggestive of underlying event rates or causes, 
can be used to generate hypotheses for future work.  While keys within the MAUDE 
database allowed for the identification of events reported by multiple sources, it is likely 
that not all such duplicative reports were known.  As such, the analyses summarized in this 




descriptions or influenced by duplicative reporting of events.  Finally, while denominator 
information is generally provided for recalled medical devices, it is not typically available for 
all products reported in the MAUDE database.  As a result, this research project was not 
able to assess biases that could have been introduced by the over or under-reporting of 
certain events or product problems. 
2.2.2 MAUDE ICD/Lead Articles 
Nine MAUDE articles pertaining to ICDs or ICD leads were reviewed.  Three articles 
were unrelated to this research and not considered further: one relating to a review of 
device-assisted lead extraction adverse events. (46) one to Guidant/CPI ICD pulse generator 
failures, (129) and one to ICD premature battery failures. (130)  Of the remaining six 
references, Deluca (131) characterized adverse events associated with automated external 
defibrillator failures.  Although not directly related to this dissertation topic, this paper was 
thought-provoking as the authors created a manual tool by which to summarize the MAUDE 
narrative data in their selected cohort.  It may be of future interest to investigate and 
compare the use of text mining (information extraction) to accomplish this work.  With the 
exception of a methodology-focused article by Duggirala (93) and discussed in Section 2.2.3, 
the remaining four cardiovascular ICD/lead articles were authored by Hauser and colleagues 
using MAUDE information alone (132, 133) or combining MAUDE data with institutional 
cases (134) or with information provided directly from the lead manufacturer (135). 
In the first of these four papers, Hauser (133) provides an analysis of MAUDE fatality 
reports associated with ICD or ICD lead use.  The authors found that 69% of death events 




malfunctioning ICD pulse generators or insulation problems and fractures of ICD leads.  This 
paper identifies the issue of pulse generator damage resulting from defective leads, and 
motivated the use of an analysis cohort that includes records associated with either ICD or 
ICD lead product codes. 
Two articles focused on adverse event reports associated with small diameter leads, 
concluding that these thinner ICD leads were prone to early failure – a finding consistent 
with reports by other groups. (76, 136, 137)  In 2007, Hauser identified fracture and 
inappropriate shocks as frequently reported issues among failed Medtronic Sprint Fidelis 
leads, (134) and in 2013 Hauser and Kallinen Retel reported oversensing and noise resulting 
in inappropriate shocks among the reported signs of failure associated with three additional 
small diameter leads, the SJM Durata, Riata ST Optim and Riata ST. (135)  The Medtronic 
Sprint Fidelis and SJM Riata ST are among the Class I recalled ICD leads included in this 
dissertation’s analyses. 
In a separate 2013 article, Hauser investigated SJM’s claim that the Optim silicone 
and polyurethane copolymer coating used on their Riata ST Optim and Durata leads was 
more abrasion-resistant and thus protective of lead failures and delivery of high-voltage 
shocks caused by short circuits. (132)  However, a MAUDE database search revealed 52 
reports of abrasions specific to the Riata ST Optim (n=15) or Durata (n=37) leads.  
Inappropriate shocks, oversensing, and low and high impedance were the most common 





In summary, these articles demonstrate the usefulness of the MAUDE database for 
investigating ICD lead problems.  Hauser and Kallinen Retel (135) reported that their 
findings contributed to SJM undertaking a design change of the Durata ICD lead, illustrating 
the potential impact that early analysis can play in discovering product design issues and 
promoting design changes that may limit the exposure of patients to problematic medical 
devices. 
2.2.3 MAUDE Methodological Articles 
Three methodology-focused MAUDE papers were identified.  In the first of the two 
applying text-based approaches, Clark (113) postulated that identifying events leading up to 
and following adverse outcomes would allow the prediction of future outcomes based upon 
a similar ordering of events or duration of times between events.  This team used the 
Clinical Narrative Temporal Relation Ontology (CNTRO) tool to analyze the temporal events 
and relationships within a small subset of fifteen late stent thrombosis adverse events 
reported in MAUDE between 2009 and 2010.  In their study, the authors manually 
annotated each of the selected reports, identifying the events and their sequential (before, 
after, overlapping) and durational time relationships.  They then used this information to 
create a gold-standard answer key to a series of time-oriented questions, and evaluated the 
performance of CNTRO against this gold standard.  The authors concluded that within 
MAUDE reports having appropriate granularity, CNTRO performed well in identifying event 
sequence patterns and would merit further investigation in examining temporal 




In the second text-based methodological paper, Chai conducted a feasibility study in 
which the use of statistical text classification was explored to automatically identify health 
information technology (HIT) incidents from amongst 515,897 MAUDE adverse event 
reports between January 2008 and July 2010. (111)  The text classification was performed 
using regularized logistic regression and evaluated using both balanced (equal numbers of 
HIT and non-HIT events) and stratified (real-world distribution) datasets for training, 
validation and testing.  In Chai’s study, stemming, defined as the determination of common 
word bases by removing prefixes and suffixes, provided the best results among the feature 
selection techniques evaluated.  The authors demonstrated that identification of HIT events 
using text classification was a practicable approach, but cautioned that a semi-supervised 
iterative process may be necessary to accurately classify records.  In my dissertation study, I 
anticipated that the exercise of labeling MAUDE ICD lead records as recalled/not recalled 
would be more deterministic than the HIT/non-HIT classifier assignment performed by Chai.  
However, as discussed in Chapter 6, the non-structured format for entering medical device 
identification information into MAUDE added a significant level of complexity to the 
classification work necessitated by this research. 
The final methodological MAUDE paper retrospectively evaluated whether a safety 
signal of Medtronic Sprint Fidelis lead fracture and inappropriate shocks could have been 
detected prior to the FDA’s awareness of the event in January 2007. (93)  This data mining 
study was conducted by the FDA using access to the complete MAUDE database, from 
which they examined records received in 2006.  Using this subset, the most commonly 




were identified for the eleven most-frequently reported ICD lead brands.  Duggirala used a 
multi-item Gamma Poisson Shrinker (MGPS) disproportionality analysis (DPA, see Section 
3.2) to identify potential ICD lead problems.  This feasibility study demonstrated that the 
Medtronic Sprint Fidelis ICD lead had the highest disproportionality signal across all four of 
the examined adverse events, and suggested that this methodology could have detected 
the potential risk of this device as early as March, 2006.  However, the signal boundary did 
not exclusively select Sprint Fidelis ICD leads – that is, the methodology demonstrated 
higher sensitivity at the expense of lower specificity (i.e., possible over-detection). 
In summary, among the MAUDE articles, the work by Chai and Duggirala are most 
closely related to the current research.  Chai with the use of text mining to classify events, 
and Duggirala in the use of DPA statistical techniques to assess the relative frequency of 
events by brand name.  Although Clark’s study suggests that it may be possible to assess 
temporal relationships within ICD lead reports, particularly those that encompass several 
updates, I did not pursue this path as: the frequency of events with updates is small; the 
majority of adverse event descriptions do not provide a report date nor or the database 
keys in sequential order, preventing a seamless way to order the various text descriptions; 
and as there is no prescribed template for reporting events, I suspect that reporting 
differences across manufacturers, centers and reporters would obviate the recognition of 





2.3 Medical Device Recall Literature 
With the purpose of gaining an appreciation of data and text mining methods used 
to analyze medical device recall data outside of that encompassed in the MAUDE literature 
discussed above, PubMed was examined between 2004 and 2014 using the medical subject 
headings (MeSH) shown in Table 2.1 (#4-#8).  Among the 112 English-language articles 
retrieved and tabulated in Appendix B, Table B.2, 23% (n=26) discussed general device recall 
information and strategies.  The majority of the remaining product citations addressed 
management or outcomes of specific medical devices under advisory (24%, n=27 ICD/lead; 
17%, n=19 hip; 12%, n=13 silicone breast implants; 6%, n=7 infusion pumps), including the 
Class I SJM Riata and Riata ST and Medtronic Sprint Fidelis ICD lead recalls.  While some of 
the reviewed articles included results of specific studies – for example, the small diameter 
ICD lead study by Hauser (135) discussed in Section 2.2.2, or a failure-free survival 
comparison of Medtronic Sprint Fidelis and SJM Riata ICD leads conducted by Liu (138) - 
none incorporated the use of data or text mining methodologies.  Thus, this dissertation 
provides a unique contribution to this current body of work. 
2.4 Spontaneous Reporting System Database Analysis Literature 
Next, the literature review was extended to review reports with mention of SRS 
databases and the use of data or text mining.  The majority of the 106 identified articles 
were based upon the United States drugs and biologics (FAERS) and vaccine (VAERS) SRS 
databases, but also included articles based upon MAUDE or data repositories maintained by 




provided in Figure 2.2.  Section 2.4.1 discusses the literature utilizing data mining methods, 
and Section 2.4.2 details the much smaller cohort that employed text mining algorithms. 
 
Figure 2.2: Spontaneous Reporting Systems Citations by Methodology. 
PubMED data mining and text mining citations related to spontaneous reporting systems 
(SRS) and grouped by methodology. FAERS = FDA Adverse Event Reporting System; VAERS = 
Vaccine Adverse Event Reporting System; MAUDE = Manufacturer and User Device 
Experience; DPA = disproportionality analysis.  “Other” SRS Data Source includes Indian 
(n=1), Japanese (n=1), Shanghai (n=1) and Vanderbilt EMR (n=1).  “Other” methodological 
approaches include Database Development (n=1), Overview (n=1) and Non-DPA data mining 
(n=3). 
 
2.4.1 Data Mining Methods used in SRS Databases 
Table 2.1 (#9-#11) details the terms used for a literature search of data mining 




DPA to detect product-adverse event combinations that occurred more often than would be 
expected if there were no association (Appendix B, Table B.3).  While disproportionality 
methods have primarily been used to detect drug-adverse event combinations, as discussed 
in Section 2.2.3 Duggirala applied a MGPS-based DPA to the MAUDE database, 
demonstrating the potential for detecting safety signals among ICD leads. 
The majority of work in the area of mining SRS databases has focused solely on 
structured data.  However, some investigators have recently begun to tune the SRS 
disproportionality results with information from other data repositories.  For example, 
Harpaz (139) and Iyer (140) utilized information from the clinical notes of electronic health 
records (EHRs) to augment the results of signal detection in the FAERS database, and Xu 
(141) used the biomedical literature within MEDLINE to boost the results of 
disproportionality analysis.  In each of these studies, findings were corroborated through 
the intersection of results from FAERS with those from external data sources.  A similar 
approach for medical device adverse event signal detection would entail utilizing EHRs or 
manufacturer’s device information to enhance DPA results from the MAUDE database. 
A different strategy adopted by Ball and Botsis (142) used network analysis to 
visualize and evaluate vaccines adverse events.  While not the focus of this research, it 
would be interesting to examine a similar approach using the MAUDE database to explore 
the interrelationship between medical device brands and product problem reports codes. 
2.4.2 Text Mining in Spontaneous Reporting System Databases 
Using the same search criteria as in section 2.4.1, but limited to text-based analytical 




Table B.4.  Four of the retrieved studies used the FAERS SRS database, (112, 143-145) three 
by Botsis (110, 146, 147) involved the VAERS database, and one by Chai (111) examined the 
MAUDE database to detect HIT events as discussed in section 2.2.3. 
A study by Wang (145) focused on creating a normalized, open-source data mining 
set of FAERS drug information aggregated with RXNorm, the National Drug File-Reference 
Terminology and the Medical Dictionary for Regulatory Activities (MedDRA).  This work 
should facilitate downstream text mining approaches within FAERS.  It also highlights the 
level of detailed effort necessary to collate the information in SRS databases such as FAERS, 
VAERS and MAUDE, where entry of non-structured product identifying data is the norm. 
The remaining studies extended further into text mining modeling.  The basic text 
preprocessing steps undertaken by both Chai and Botsis are those recommended in Miner, 
(85) Hotho, (148) and Garg, (149) and included: 
• Tokenizing (breaking) a stream of text into words; 
• Removing numbers and punctuation; 
• Eliminating stop words (e.g., common articles, conjunctions, and prepositions);  
• Normalizing word forms by removing prefixes and suffixes. 
As described in Chapter 4, this research utilized the above preprocessing techniques to 
transform the MAUDE adverse event narrative text into simple structures that can be 
processed by statistical models. 
Chai and Botsis (110) adopted a bag-of-word approach to create a vector of terms 
subsequently used in text classification modeling.  As described previously, Chai in order to 




vaccine records as positive/negative for anaphylaxis.  The bag-of-words model has an 
implicit assumption that the order of the words in a document does not matter.  Although 
this construct may be extended to consider multi-word n-grams, collocations and co-
occurring words, a simple bag-of-word approach has been found in some studies to be as 
effective as using multiple-word phrases for text classification problems. (150, 151) 
In more recent text mining SRS papers, Botsis and colleagues incorporated semantic 
information into their model, creating (146) and applying (147, 152) a vaccine adverse event 
text mining (VaeTM) information extraction/retrieval system to build a vaccine-specific 
dictionary of vaccines and events.  In the words of Botsis, the rationale for this approach 
was “The existing (vaccine) adverse event ontologies and terminologies have been either 
inadequately described or developed for different purposes.” (146)  In the VAERS database, a 
medical officer manually reviews and assigns a MedDRA preferred term to each record, and 
the authors stated that one goal of the VaeTM system was to reduce this manual effort.  
Although a similar regulatory term classification step is not currently applied to MAUDE 
records (instead problem code terms are provided by users and are present in in 
approximately two-thirds of records), the basic problem of an inadequate ontology is one 
shared by the medical device space. 
A detailed comparison of syntactic and semantic approaches was undertaken by 
Polepalli Rames (144) to identify medication and adverse event information in the FAERS 
database.  In this study, SRS records were tagged with part-of-speech, semantic, affix, 




incorporation of the additional taggers, they note that this work was “expensive” and did 
not result in statistically significant gains. 
A number of machine learning classifiers have been used for medical text 
classification problems.  Chai adopted logistic regression, while Botsis evaluated several 
models, including maximum entropy (a multi-class instance of logistic regression), Naïve 
Bayes, decision trees, support vector machines (SVMs), and k-nearest neighbors.  Chee and 
Polepalli Ramesh both explored Naïve Bayes and SVM models, and Polepalli Ramesh also 
evaluated a conditional random fields model. 
This research utilized a unique, two-prong approach incorporating both text mining 
and DPA.  As discussed in Chapters 3 and 4, three standard text classification algorithms: 
decision trees (recursive partitioning), Naïve Bayes, and support vector machines (SVMs) 
were explored to predict ICD lead recall predictions from adverse event text descriptions in 
the MAUDE database.  These predictions were then evaluated using customary DPA 
techniques to determine whether the text mining results provide early signals of known, 
subsequent ICD lead problems. 
2.5 Related Work in Other Fields 
Finally, additional searches were conducted with the purpose of discovering 
literature outside the medical domain that might guide or contribute to this current work.  
Although no references were found that specifically investigated the prediction of product 
recalls using text or data mining, text mining has been utilized in manners that are 
tangentially related to the work performed as part of this dissertation study and are 




grouped into four areas: novelty detection, sentiment analysis, problem isolation, and 
warranty and claims data analysis. 
2.5.1 Novelty Detection 
Novelty detection is the identification of new findings not previously seen in a 
dataset that a classifier was trained upon. (153-155)  It is a technique that has been applied 
to the detection of security intrusions, mammography masses, and structural faults.  One 
approach used by Glänzel and Thijs (156, 157) divided a space of bibliographic references 
both horizontally (by topic) and vertically (by time), identifying new emerging topics 
through cross-citation of core documents with clusters in different time periods.  Although 
failure mechanisms for ICD leads appear well-defined, (63, 75) one could anticipate that the 
approach proposed by Glänzel and Thijs might be advantageous for detecting previously-
unrecognized medical device failure modes, particularly among new categories of medical 
devices. 
2.5.2 Sentiment Analysis 
Sentiment analysis is a text mining technique used to detect highly emotive content 
from data sources such as social media.  Holton (158) explores this methodology for 
detecting disgruntled employees who may be at higher risk of committing fraud, and as 
discussed by Mostafa (159) several investigators have used the technique to classify movie 
review postings.  A related inquiry in the MAUDE database might be “do reports of products 
that are eventually recalled suggest more negative sentiments than do those of non-
recalled products?”  Abrahams (160) discovered that vehicle safety defect discussions 




the utility of conventional sentiment analysis to identify vehicle defects.  The 
implementation of domain-specific sentiment words overcame this obstacle, but Abrahams’ 
results suggest that a sentiment-analysis approach undertaken in the medical device field, 
where defect words are often product-specific, could require substantial customization to 
be successful. 
2.5.3 Problem Isolation 
A separate study by Abrahams and colleagues (161) found that vehicle components 
could be isolated within the contents of social media discussions.  In the MAUDE database a 
report of an ICD lead may be coded as a problem with the ICD itself, or even as a hip or 
other medical device product problem because product codes are neither structured in a 
hierarchical manner nor validated upon entry.  The use of text mining as a quality-control 
tool to review coded injury entries has been suggested by Jones (162) and Brooks. (163)  
The work by Abrahams, Wang (145) and others demonstrates that such an approach might 
prove useful for improving the quality of data within the MAUDE database. 
2.5.4 Warranty and Claims Data Analyses 
Many manufacturing companies offer product warranties during which time a 
product failure will be repaired or replaced at no or reduced cost.  A large body of literature 
(164, 165) documents the analysis of warranty database information, ranging from the early 
detection of faulty designs or defective parts, to the estimation of warranty claims and 
costs.  While this work has yet to be extended to unstructured text fields, (166, 167) Wu 
(164) suggests that text mining of end-user problem reports or engineering failure mode 




from warranty databases.  Although not all medical devices are covered by warranties (hip 
and knees replacement devices typically are not, while pacemaker and ICD leads typically 
are), it is conceivable that medical device warranty databases could provide a valuable 
resource for text mining approaches. 
Ghazizadeh (168) did use text mining methods to extract clusters of vehicle 
problems from the National Highway Traffic Safety Administration's vehicle owner's 
complaint database.  Applying latent semantic analysis and hierarchical clustering, fatal and 
injury-causing incidents were analyzed across time.  The time-trend analysis performed as a 
part of this study showed an increase in the count and normalized frequency of complaints 
surrounding both the Ford/Firestone tire and Toyota unintended acceleration recalls.  This 
work demonstrates the potential for utilizing free-response complaint databases for the 
early identification of product problems. 
2.6 Summary 
No published literature using data or text mining to predict ICD lead or other 
medical product recalls from SRS databases was discovered in a comprehensive literature 
review.  Most of the published works based upon the MAUDE database summarize specific 
product issues using simple, descriptive statistics.  Data mining methods have been 
extensively utilized in drug and vaccine SRS databases, but the application of such methods 
to the MAUDE database are extremely limited, with only one published account.  Similarly, 
the application of text mining methods to SRS databases has been demonstrated, but is 
seemingly only in its infancy with three papers each reporting the application of text mining 




HIT-related report.  By utilizing the MAUDE database to predict ICD lead recalls using text 
mining methods, this research addressed several gaps in the current literature, as 
summarized in Table 2.3. 
Table 2.3: Limitations of Current Literature. 
 
Limitation of Existing Literature 
Addressed in 
this Research? 
MAUDE data had not been used to predict medical device recalls Yes 
Text mining methods had not been applied to MAUDE ICD lead reports Yes 
The usage of text mining results to inform DPA signal detection had not 
been performed 
Yes 
Comparative analysis of text classification results across a series of 
increasingly differentiated medical devices had yet to be reported 
Yes 
Comparative analysis of text classification results across product recalls of 







TEXT MINING AND DATA MINING METHODOLOGIES 
 
This chapter summarizes the text mining and data mining techniques used in this 
research.  As discussed in Chapters 1 and 2, I believe the application of disproportionality 
analysis (DPA) to identify signals from the results of text mining models is unique; however, 
the methodologies themselves are well-established.  The intent of this chapter is to provide 
an introductory review of the specific techniques that were used in this project, particularly 
for readers less familiar with these subjects.  Section 3.1 summarizes the three text mining 
approaches that were evaluated, and Section 3.2 provides a synopsis of the DPA methods 
that were employed.  The applications of these techniques to this project are discussed in 
Chapter 4. 
3.1 Text Categorization 
Text categorization is the assignment of natural language texts to one or more 
predefined categories.  The automated, supervised assignment of predefined categories to 
unstructured text documents based upon models derived from a set of labeled examples 
has grown in popularity since the 1990’s. (169, 170)  Sebastiani (169) and Dumais (171) 
provide excellent overviews of a wide variety of learning algorithms appropriate for text 
categorization.  This dissertation research utilized three standard text classification 
algorithms to predict recalled and non-recalled ICD leads: decision trees (recursive 




vector machines (SVMs) outlined in Section 3.1.3.  Section 3.1.4 then describes the 
measures of model performance used in this research project. 
3.1.1 Decision Trees 
Decision trees provide a simple, yet powerful tool for learning and predicting 
classifiers.  These algorithms ascertain the boundaries between classes by learning rules 
that recursively split data into categories based on the words (attributes) and labeled 
classifications in the training dataset.  For example, determining which attributes are the 
most useful for discriminating between recalled and non-recalled ICD leads.  Decision tree 
models offer a distinct advantage in that the results are easy to interpret and can be readily 
translated into human-understandable if…. then… rules that can be reviewed and evaluated 
by experts. (172) 
The rules determined by decision trees can be graphically represented in a top-down 
fashion as illustrated in Figure 3.1 or in a left-to-right manner (not shown).  In graphical 
representations of decision trees such as shown in Figure 3.1, “decision nodes” represent a 
test of an attribute.  The “branches” emanating from each decision node denote the 
outcome of the test, typically with one branch per each possible value of a categorical 
variable, or of a continuous variable discretized into groups.  Finally, “leaves” corresponding 
to the classification decision terminate each branch.  After a decision tree has been learned, 
a new observation is assigned the classification (e.g., recalled, not recalled) in the leaf node 






Figure 3.1: Simple Decision Tree Graphical Example. 
Top-down graphical depiction of an example decision tree illustrating decision nodes, 
branches and leaves in a binary classification decision tree. 
 
A multitude of decision tree algorithms have been developed, with variations 
generally representing choices in how attributes are evaluated, branching requirements 
(e.g., always binary versus any number of branches), the means by which trees are pruned 
thereby reducing their complexity, and the handling of missing values and noise. (173)  This 
research utilized an algorithm known as C4.5, historically one of the most popular and 
widely used decision tree induction methodologies. (174)  Developed by Quinlan, (175) C4.5 
decision trees allow any number of branches, select attributes using the highest information 




probabilistically apportion missing values according to the relative frequency of known 
values. (176) 
Let us first examine the gain ratio used to select attributes in the C4.5 algorithm.  
Starting at the root (top) node, decision trees progressively partition the data by 
determining the attribute which best divides the data into homogenous subsets.  A 
completely homogenous subset has zero entropy (uncertainty), whereas one with no 
homogeneity has entropy of one.  Information gain is defined as the expected reduction in 
entropy after a dataset is split on an attribute.  In a two class problem such as predicting 
recalled/not recalled ICD leads, the entropy prior to splitting a dataset S is calculated as: ������� (�) = �(�) =  − � log� − � log� 
where p is the proportion of positive recall instances and n that of negative recall instances.  
Then for a given non-missing attribute A having i = 1 to v branches, the entropy for each 
branch of A is calculated and added proportionally to get the total weighted entropy for S 
after the split on attribute A: 
������� (�,�) = �(�,�) = ��� + ��� + �� �(�,��) 
The information gain for splitting on attribute A is thus the (parent) entropy before the split 
minus the average (children) entropy after the split: ����������� ����(�) =  ��(�) = �(�)− �(�,�) 
Because information gain can favor attributes having numerous outcomes, a normalized 
value of the information gain accounting for the number and size of branches may be 




���� ����� (�) =  ��(�) =   ��(�)�(�,�)  
The attribute with the largest gain ratio is selected as the decision node for the split. 
In decision trees, splitting occurs recursively until a branch has zero entropy and thus 
terminates in a leaf node.  As such, the resulting decision tree is typically one that has 
reduced training set error at the cost of higher test set error.  To alleviate this overfitting, 
the C4.5 algorithm employs a post-pruning methodology – that is, one that discards 
portions of a decision tree after the full tree has been developed.  Decision trees are pruned 
by estimating the error for a parent node and its subtree, typically choosing the option that 
provides the lowest 75% 1 confidence limit, e, defined as: 
� = � + ��22� + ����� − �2� + ��24�2
1 +
��2�  
where f is the observed error of the training data, N is the number of instances at a node or 
branch, �� is the critical value corresponding to the selected significance level (e.g., z=0.69 
for a one-sided α=0.25 corresponding to a 75% confidence bound), and where the 
estimated error for a subtree is calculated as the average of the upper confidence bound 
estimates for each branch in the tree, weighted by the frequency of instances in each 
branch.  At each node, a pruning decision is made to either: 
                                                     
 
1 Pruning by error estimation is typically used with the C4.5 algorithm using a 25% 
alpha-level (Weka confidenceFactor=0.25); however, many software packages such as Weka 




1. Leave the tree as-is; 
2. Replace the node with a leaf corresponding to the majority class going to that 
part of the tree; 
3. Replace the node with the subtree corresponding to the most common branch 
(subtree raising illustrated in Figure 3.2). 
 
 
Figure 3.2: Subtree Raising in a Decision Tree. 
Figure (a) shows the original decision tree and Figure (b) the result after pruning using 
subtree raising.  In this example, the entire subtree from Z downward in (a) is raised to 
replace the Y subtree, with the resulting pruned decision tree shown in (b).  Note that the 
instances in Y’s subtree – those labeled 4 and 5 - must be redistributed when the Z subtree 
is raised.  As such, the daughters of the raised subtree Z in (b) are labeled 1’, 2’ and 3’, 
indicating that they differ from the original contents of Z by the inclusion of the reclassified 
instances from 4 and 5. 
 
Decision trees are robust to outliers, non-linearly separable data, and to a variety of 
data and measurement levels.  Decision trees can reduce problem complexity and are 
appealing in the relative ease of interpretability they afford through ready translation into a 
series of if…then rules.  While decision trees can be prone to over-fitting and are less easily 
explained when large trees are generated, algorithms such as C4.5 employ methods to help 




methodology does not have a strong statistical foundation, it typically works well in 
practice. (80, 172, 173, 177) 
3.1.2 Naïve Bayes 
Naïve Bayes models provide another standard text classification methodology, that, 
while simple to implement, tend to work well with large datasets providing results that are 
often as good as or better than those generated by other models. (110, 150, 178)  Naïve 
Bayes algorithms use the training samples to build a model for the distribution of each 
category, and then makes classification predictions for a new record by determining the 
modeled category (e.g., recalled/not recalled) to which the record is most similar.  A simple 
graphical illustration is shown in Figure 3.3. 
Bayes rule is defined as: 
 
�(��|��) = �(��|��)�(��)�(��)  
 
where in this research �� is a feature vector corresponding to the ith training example and �� 
is the class assigned to the ith training example (recalled/not recalled).  �(��) is the prior 
probability of an ICD lead being recalled/not recalled, which was initially be set to the 
proportion of records in each class.  The simplifying assumption in the Naïve Bayes 
approach is that given a class label, the features x1,…,xn ∈ �� are independent of each other, 
allowing: 
��������� ����� ����� ← ��������(��)��(��|��).��=1  







Figure 3.3: Naïve Bayes Graphical Example. 
This graph shows 100 objects, 70 classified as BLUE and 30 as RED.  Based on the simple 
proportion in each class, it is reasonable to assume that a new, unobserved case (the open 
‘?’ circle) is more than twice as likely to be BLUE rather than RED.  That is, the prior 
probability of BLUE is 70/100 = 70%, and the prior probability of red is 30/100 = 30%.  Now 
let’s assume that each circle with an X in it represents a defective part.  There are 7 
defective BLUE parts and 9 defective RED parts.  Let us also assume that we have evidence 
that ‘?’ is defective.  Given this evidence, would we still make the same determination 
about the color of the open circle?  The likelihood of ‘?’ being defective if it is BLUE = # 
defective BLUE parts ÷ total number of BLUE objects = 7/70 = 10%, and the likelihood ‘?’ 
being defective it is RED = 9/30 = 30%.  We can use this information to calculate the 
posterior probability of ‘?’ being RED or BLUE given that it is defective as prior probability × 
likelihood.  Thus, the posterior probability that ‘?’ is BLUE, given it is defective = 70% × 10% 
= 7%, and the posterior probability that ‘?’ is RED = 30% × 30% = 9%.  Thus, using a Naïve 
Bayes approach and knowing that the open circle is defective, we would classify it as RED as 
RED provides the largest posterior probability. 
 
Although the assumption of feature independence is generally not valid, in practice 
the Naïve Bayes classifier has been shown to work well for text classification problems. 
(171)  Generative learning algorithms, such as Naïve Bayes, have the ability to introduce 




are also generally quick to implement and run, and due to this efficiency Naïve Bayes 
classifiers often scale well to large datasets. (179)  These algorithms tend to be robust to 
irrelevant features, work well with many equally important features, and provide a good, 
dependable baseline for text classification.  However unlike Decision Trees, the 
determinations made by Naïve Bayes classifiers are not explicitly manifest and therefore are 
more difficult to interpret. (150, 180) 
3.1.3 Support Vector Machine (SVM) 
SVMs have been shown to be well-suited to the task of text classification, and 
generalize well in high-dimensional feature space. (181)  SVMs attempt to find a decision 
boundary that best separates the classes in a training set and using this boundary to predict 
the class to which a new observation should be assigned. (80, 171, 182)  More specifically, 
given a training set in the form of {��,��}, where �� is a feature vector corresponding to the 
ith training example, and �� ∈ {−1, +1} is the class assigned to the ith training example (e.g., �� = −1 for a non-recalled ICD lead, and �� = 1 for a recalled ICD lead), SVMs seek to find a 
hyperplane 2 that maximizes the distance between the points where �� = 1 and �� = −1.  A 
new observation x can then be classified by testing which side of the hyperplane the point 
lies on.  As illustrated in Figure 3.4, SVMs select a small number of critical boundary 
instances (support vectors) from each of the two classes and determine a linear 
                                                     
 
2 A hyperplane is an n-1 subspace dividing an n-dimensional space into two parts.  In 
2-dimensional space, a hyperplane is a 1-dimensional line; in 3-dimensional space, a 
hyperplane is a 2-dimensional plane; and in n-dimensional space, the hyperplane is the n-1 








Figure 3.4: Support Vectors and Hyperplane in 2D Space Graphical Example. 
Example of a hyperplane separating two classes in 2-dimensional space.  The same concept 
applies to higher-dimensional space with vectors and hyperplanes, rather than 2D points 
and lines. 
 
What about data that is not linearly separable?  Although data may not be linearly 
separable in its original space, linear separation can often be achieved by finding a function � that transforms the data into potentially higher-dimensional feature space where it can 
be separated with a linear hyperplane.  An illustration of this concept is shown in Figure 3.5.  
While Figure 3.5 shows a simple example where linear separation is achieved by 




data that has been mapped into higher dimensional spaces can require significant 
processing time and storage requirements. 
 
 
Figure 3.5: Example of Linear Separation Achieved through Projection to a Higher 
Dimensional Space. 
Figure (a) shows an example in 1-dimensional space of two classes (represented by the 
closed blue circles, and the open red circle) that are not linearly separable – that is, a line 
cannot be drawn that separates the two classes.  Figure (b) illustrates that by projecting all 
points x in Figure (a) up to 2-dimensional space using the mapping � → (�, �2), linear 
separation shown by the solid black line can be achieved. 
 
To avoid these expensive computations, SVMs make use of kernel functions which 
provide a means to implicitly project the data as if it were in higher dimensional space, 
while allowing straightforward computations in the original space.  For example, if �� and �� 





����,��� = �(��) • �(��). 
This dissertation examined the four kernels defined below, where c is a parameter 
that trades off margin width and misclassifications. (183-186)  However, as discussed in 
Chapter 7, the computational times for the Gaussian and string subsequence kernels were 
excessive and the evaluations were limited to linear and quadratic kernels. 
• Linear kernels:  ����,��� = (��) • ����+ �;  
• Quadratic kernels:  ����,��� = �(��) • �����2 + �; 
• Gaussian Radial Basis Function (RBF) kernels:  
����,��� = ��� �− ���−���22�2 �+ �, 
• String Subsequence kernels:  See Lodhi (186). 
Although SVMs can be slow to train, particularly in nonlinear settings, they tend to 
be very accurate and are less prone to over-fitting than other classifier methods.  They 
generally work well for text classification as learning is independent of the dimensionality of 
the feature space.  However, like Naïve Bayes classifiers, SVMs are a “black box” 
methodology for which the results do not necessarily lend themselves to easy 
interpretability. (169, 171, 182) 
3.1.4 Text Classification Performance Measures 
The standard evaluation measures in classification problems are defined from a 
confusion matrix with the numbers of records correctly and incorrectly classified for each 
class.  The confusion matrix and typical effectiveness measures for a binary classification 




error rates are highly influenced by unbalanced datasets where the number of samples in 
each class vary greatly, for the evaluation of models this research primarily relied upon 
measures of prediction, recall and F1 scores, (78, 148) as well as computational time. 
Table 3.1: Binary Text Classification Performance Measures. 
TP = True positive; FP = False positive; FN = False negative; TN = True negative. 
 Actual Classification 
Total 
Recalled Not Recalled 
Model Prediction 
Recalled TP FP TP+FP 
Not Recalled FN TN FN+TN 
Total TP+FN FP+TN N=TP+FP+TN+FN 
 















The proportion of predicted recalls that are 
correct (“signal-to-noise”). 
 






The proportion of actual recalls correctly 
predicted by the model (“hit ratio”). 
 
In clinical science, often referred to as 
“sensitivity”. 
F1 Measure 2 ×
��������� × ��������������� + ������ A composite measure of model effectiveness, calculated as the harmonic mean of precision 
and recall. 
 
3.2 Data Mining Methods used in SRS Databases 
As discussed in Chapter 2, the majority of SRS data mining is accomplished using DPA 




expected if there were no association.  However, this methodology translates well to 
examining the observed and expected frequencies of other types of events, such as a 
medical device recall. 
In DPA, 2×2 contingency tables are used to classify reports by the presence / 
absence of an event and product as shown in Table 3.2.  These tables are used to generate 
measures of association or “interestingness”, with those measure that exceed a predefined 
threshold defining “signals” for further evaluation.  Among the most common frequentist 
measures of association are the proportional reporting ratio (PRR) and the reporting odds 
ratio (ROR).  Bayesian methods account for uncertainty in 
disproportionality ratios when cell counts are small, by “shrinking” estimates toward the 
null hypothesis of no association by an amount proportional to the disproportionality 
statistic.  The two primary Bayesian methods utilized in SRS databases adapt the relative 
reporting ratio (RRR) measuring the observed / expected probability of an event by 1) a 
Bayesian confidence propagation neural network (BCPNN) approach using the information 
component (IC) or 2) a multi-item Gamma Poisson shrinker (MGPS) using the empirical 
Bayes geometric mean (EBGM). (44, 81)  More complex algorithms have also been 
developed to address multiple comparisons, multiple products/events, and higher-order 
associations, (43, 187) and several researchers have explored the relative performance of 





Table 3.2: 2×2 Contingency Table Statistics Used in Disproportionality Analyses. 
RRR=Relative Reporting Ratio, PRR=Proportional Reporting Ratio, ROR=Reporting Odds 
Ratio, IC = Information Component. 
 Reports for Event 
‘X’ 
Reports for All 
Other Events 
Total 
Reports for Product ‘J’ A B A+B 
Reports for All Other 
Products  
C D C+D 
Total A+ C B+ D N=A+B+C+D 
 











��(������� ����� �|������� �)�� (������� ����� �|��� ������� �) 
ROR 
� �⁄� �⁄  ��(������� ����� �|������� �)��(������� ����� �|��� ������� �)��(��� ������� ����� �|������� �)��(��� ������� ����� �|��� ������� �)  
IC ���2 ��� ���2 ��(������� ����� �|������� �)�� (������� ����� �)  
EBGM ��������� �����(log�) λ=RRR, where A is assumed to represent a Poisson process in which the Poisson parameter is a mixture 
of two gamma distributions 
 
As summarized by Hauben in 2005, (88) “The question of which, if any, data mining 
algorithm outperforms the others has been vigorously debated… There is currently no 
theoretical basis or firm empirical support establishing universal thresholds defining a 
potential signal, although some have been recommended”.  Nearly a decade later, Ahmed 
noted that none of the current methods could yet be “considered an undisputed 
reference”. (193)  In this research, the EB05, defined as the one-sided 95% lower confidence 




problem, consistent with usage within the FDA. (139)  The FDA typically uses an EB05 ≥ 2 to 
indicate a high level of confidence that a product-adverse event combination occurs two 
times more often than would be expected by chance and is frequently used to identify 
signals for further evaluation.  However, Harpaz (194) recently demonstrated that values 
closer to 1 provide a better balance between sensitivity and specificity, albeit with a 
potentially higher false positive rate.  Thus, heat map displays (195) were used to explore 
the signaling strength over a range of values.  In addition to the EB05, two additional widely 
used signal measures were also assessed: the lower two-sided 95% confidence interval of 
the PRR (PRR025) and the lower two-sided 95% confidence interval of the BCPNN 
(BCPNN025).  The PRR05 is used by the European Medicines Agency (EMEA) and the 
Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom, and 
their signal threshold definition of a PRR05 > 1 where the number of individual cases is ≥ 3 
was utilized in this research. (196)  Adopting the criterion used by the World Health 
Organization’s Uppsala Monitoring Centre, a positive value of the BCPNN025 was used to 
denote a potential signal. (197) 
3.3 Summary 
Together with Chapters 1 and 2, this chapter provides a brief overview of the text 
classification algorithms and the DPA signal detection measures that were utilized in this 
project.  For the interested reader, the fields of text and data mining are endowed with a 
rich library of reference material.  This chapter includes citations to some of the material 
that I found to be the most useful.  These references or simple internet searches will 












Chapter 3 introduced the reader to the analytical techniques used in this research, 
focusing on their methodological foundations.  This chapter describes the specific 
implementation of the text and data mining methods discussed in the previous chapter.  
Section 4.1 details the study design, and Section 4.2 discusses the data sources that were 
used in this research.  Sections 4.3-4.7 then specify the methods used to accomplish the 
goals of this project.  Finally, recognized limitations of this research are discussed in Section 
4.8. 
4.1 Study Design 
This was a retrospective cohort study using records from the publicly available 
portion of the MAUDE database from June, 2001 (the date of first manufacturing of an ICD 
lead in the FDA’s Medical Device Recalls Database (198)) through 2013.  As discussed in 
Sections 1.2.5, 2.3 and Appendix D, since 2004 ICD leads from two companies have been the 
subject of Class I recalls – Medtronic’s Sprint Fidelis and SJM’s Riata and Riata ST.  These 
recalls provided an opportunity to retrospectively evaluate MAUDE adverse event narrative 
reports for potential predictive safety signals. 
This study (Protocol Number 14-1884) was reviewed by the Colorado Multiple 
Institutional Review Board (COMIRB) on October 9, 2014.  As the primary data source used 
in this research was the de-identified, publicly available FDA MAUDE database, this study 




current regulations and in accordance with the Office for Human Research Protections and 
FDA guidelines. 
4.2 Data Sources 
The primary data source for this study was the FDA’s medical device spontaneous 
reporting system database known as MAUDE.  In addition, the FDA’s database of recalled 
medical devices was utilized to identify those records in the MAUDE database that were 
associated with products that have been recalled from the market.  Section 4.2.1 describes 
the MAUDE database, and Section 4.2.2 discusses the database of recalled medical devices. 
4.2.1 FDA MAUDE Database 
The FDA’s MAUDE database contains reports of adverse events and product 
problems involving medical devices, including reports of suspected device-associated 
deaths, serious injuries and malfunctions.  The publicly-available MAUDE database used for 
this research contains manufacturer, device, (non-identifiable) patient, and narrative 
adverse event information from MedWatch Form 3500 (Appendix A).  The MAUDE database 
includes reports submitted by user facilities since 1991, those from distributors and 
voluntary submitters since 1993, and reports submitted by manufacturers since 1996. 
The FDA’s Center for Devices and Radiological Health (CDRH) provides access to 
MAUDE information through two mechanisms: a search engine which includes data up to 
the most recent monthly update, and downloadable zipped data files updated weekly.  
Because the search engine results only span the last 10 years, are limited to a maximum of 




processed (Figure 4.1), the analyses for this research utilized the downloadable MAUDE 
data files. (36)  Retrieval of records from this database is discussed in Section 4.4.1. 
 
 




4.2.2 FDA’s Medical Device Recalls Database 
The FDA’s database of recalled medical devices (198) contains medical device recalls 
since November, 2002, and is updated frequently as new recalled products become known.  
As of the time of this project, files containing aggregate recalled medical device information 
are not available.  Instead, information from this database was retrieved through a quick or 
advanced search (Figure 4.2), returning a maximum of 500 records.  This database was used 
to inform the recalled lead indicator (LEAD_RECALL: yes/no) assignments attached to each 
MAUDE record as further described in Section 4.5.1. 
 
 
Figure 4.2: FDA Medical Device Search Screens. 
The Quick (a) and Advanced (b) search screens used to access the FDA’s Medical Device 
Recalls database. 
 
4.3 Research Methods 
To accomplish the goals of this project, the research methods were divided into the four 




analysis database, processes which Witten states “usually consumes the bulk of the effort 
invested in the entire data mining process.” (80)  The third step entailed training and 
selecting the text classification model and using it to generate recall predictions.  Lastly, 
hypothesis testing and sensitivity analyses were accomplished in Step 4.  The next four 
sections (Sections 4.4-4.7) detail the methods utilized in each of these steps: 
 
 
Figure 4.3: The Project’s Research Methods in Four Steps. 
The four research method steps are identified in the center blue blocks.  The data source 
input and resulting data output files are shown as gray blocks.  1° = Primary; 2° = Secondary; 
ICD = implantable cardioverter-defibrillator; SVM = support vector machines.  SAS and Weka 
were software packages used to accomplish the data processing and analyses. 
 
4.4 Create Analysis Dataset 
The process of creating the initial analysis dataset was divided into two phases: 1) 




date range and products of interest to this research project.  The methods used for each of 
these phases are detailed below.  
4.4.1 Import and Link the MAUDE Files 
MAUDE data files are grouped into four primary types (Master, Device, Patient and 
Text) and two related supplemental files (Device Problems and Problem Code Descriptions) 
as described in Table 4.1.  Data elements within each file are pipe-delimited, with one 
record per line.  A header row containing field names is present for the Master and Device 
data files.  Field names were manually entered for the remaining files using information 
provided on the MAUDE download file web page. (36)  A full list of data elements contained 
in each file is provided in Appendix C.  When referencing fields by name, they appear in 
SMALL CAPITAL LETTERS. 
Each of the individual MAUDE zipped files were downloaded and extracted using 
WinZip (199) and then imported into and saved as SAS data files. (200)  During the import 
process, the “main” files (i.e., those files in Table 4.1 without a file name suffix) were 
updated in SAS with data received prior to 2014 from the “change” files so as to ensure 
inclusion of the most complete information available through 2013.  All file imports were 
reviewed against the raw data to verify record counts and inclusion of the first and last 
records within each raw data file.  To insure appropriate file updating, validation checks 
were performed to verify that counts remained constant after applying the “change” files, 





Table 4.1: MAUDE File Types and Naming Conventions. 
 
File Type File Name File Name Suffix Description 
Master mdrfoi None Master records for the current year 
# Fields: 75 
Header Row: Yes 
add New Master records for the current 
month 
thru<year> Cumulative Master records from 
1991 through the previous calendar 
year  
  change Changes to existing Master records 
Device foidev None Device data for the current year 
 
# Fields: 45 
Header Row: Yes 
add New Device data for the existing 
month 
thru1997 Cumulative Device data through 
1997 
<year> Annual Device data, year = 1998-
previous calendar year 
change Changes to existing Device data 
Patient patient None Patient data for the current year 
 
# Fields: 5 
Header Row: No 
add New Patient data for the current 
month 
thru<year> Patient data through the previous 
calendar year 
change Changes to existing Patient data 
Text foitext None Text data for the current year 
 
# Fields: 6 
Header Row: No 
add New Text data for the existing 
month 
thru1995 Cumulative Text data for data 
through 1995 
<year> Annual Text data for data, year = 
1996-previous calendar year 
change Changes to existing Text data 
Device 
Problem 
foidevproblem None Device Problem codes 
 
# Fields: 2 




deviceproblemcodes None Mapping of problem codes to their 
description 
 
# Fields: 2 







The FDA-generated MDR REPORT KEY was used to link files in SAS.  DEVICE SEQUENCE NO 
and PATIENT SEQUENCE NO information were also utilized to identify records linked to multiple 
devices or patients as described in Chapter 5. 
4.4.2 Select Cohort Records 
The analysis dataset was limited to non-duplicative MAUDE adverse event reports 
with a non-null adverse event narrative description received between June 2001 (the date 
of first manufacturing of an ICD lead in the FDA’s Medical Device Recalls Database) and 
December 2013.  An internally-generated FDA EVENT KEY field links multiple sources to a 
single event.  The EVENT KEY and the MDR REPORT KEY were used to identify duplicate records. 
As shown in Table 4.2, Cohort 1 was comprised of all records having an ICD lead 
product code (NVY), or an ICD product code (MRM, NIK, LWS) where the product name 
contained the word “lead” or “electrode”.  To evaluate the model’s ability to predict recalls 
of medical device products that were increasingly differentiated from ICD leads, the analysis 
dataset was augmented to include records from three other types of medical devices: non-
wearable automated external defibrillators (AEDs) identified by device product code MKJ 
(Cohort 2, most closely related to ICD leads); intra-aortic balloons (IABs) identified by device 
product code DSP (Cohort 3); and uncemented metal-on-metal total hip replacement (MoM 






Table 4.2: Analysis Cohorts. 
ICD = implantable cardioverter-defibrillator; AED = automated external defibrillator; IAB = 
intra-aortic balloon; MoM THR = metal-on-metal total hip replacement.  In order to 
distinguish between ICD and ICD lead problem reports, product codes LWS, MRM and NIK 
were limited to records where BRAND NAME, BASELINE BRAND NAME, GENERIC NAME or GENERIC 
BRAND NAME contained the word “LEAD” or “ELECTRODE”. 
Cohort Product Area Product Code FDA Device Name 
1 - ICD Leads Cardiovascular LWS Implantable Cardioverter Defibrillator  
MRM Defibrillator, Implantable, Dual-Chamber 
NIK Defibrillator, Automatic Implantable 
Cardioverter, With Cardiac 
Resynchronization (Crt-D)  
NVY Permanent Defibrillator Electrodes 
2 – AEDs Cardiovascular MKJ Automated External Defibrillators (Non-
Wearable) 
3 – IABs Cardiovascular DSP System, Balloon, Intra-Aortic And Control 
4 – MoM THR Non-Cardiovascular KWA Prosthesis, Hip, Semi-Constrained (Metal 
Uncemented Acetabular Component) 
 
Record selection in Cohorts 2-4 followed the same criteria used for Cohort 1 (non-
duplicative, non-missing adverse event narrative description, submitted between June 2001 
and December 2013), but was additionally limited to recalled products only.  Using the SAS 
PROC SURVEYSELECT procedure, one thousand records were randomly selected from each 
of the non-ICD lead groups having a total in excess of 1,000 MAUDE reports; otherwise, all 
records within the cohort were used. 
Finally, for recalled products, only reports received by the FDA prior to the date of 







Figure 4.4: Analysis Cohort Selection from the MAUDE Database. 
ICD = implantable cardioverter-defibrillator; AED = automated external defibrillator; IAB = 




4.5 Prepare Analysis Database 
Prior to building and evaluating the machine learning models, the data had to be 
prepared for subsequent analysis.  This activity was divided into two phases: 1) labeling 
each MAUDE record with a product identifier, recall classifier and censoring indicator 
(Section 4.5.1), and 2) pre-processing the adverse event narrative field to ready it for text 
classification modeling (Section 4.5.2). 
4.5.1 Product, Recall and Censoring Information Labeling 
MAUDE information identifying the medical device associated with a reported 
adverse event or product problem is contained in free-entry text fields.  In order to identify 
records associated with recalled products, this unstructured information had to first be 
coalesced into a meaningful product identifier.  Using the manufacturer, brand name, 
generic name and model number information provided in the MAUDE database, and 
matching this to product information published by manufacturers, regulatory agencies and 
scientific journals, a product identifier was assigned to each record in Cohorts 1-4. 
Next, as illustrated in Figure 4.5, using the assigned product identifier and data 
reported through 2013 in the FDA’s database of recalled medical devices (Section 4.2.2, 
Appendix D), each MAUDE record was labeled with a recalled lead indicator (LEAD_RECALL: 
yes/no) and recall level (RECALL_CLASS: 0=Not Recalled, 1=Class I Recall, 2=Class II Recall, 
3=Class III Recall).  This labeled data was used to train the text classification models and to 






Figure 4.5: Process for Labeling MAUDE Records with Recalled Product and Recall Level 
Indicators. 
Finally, in order to minimize the impact that product recall knowledge may have on 
the information reported in the MAUDE database, a Class I recall censored indicator 
(CENSOR_1: included/not included) was assigned to each record.  Table 4.3 summarizes the 
LEAD_RECALL, LRECALL_CLASS and CENSOR_1 designations that were assigned to each record in 
SAS.  This table also provides the Appendix location containing the detailed product 
information determined for each cohort using the FDA’s database of recalled medical 
devices.  All non-recalled products were assigned CENSOR_1 = included (uncensored).  As 
shown in Table 4.3 and illustrated in Figure 4.6, the CENSOR_1 indicator for recalled products 
was based upon the date the MAUDE report was received and the date of device recall in 
the FDA’s database of recalled medical devices.  For records associated with recalled 
medical devices, a report was censored (CENSOR_1= not included) when the MAUDE report 




Table 4.3: Assignment of ICD Lead and Medical Device Recalled Indicators. 
This table summarizes the recalled lead, recall class, and censored indicator assignments 
made for each MAUDE record.  Product-specific recall information used to label each record 
is provided in Appendix D table cited in the last column.  ICD = implantable cardioverter-
defibrillator; AED = automated external defibrillator; IAB = intra-aortic balloon; MoM THR = 
metal-on-metal total hip replacement. 
Cohort 
Recalled 








1=Class I Recall, 
2=Class II Recall, 
3=Class III Recall 
Recalled Medical Device: 
Censored = Included, if 
MAUDE Date Received < 
Product Recall Date 
Censored = Not Included, 
otherwise 
Non-recalled Medical 
Device (ICD Lead): 
Censored = Included 
Table D.1 
2 - Recalled AEDs 
No 
1=Class I Recall, 
2=Class II Recall, 
3=Class III Recall 
Table D.2 
3 - Recalled IABs Table D.3 







Figure 4.6: Illustration of Process Used to Determine the Censoring Indicator. 
As shown in this figure, for recalled medical devices such as the Riata ICD lead, MAUDE 
reports received between the date a product enters the market through the data of the 
recall were included in subsequent analyses.  Reports received after the recall notification 




4.5.2 Preprocess the Adverse Event Text 
Both SAS and Weka were utilized to preprocess the adverse event narrative text.  
Within SAS, Perl regular expression matching was used to replace (anonymize) specific 
mentions of manufacturer and product names/model numbers with placeholder text so as 
to avoid building models that predicted a recall by virtue of mention of a recalled product 
name.  For example, manufacturer references such as Medtronic and Boston Scientific were 
replaced with the generic placeholder text MFRREF.  Model name and number references 
such as Sprint Fidelis, 6948, Riata, and 7041 were also replaced, using the generic text 
MODREF. 
Once the data anonymization was complete, Weka, a machine learning software 
suite developed at the University of Waikato, New Zealand, (201) was used to further 
preprocess the adverse event narrative text.  The text field was converted into a feature 
vector using the StringToWordVector filter.  As shown in Figure 4.7, there are several 
possible configurations available for this filter.  The StringToWordVector filter was typically 
configured to implement the AlphabeticTokenizer which created a feature set of single 
words, removing numbers and punctuation.  As discussed in later Chapters, since use of a 
string subsequence kernel with the SVM classifier proved to be computationally unfeasible, 
the NGramTokenizer was also used to create datasets that also included word bigrams 






Figure 4.7: Weka StringToWordVector Attribute Filter. 
Among the other StringToWordVector configurable settings, stemming, stop words 
and feature reduction were explored to reduce data noise.  Stemming is a method of 
reducing variance in data by regularizing grammatical variants such as singular/plural and 
present/past tense forms (e.g., exchanging “displ” for the words “display”, “displays”, 






employed to recursively stem words longer than two characters until there were no further 
changes.  Variance can also be reduced by removing stop words - frequently occurring 
words such as articles, conjunctions, and prepositions (e.g., “and”, “the”, “as”, “at”, “be”).  
When employed, the standard (Weka-3-7) stop words list was utilized.  For longer narrative 
text, it may be beneficial to explore the use of word counts; however, as the MAUDE 
adverse event descriptions were not extremely lengthy, simple presence/absence of 
features was assumed to be sufficient, and the option for normalizing word frequencies by 
the document length was not used. 
Finally, in order to reduce the dimensionality of the data, the unigram models were 
generated with and without first performing attribute selection using the 
GainRatioAttributeEval attribute evaluator in Weka’s AttributeSelection filter.  This attribute 
evaluator uses the Ranker search algorithm to rank attributes according to their Gain Ratio 
(see Section 3.1.1 for a related discussion of Gain Ratio).  The Ranker was configured to 
keep all attributes providing any additional information (i.e., threshold of 0). (78, 85)  
Because of the large number of potential attributes for the bigram and trigram datasets (as 
these also included lower-level n-grams), both stemming and feature reduction were 
utilized to reduce the number of features to a more computationally manageable size.  
Table 4.4 presents a summary of the pre-processing parameter combinations that were 





Table 4.4: Data Pre-Processing Matrix. 
The parameter filtering configurations used to pre-process the data prior to model building. 
Stemming Stop Words Feature Reduction N-Grams 
No No No Unigrams 




No Yes No Unigrams 
No No Yes Unigrams 
Yes Yes Yes Unigrams 
 
4.6 Train, Select and Test Text Classifiers 
Section 4.5 detailed the methods which were employed to transform the MAUDE 
records into a form suitable for text mining.  Using the labeled records (supervised learning) 
determined in Section 4.5.1 and the feature vectors determined from preprocessing the 
text data as described in Section 4.5.2, the text classifiers were then trained to predict 
recalled leads (PREDICTED_WEKA: yes=recalled, no=not recalled).  This section describes the 
implementation in Weka of the three alternative text classification models utilized in this 
research.  Application of decision trees methods is discussed in Section 4.6.1, Naïve Bayes 
models in Section 4.6.2, and support vector machines (SVMs) in Section 4.6.3.  Section 4.6.4 
discusses approaches for addressing class imbalanced data, and Section 4.6.5 then details 
the model training, testing and selection procedures. 
4.6.1 Build Decision Tree Models 
Section 3.1.1 describes the process by which decision trees are generated.  In Weka, 
C4.5 decision trees are generated using the trees > J48 classifier.  Figure 4.8 depicts the full 




confidence factor used for pruning, the default parameters for this classifier were used in 
this project.  The J48 confidenceFactor was initially evaluated at 0.01, 0.10, and 0.25 










4.6.2 Build Naïve Bayes Models 
Section 3.1.2 provides a methodological foundation for Naïve Bayes models.  In 
Weka, the Naïve Bayes classifier is implemented using the bayes > NaïveBayes classifier.  




Figure 4.9: Weka NaïveBayes Classifier Parameters. 
 
 
4.6.3 Build Support Vector Machine (SVM) Models 
Section 3.1.3 discusses the motivation behind SVMs.  In Weka, the SVM model was 
implemented using the functions > SMO (sequential minimal optimization) classifier.  Figure 
4.10 shows the default parameter settings for the SMO function.  With the exception of the 




for the model generation performed for this dissertation Table 4.5 shows the complexity 









Table 4.5: Initial Weka SMO (SVM) Parameter Selection Matrix. 
 
Kernel Parameter Values 







































                                                     
 




4.6.4 Learning from Imbalanced Data 
Imbalanced class distributions, where the representation of one class (e.g., non-
recalled leads) is much more prevalent than the other class or classes (in this work, the 
opposing class of recalled leads), can seriously impact machine learning algorithms.  
Because standard classification algorithms attempt to minimize the percentage of incorrect 
predictions, with unbalanced data the model becomes weighted to the predominant class.  
For example, in a dataset with 99% negative and 1% positive samples, one can generate a 
model with 99% accuracy simply by predicting that all new samples are negative.  Figure 
4.11a illustrates an example based on MAUDE data where a classifier trained on imbalanced 
class data demonstrated good performance overall (Weighted Avg. row) and for the 







Figure 4.11: Example showing Machine Learning Results with Class-Imbalanced Data. 
This example shows the performance results of a Linear SVM classifier, by Class, on original 
class-imbalanced data (a) and class-balance adjusted data (b).  Note in (a) that the model 
performance is quite good for the majority Class = “No” (non-recalled leads), but it is much 
poorer for the class of interest, the recalled (Class = “Yes”) group.  The Weighted Avg. row 
demonstrates that the overall model performance is heavily weighted to the majority class 
results.  Class balance adjustment techniques can provide greater emphasis on the minority 




The performance of classifiers trained on imbalanced data, where records belonging 
to the minority class are misclassified more often than those belonging to the prevalent 
class, is often suboptimal. (202)  Much research has been devoted to exploring approaches 
for adjusting class-imbalanced datasets. (202-208)  As shown in Figure 4.11b, these 
adjustment approaches can provide improved model performance within the minority class.  
Since the intent of this dissertation research was to recognize lead recalls, errors within this 
group were of more importance than those for non-recalled leads.  Therefore, along with 
evaluating text classification models on the unadjusted datasets, the following standard 
adjustment approaches were also evaluated: 
1. Cost adjustment:  Training instances are reweighted to increase the weight of 
mistakes made on the minority (recalled ICD lead) class. (209)  Table 4.6 shows 
an example of error weighting without (unadjusted) and with cost adjustments.  
In this cost-adjusted example, false negative errors are assigned twice the 
weight as false positive errors.  Different cost adjustments were explored until 
model performance deteriorated.  In addition, Weka’s ClassBalancer instance 
filter was utilized to achieve a model with equal class weighting – that is, one 
balancing positive and negative examples. 
2. Under-sampling:  A random subset of the majority class is selected and 
combined with the entirety of the minority class records to form a training 
dataset in which the recalled and non-recalled lead classes are better balanced.  




Weka’s SpreadSubsample instance filter to achieve equal numbers of recalled 
and non-recalled ICD leads. 
3. Over-sampling:  A technique in which the minority class is randomly over-
sampled to increase its representation.  A particular over-sampling technique 
referred to as SMOTE (synthetic minority over-sampling technique), in which 
the minority class is over-sampled by synthetic examples approximating the 
closest class nearest neighbors, was used in this study. (208) 
Table 4.6: Cost Adjustment Matrices. 
The first table (a) shows the standard weighting of false negatives (FN) and false positives 
(FP), and the second table demonstrates a weighting scheme in which FNs are assigned 
twice the weight of FPs.  Correct classifications (true positives and true negatives) are 
typically assigned a value of 0 signifying that a success incurs no cost. 
Table 4.6a:  No Cost Adjustment  Actual Classification 




Recalled 0 FP = 1 
Not Recalled FN = 1 0 
 
Table 4.6b:  Cost Adjustment Cost2  Actual Classification 




Recalled 0 1 
Not Recalled 2 0 
 
Cost-sensitive learning has the effect of duplicating the instances of the minority 
class by multiplying their occurrences by the assigned weight; however, the size of the initial 
dataset is not increased.  Under-sampling results in a smaller, and hence, more 
computationally efficient dataset, but at the potential expense of discarding potentially 





load and can be prone to over-fitting.  As a result, ensemble class-imbalance adjustment 
approaches are often recommended. (202, 210, 211)  This study evaluated several class-
imbalance adjustment approach combinations, particularly the sequential usage of SMOTE 
to increase the representation of the minority class, followed by under-sampling to balance 
the number of recalled and non-recalled records. 
4.6.5 Select Text Classification Model 
In order to learn a model, optimize its parameters and measure its performance 
while minimizing the risk of model over-fitting, the analysis data were randomly divided into 
subsets used for training (67%) and for testing (33%).  Model training was accomplished 
using ten-fold cross-validation as shown in Figure 4.12.  Various performance measures, 
including recision, recall and F1 scores (defined in Chapter 3, Table 3.1), were generated for 
each iteration, and the results averaged to provide an estimate of model performance for 
each text classification approach (decision tree, Naïve Bayes, and SVM), parameter 
configuration and class imbalance strategy. (78, 80, 212, 213)  Considering F1 scores, areas 
under the precision-recall curves (PRC), and execution times, models were compared 
within, and then across, text classification approaches to select the modeling approach to 
be applied to the held-out test data.  Final model performance statistics were then 
generated from the held-out test data.  As discussed in the Section 4.7, this model was used 






Figure 4.12: Training, Validation and Testing Methodology. 
A random sample of 67% of records were selected for training, with the remaining records 
used for testing.  Ten-fold cross-validation (10-fold CV) was used in the training and 
validation phase, with the averaged results used to select the best parameter configuration 
and text classification approach among decision trees, Naïve Bayes, and support vector 
machines.  Final model parameters were generated by applying the selected model and 
parameter configurations to the held-out testing dataset. 
 
4.7 Perform Hypothesis Testing and Sensitivity Analyses 
The ultimate goal of this research was to determine whether early signals of 
subsequent Class I ICD lead recalls can be predicted using adverse event report descriptions 
in the MAUDE database.  Methods used to accomplish this goal are provided in Section 
4.7.1.  This project also evaluated the model’s ability to predict recalls of medical device 
products that were increasingly differentiated from ICD leads (Section 4.7.2) and to forecast 
less serious ICD lead recalls (Section 4.7.3).  Finally, sensitivity analyses examined the 
influence of MAUDE reports submitted for particular ICD lead brands on the overall 
predictive ability of the model, and the effect of using cumulative data cohorts over time to 




methodology.  Methods used for these analyses are described in Sections 4.7.4 and 4.7.5, 
respectively.  SAS, Weka and RStudio software were used to accomplish these analyses. 
(200, 201, 214)  All statistical tests were conducted using a significance level of 5%. 
4.7.1 Evaluate Primary Hypothesis of Early Prediction 
Once a text classification model was determined (Section 4.6), the goal was to 
determine whether the model predictions provided an early signal of product problems in 
advance of the actual Class I recalls of the Medtronic Sprint Fidelis and SJM Riata and Riata 
ST ICD leads.  To accomplish this, the selected text classifier was applied to the entire 
dataset (training and testing) in Weka, generating a Class I ICD PREDICTED_WEKA (yes/no) for 
each record.  The Weka predictions were then re-merged with other dataset variables in 
SAS, and the resulting data were analyzed using the RStudio PharmacoVigilance Signal 
Detection (PhVidD) package (214) to generate  disproportionality statistics (Section 3.2).  
The DPA measures were generated for the entire dataset, and separately for the held-out 
test data only.  Analyses were generated by individual quarter, and for cumulative data 
subsets across time using quarter-year increments in a manner similar to Hauser (94) and 
Duggirala. (93)  DPA estimates were also generated by specific ICD leads, and leads grouped 
by brand.  Statistics were tabularized and graphically presented using heat maps (195) to 
determine whether any ICD lead models were associated with disproportionately more 
predicted recalls than would be expected by chance alone, and at what point in time a DPA 
signal, if present, first became apparent.  DPA heat map color breaks were generated at the 




Table 4.7: Color Break Points by DPA Signal Strength. 
EB05 = 90% lower confidence interval of the empirical Bayes geometric mean; BCPNN025 = 
95% lower confidence bound of the Bayesian confidence neural network; PRR025 = 95% 
lower confidence bound of the proportional reporting ratio. 
DPA Statistic Signal Strength by Color 
EB05 1 - 1.5 1.5 - 2 2 – 2.5 2.5 – 3 3 – 4 4 – 5 5-7 > 7 
BCPNN025 0 - 0.25 0.25 - 0.5 0.5 - 0.75 0.75 - 1 1 - 1.5 1.5 - 2 2 - 2.5 < 2.5 
PRR025 1 - 1.25 1.25 - 1.5 1.5 - 1.75 1.75 - 2 2 - 2.5 2.5 - 3 > 3 
 
4.7.2 Evaluate Secondary Hypothesis 1 of Model Performance across Non-ICD Lead 
Medical Devices 
Cohorts 2-4 (see Section 4.4.2) were selected to represent an increasing order of 
expected differentiation from the ICD leads comprising Cohort 1 in order to test the 
hypothesis that the model’s predictive ability would increasingly deteriorate when applied 
to medical devices less increasingly dissimilar to ICD leads.  The selected text classification 
model (Section 4.6.5) was applied to each of the Cohort 2-4 datasets to obtain a recall score 
(sensitivity) for each cohort.  Spearman’s rank-correlation coefficient (215) was utilized to 
examine the association between data cohort and model performance. 
4.7.3 Evaluate Secondary Hypothesis 2 of Model Performance for Non-Class I Recalls 
The text mining models were trained using a dataset labeled with Class I lead 
recalled indicators.  To test the hypothesis that the model’s predictive ability would be 
higher for the group of Class I recalled ICD leads than for less serious (Class II or Class III) 
recalls, a subset consisting of all recalled ICD leads was selected, and then grouped by recall 




period, the proportions of true positives and false negatives for each group were compared 
using a chi-square test. (215, 216). 
4.7.4 Sensitivity Analyses Exploring the Impact of Specific Lead Information 
The ICD lead predictions were based upon a text classification model trained on 
known recalls.  A practical question is how useful will this model be in signaling potential 
product problems of future ICD leads?  As discussed in the Literature Review, one could 
apply novelty detection methods to identify new findings signaling a potential ICD lead 
problem; however, failure mechanisms for ICD leads are well-defined (63, 75).  As such, one 
way to evaluate the future predictive ability of the model is to assess the influence on the 
developed model of adverse event reports submitted for particular ICD lead products.  That 
is, if reports for a particular ICD lead product were excluded from the model training, does 
the resulting model still perform well when predicting the ICD Lead Recalled classifiers? 
To conduct this sensitivity analysis, the same classifier methodology and parameters 
selected for the primary model (Section 4.6.5) were applied to each “leave one out” training 
dataset.  The resulting “leave one out” text classification model was then applied to the full 
complement of test data, including records for the ICD lead removed from the training 
dataset.  Training and testing results (precision, recall, F1 score, PRC area) were generated 
for each “leave one out” dataset across all ICD leads combined.  Using the held-out testing 
data, the proportions of correct predictions, by ICD lead, for each “leave one out” model 




4.7.5 Sensitivity Analyses Exploring Data Accumulated Over Time 
The primary analysis in this dissertation applied the trained text classification model 
to all records across the entire study period.  To investigate the impact of using only those 
records accumulated up to a particular time point – which may more closely resemble how 
this methodology may be used in practice – composite training and testing datasets were 
created using only those MAUDE records received thru 20XX (where XX = 04 to 12).   
The same classifier methodology and parameters selected for the primary model 
(Section 4.6.5) were applied to each cumulative time group, and the resulting trained model 
was then applied to the corresponding cumulative time test dataset.  A variety of 
performance metrics, including recision, recall, F1 score, and PRC area, were generated for 
each cumulative time subset for both the training and testing subsets.  In addition, a 
detailed evaluation of the percentage of correction predictions, by ICD lead, was generated 
for each time subset. 
4.8 Study Limitations 
Although regulation mandates the reporting of certain device-related problems, 
underreporting of adverse events is a known issue, and it is estimated that only  
1-10% of events are reported to the FDA despite recognition of the importance of 
comprehensive reporting. (37, 217)  The results of this research reflect data submitted to 
the FDA, which may not be representative of all experience with ICD leads.  In addition, 
MAUDE data is not independently verified.  Consequently, it may be incomplete or contain 
errors which resulted in the misclassification of the product and/or recall status of some 




lead when an adverse event report was submitted to the FDA, would have (incorrectly) 
been assigned a LEAD_RECALL = no; whereas a non-SJM Riata ICD lead misidentified as a Riata 
ICD lead would have been (incorrectly) labeled as LEAD_RECALL = yes.  While such mistakes 
were expected to occur randomly in both directions (non-differential misclassification) and 
pose an issue for any public-reporting database, they could weaken the predictive model.  
Non-random misclassification, if present, could bias the modeling results. 
This analysis was based on the date the MAUDE report was received, rather than the 
date the event occurred.  This choice was made as 1) the DATE OF EVENT field was only added 
to the MAUDE database in 2006 and is missing for 19% of records, and 2) the DATE OF EVENT 
field is not quality controlled and included dates ranging from 1901 through 3013.  For 
records in which both date of event and date received were populated, the majority of 
reports were submitted promptly (75% within 3 months and 90% within 6 months).  
Therefore, using the date the report was received in lieu of the event data likely had 
minimal impact; however, reporting delays could have resulted in a small number of records 
to be mistakenly censored (excluded) from the analysis if the event occurred prior to the 
date of the product’s recall, but the report was not received until after the recall.  Long lags 
between the occurrence of an adverse event and its reporting hampers the usefulness of 
any signal-detection approach. 
In order to minimize the potential impact that recall knowledge may have on how an 
adverse event was described, reports pertaining to a product that was recalled were 
censored if they were received after the recall date.  However, public dissemination of 




considering the results presented in Chapter 7, one should consider the possibility that early 
signals could reflect changes in the reporting of information based upon prior knowledge of 
a product’s problem. 
Ambiguity is a primary problem when assessing narrative data. (218)  For example, 
the term “lead” when used as a noun may refer either to the wire connecting the 
pacemaker or defibrillator to the heart or to the chemical element “Pb”; as an adjective, the 
word “lead” may describe the principal problem or presenting symptom; and as a verb, 
“lead” may describe how the event was managed or directed.  Signals generated in this 
dissertation, or for other domains, are not intended, nor should be considered, as “proof” 
of a product problem.  Any signals determined by the developed model require human 
review and likely subsequent verification, for example through targeted studies or more 
intensive monitoring. 
The “best” model choice involves a host of tradeoffs, and each model has 
disadvantages: decision tree models are easy to interpret, but can get quite large and 
complex, cannot predict beyond the range of the training data and often don’t predict 
extreme values accurately; Naïve Bayes models assume conditional independence; SVM 
models require the selection of a kernel and can be slow to train; and neither Naïve Bayes 
or SVM results are easily interpretable.  While the selected modeling approach is defended, 
others may weigh the pros and cons of various models differently, and detailed results are 
provided to allow readers to form their own conclusions about the best modeling approach 
In its September 2012 report, Strengthening Our National System for Medical Device 




old system, and announced its plan to develop a replacement.  A year later, the November 
Research Group announced that its Pharmacovigilance Report Intake and Managed Output 
(PRIMO) software system had been selected as the new system. (219, 220)  I anticipate that 
any medical device SRS replacement will incorporate some form of adverse event narrative 
description, and as such, the methods developed using the MAUDE database should 
translate to its replacement.  However, it is likely that aspects of the developed approach – 
for example, how duplicate records or recalled products were identified - will need to be 
revised to accommodate the new system, once available. 
Recent technological innovations may ultimately replace the use of leads to connect 
an ICD with the heart.  Subcutaneous ICDs eliminate the need for conventional transvenous 
leads by placing a sensor under the skin along the breastbone in front of the heart to both 
monitor the heart's rhythm and deliver shocks when needed. (221, 222)  Small, leadless 
cardiac pacing devices implanted directly in the heart have also demonstrated promise 
(223, 224) and may one day be extended to cover ICD functionality.  While these therapies 
are currently limited to certain patient populations, the recent spate of innovations 
designed to avoid the ICD and pacemaker’s “Achilles heel” (225) may one day remove the 
need for a wire tether between the ICD and heart altogether.  Although this research will 
hopefully lay the foundation for using text mining within SRS databases to predict 
subsequent corrective actions across multiple product and event types, it is directly tied to 
problems associated with ICD leads.  As such, it is possible that the above or future 






CREATE ANALYSIS DATASETS4 
 
Creating the analysis datasets was the first of the four research method steps 
undertaken as part of this project.  This first step was divided into three phases: 1) 
importing the native MAUDE files; 2) determining their structure; and 3) selecting and 
merging the records specific to the date range and products of interest to this research.  
The results of these phases are detailed below. 
5.1 Import MAUDE Files 
Spanning a total of 135 fields, as discussed in Section 4.4.1, MAUDE files are grouped 
into four primary types (Master, Device, Patient and Text) and two related supplemental 
files (Device Problems and Problem Code Descriptions).  The Master and Patient files 
aggregate data across time, while the Device and Text files are grouped by year.  Both base 
and change data files are available for the four primary file types.  As a result, a total of 
forty-four zipped files containing data through 2013 were downloaded on February 15, 
2014 from the MAUDE download file website.  A GitHub repository with the programs used 
to import the MAUDE data sets into SAS is available. (226)  Table 5.1 summarizes the 
number of native files and records processed.  Validation checks confirmed that record 
counts in SAS matched those of the raw files.  In addition, dataset totals were verified 
                                                     
 




before and after applying the change file updates to insure that only change data 
information received prior to the study’s 2013 cut-off date was incorporated. 
Table 5.1: Number of Files and Records Imported into SAS by MAUDE File Type. 
 
MAUDE File Type 
Number of Imported Files 
(Including Change Files) 
Number of 
Records 
Master 2 3,216,343 
Device 18 3,234,297 
Patient 2 3,200,626 
Text 20 6,528,441 
Device Problems 1 1,496,584 
Problem Code Descriptions* 1 1,597 
* Includes 598 component codes and 13 patient codes. 
 
The MAUDE download file webpage provides a brief description of the fields 
contained in each file type, along with information for joining the files together.  Although 
this site indicates it might be necessary to add an extra character at the end of the first 
record prior to importing some of the MAUDE files, this step was not required when reading 
the datasets into SAS or RStudio.  However, it was necessary to account for the infrequent 
occurrence (approximately one in every two to four million records) of non-printing 
characters.  When present, these characters initially caused SAS to process a single record 
as if it represented multiple observations, resulting in data type and size conflicts during the 
file import process.  After determining the underlying issue, the appropriate string 
termination was accomplished using the TERMSTR=CRLF option which directs SAS to only 
accept a “complete return and line feed as an end-of-record marker.” (227) 
In addition, several files used double quotation marks to denote an exact word or 




inches, e.g., 7" MICROBORE NON-VENTED EXTENSION SET.  However, in one file 
(foidevthru1997), a double quotation mark was also intermittently used to signify missing 
values, e.g., |"|"|"|.  As a result, informative quotation marks had to be distinguished from 
those indicating a null entry, as the latter caused errors by obscuring pipe-delimiters used to 
separate fields.  To address this issue, the SAS TRANSTRN function was used to remove a 
quotation mark when it was the only character occurring between two pipe-delimiters.  
Finally, given the size of the datasets, compression and keyword indexing were used to 
facilitate more efficient file processing. 
5.2 Determine MAUDE File Structures 
Once the data resided in SAS, it was anticipated that the process of joining the 
different files together would be a straightforward one given the MAUDE website 
instructions stating “All record types are linked via the MDR REPORT KEY.” (36)  In actuality, 
the linking was much more complex and required significant effort to discover nuances 
specific to each file type.  The culmination of this work is depicted in Figure 5.1 which 
illustrates the full interrelationships among the MAUDE datasets.  Sections 5.2.1-5.2.5 
describe the individual file types, including their inherent data structures and the elements 
linking the files to each other.  Section 5.2.6 summarizes the key points realized during this 
work. 
5.2.1 Master File 
As the name infers, the Master file is the centerpiece to which all of the other 
MAUDE files eventually relate.  Data in the Master file include adverse event and product 




Appendix A), along with detailed distributor and manufacturer contact and address 
information from sections F and G.  Appendix C, Table C.1 provides a complete list of the 
Master file fields and the subset used in this project. 
 
 
Figure 5.1: MAUDE File Relationship Diagram. 
A pictorial representation of the relationships among the six MAUDE file types. 
 
The majority (94%) of MAUDE reports were submitted by the medical device 
manufacturer (Figure 1.1), with the remaining adverse event reports provided by user 
facilities (3%), distributors (1%), and voluntary submitters (2%), including health 
professionals or consumers/patients.  However, these percentages are somewhat 
misleading as although the manufacturer may be the entity logging the issue, the company 





Table 5.2: Originating Source for Manufacturer-Submitted MAUDE Adverse Events. 
This table summarizes the MAUDE SOURCE TYPE field for those adverse event reports 
submitted by a manufacturer.  Percentages total more than 100% as this field allows entry 
of multiple entities. 
Source Type % 
Company Representative 40% 
Health Professional 36% 






Because multiple sources may report the same event, the Master file contains two 
identification fields: an MDR REPORT KEY which distinguishes unique adverse event reports; 
and an internally-generated EVENT KEY which links related reports, thereby identifying unique 
events.  Thus, MDR REPORT KEY is unique within the Master file whereas EVENT KEY is not.  The 
3,216,343 Master file records downloaded for this study represented 2,802,562 uniquely 
identified events. 
The MAUDE download file webpage states “A distinct master event data record will 
be present for each source reporting an event.  In other words, if a User Facility, Distributor, 
Manufacturer, and voluntary submitter all report an event, there will be four event 
records.“ (36)  Among the MAUDE records downloaded for this research, 8% shared an 
EVENT KEY, that is, had two or more unique records present in the MAUDE database 
identified as pertaining to the same event.  One might surmise that reports with duplicate 
EVENT KEYs would likely correspond to different REPORT SOURCE CODES (M=manufacturer, 
D=distributor, U=user facility, and P=voluntary submitter) and that a given EVENT KEY could 




MAUDE reports.  However, in practice 84% of reports sharing an EVENT KEY were reported 
only by the manufacturer, with an average number of eight “linked” events (range: 2 - 595).  
Through a detailed investigation of shared EVENT KEY records, it was apparent many 
connected reports pertained to devices sharing a common lot number.  In other cases, the 
reason for the linkage was not always clear based upon the information available in the 
publicly-accessible portion of the MAUDE database as demonstrated in Table 5.3.  Since the 
text mining activities encompassed in this research were based upon the narrative adverse 
event descriptions, unique reports rather than unique events were emphasized, and the 
event key was taken at face-value. 
Table 5.3: Example of Two Adverse Event Reports Linked to the Same Event. 
The data below shows two records having the same EVENT KEY, indicating they were 
internally linked to the same issue.  However, from the data provided in the publicly-
available portion of the MAUDE database, it is not directly apparent why these two 
manufacturer-submitted reports were linked as belonging to a single event. 
Date of 
Event Date Rcvd 
Device Date 
Mfg Device Age Text 
5/24/2006 6/9/2006 2/3/2003 3 YEAR IT WAS REPORTED THAT NOISE 
OBSERVED ON THE EGMS, WHICH 
APPEARED TO BE RELATED TO A LEAD 
FRACTURE. THE LEAD WAS CAPPED ON 
05/30/2006. 
5/28/2006 6/8/2006 11/1/2005 7 MONTH THE ST. JUDE MEDICAL REP PHONED TO 
REPORT THAT THE DEVICE EXHIBITED 
NOISE ON THE HIGH VOLTAGE 
VENTRICULAR LEAD. THE NOISE CAUSED 
THE DEVICE TO DELIVER 
INAPPROPRIATE THERAPY. TECHNICAL 
SERVICES REVIEWED THE FAXED 
ELECTROGRAMS AND DISCUSSED THAT 
THE NOISE WAS INDICATIVE OF A LEAD 
FRACTURE. AS A RESULT, THE LEAD WAS 





Finally, when the Master file had values for the NUMBER DEVICES IN EVENT or NUMBER 
PATIENTS IN EVENT greater than one, this indicated that an individual adverse event report in 
the Master file is associated with multiple device or patient records.  As discussed in the 
next three sections, when multiple products or patients are associated with one Master file 
record, the linking of the Master file to the Device, Patient and Text files became more 
complex. 
5.2.2 Device File 
The majority of the Device file data represents information reported in section D of 
the MedWatch Form 3500, including device identifiers such as manufacturer, product name 
and model number.  Baseline reporting information may also be provided, but the baseline 
reporting requirement was removed in 2008, (228) and baseline data was only supplied for 
1- 20% of records, depending upon the field.  Appendix Table C.2 provides a complete list of 
the Device file fields and the subset of these used in this research. 
Included in the Device file is a DEVICE REPORT PRODUCT CODE (DRPC) field, a unique three-
letter identifier indicating the type of device associated with an adverse event, as 
determined by the reporter (Table 5.4).  There are currently over 6,000 medical device 
product codes, and the list is updated weekly. (2)  Most (99.9%) Device file records include a 
DRPC value.  As discussed in Section 5.3, this DRPC code was used to determine records 





Table 5.4: FDA Medical Device Product Code Examples. 
 
Device Report Product 
Code Device Name Device Class 
DTB Permanent Pacemaker Electrode 3 
DTC Analyzer, Pacemaker Generator Function 2 
DTD Pacemaker Lead Adaptor 2 
DTE Pulse-Generator, Pacemaker, External 3 
DTF Tools, Pacemaker Service 1 
DTG Magnet, Test, Pacemaker 1 
DTI Sizer, Heart-Valve, Prosthesis 1 
DTJ Holder, Heart-Valve, Prosthesis 1 
 
The Device file also contains an MDR REPORT KEY field which facilitates linking data in 
this file to the Master file.  The vast majority (99.7%) of adverse events were associated 
with only one medical device (Master file NUMBER DEVICES IN EVENT = 1); however, a MAUDE 
report can be linked to multiple products.  This may arise, for example, if the adverse event 
reporter cited both the ICD and ICD leads when a defibrillator problem occurs, or listed all 
of the devices relating to a hip replacement system problem, including the metal-on-metal 
hip implant, the metal liner and the femoral stem.  In other cases, the same problem may 
be linked to different instances of a medical device.  For example, an infusion pump 
problem observed eight times, each time involving a different pump, may have been 
submitted as one adverse event report tied to eight Device file records.  In each of these 
examples, the association of multiple devices to a single report is signaled by the Master file 
NUMBER DEVICES IN EVENT > 1.  When this occurs, the Device file includes n= NUMBER DEVICES IN 
EVENT records having the same MDR REPORT KEY, with each linked record sequentially 
identified by a DEVICE SEQUENCE NO ranging from 1 through n as shown in Figure 5.2.  As such, 








Figure 5.2: Master and Device File Relationship Diagram. 
 
5.2.3 Patient File 
Similar to the structure of the Device file, a reported event may be linked to several 
patients, which typically occurs when a manufacturer submitted one report for a problem 
observed in multiple individuals.  In these cases, the Patient file included n = Master file 
NUMBER PATIENTS IN EVENT records, each sharing the same MDR REPORT KEY but having a unique, 
sequentially assigned PATIENT SEQUENCE NUMBER ranging from 1 to n, comparable to the 
configuration shown in Figure 5.2.  Consequently, in the Patient file, the combination of MDR 
REPORT KEY and PATIENT SEQUENCE NUMBER uniquely identifies a Patient file record. 
Patient identifying information populated in section A of the MedWatch Form 3500, 
including age at the time of the event, date of birth, gender and weight, is not provided in 




and outcome information, one or both of which are present for approximately three-
quarters of Patient records.  Because the structure of these fields differs from the 
instructions on the MAUDE website, their composition is discussed in detail below. 
The structure of the OUTCOME field is specified as “Sequence Number||','|| Outcome 
-- multiple source type, separate by ';'”.  However, it became clear that this pattern was only 
followed when a single patient was linked to a report (Master file NUMBER PATIENTS IN EVENT = 
1).  For example, when a report was associated with (just) one patient having outcomes 
indicative of a life-threatening event (OUTCOME =L), requiring intervention (OUTCOME =R) 
leading to hospitalization (OUTCOME =H), the OUTCOME field displayed as “1,L;2,R;3,H”.  
Enumerating a certain outcome of interest required simply counting mentions of a 
particular code or summing over indicator variables signifying the absence or presence (0/1) 
of an individual outcome as shown in Table 5.5. 
Table 5.5: Example of Patient Outcome Data Parsed into Indicator Variables. 
This table shows four representative Patient file records, each associated with a different 
MAUDE report.  The Outcome column depicts the raw data as it would be presented in the 
native MAUDE Patient file: H=Hospitalization; R= Required Intervention; L=Life-Threatening; 
D=Death.  0/1 Outcome Event Indicator variables (e.g., Hospitalization, Required 














123 1 1,H;2,R;3,L;  1 1 1 0 
234 1 1,D; 0 0 0 1 
345 1 1,H;2,R; 1 1 0 0 
456 1 1,R; 0 1 0 0 






However, after identifying several records in which an outcome sequence number 
was repeated within an observation (e.g., OUTCOME =1,H;1,H;2,R;3,L;) and then reviewing the 
patterns within these records, it became clear that when a MAUDE report was linked to 
multiple patients (as indicated when the Master file NUMBER PATIENTS IN EVENT > 1), the 
structure of the OUTCOME field deviated from the specified pattern on the MAUDE website in 
an important way.  Namely, the contents of the OUTCOME field are not solely specific to the 
patient record with which they were reported.  Rather, the OUTCOME field represents a 
sequential concatenation of findings across patient records sharing a common MDR REPORT 
KEY.  That is, the outcomes of each successive patient associated with an MDR REPORT KEY were 
prepended to the outcomes for all of the previous patients having the same MDR REPORT KEY.  
This is best demonstrated through an example.   
Table 5.6a illustrates a case in which a single adverse event report was associated 
with five patient records (Master file NUMBER PATIENTS IN EVENT = 5).  As can be seen in this 
table, the first patient associated with the adverse event report had three outcome results: 
1) hospitalization (H), 2) required intervention (R), and 3) life-threatening (L).  The next 
patient record linked to this event (PATIENT SEQUENCE NUMBER = 2) contained both the 
OUTCOMEs for the second patient: 1) hospitalization, and those of the first patient; the third 






Table 5.6:  Outcome Field Structure when Multiple Patients Are Associated with One 
Adverse Event Record. 
Table 5.6a shows the raw Patient file outcome data for an example in which five patients 
are associated with the same adverse event report.  Color coding is used to highlight the 
outcomes pertaining to a specific patient: cyan for patient 1, magenta for patient 2, yellow 
for patient 3, gray for patient 4 and green for patient 5.  In the raw data, the OUTCOME field 
for the 3rd patient associated with the adverse event report actually contains the outcomes 
for the 1st, 2nd, and 3rd patients.  Erroneous, inflated totals for individual outcome events 
would be obtained if one were to naively count the mentions of each particular code as is 
illustrated in the added Hospitalization, Required Intervention and Life-Threatening 
Outcome Event Indicator columns and Incorrect Totals row. 
To enable correct enumeration of outcomes, Table 5.6b illustrates how the original OUTCOME 
field shown in Table 5.6a must first be deconstructed so that the parsed OUTCOME result is 
specific to the patient referenced by the PATIENT SEQUENCE NUMBER field.  Once this has been 
accomplished, one can correctly sum over 0/1 Outcome Event Indicator variables to obtain 















567 1 1,H;2,R;3,L; 1 1 1 
567 2 1,H;1,H;2,R;3,L; 2 1 1 
567 3 1,H;2,R;1,H;1,H;2,R;3,L; 3 2 1 
567 4 1,H;2,R;1,H;2,R;1,H;1,H;2,R;3,L; 4 3 1 
567 5 1,H; 1,H;2,R;1,H;2,R;1,H;1,H;2,R;3,L; 5 3 1 








Number Parsed Outcome 







567 1 1,H;2,R;3,L;  1 1 1 
567 2 1,H; 1 0 0 
567 3 1,H;2,R; 1 1 0 
567 4 1,H;2,R; 1 1 0 
567 5 1,H; 1 0 0 






As shown in Table 5.6a, simple enumeration of outcomes without taking the 
concatenation structure into account resulted in greatly inflated totals.  Because the 
proportion of records associated with multiple patients is quite small (0.2%), failure to 
account for the sequential stratification of outcomes has only a minimal impact when 
considering the total cohort of Patient records.  However, as demonstrated in Tables 5.6a 
and 5.6b, the potential influence on outcome event totals can be quite sizeable if one 
happened to examine a small subset in which many of the adverse event reports were 
linked to multiple patients. 
A similar situation occurred within the TREATMENT field.  One difference with this field 
is that unlike the OUTCOME field, the TREATMENT field does not always contain the sequence 
numbers specified in the MAUDE website instructions.  Instead, a simple list of treatments 
is typically provided, such as “COUMADIN;SYNTHROID;METFORMIN;IRON;FOSAMAX.”  Even 
when present, sequence numbers often did not follow the stated format and instead were 
listed in a variety of manners, complicating parsing algorithms, e.g.: “(1) ACCU-CHEK 
COMPACT METER,;(2) METOPRODOL, (3) CLONIDINE;(4) NORVASC, (5)GLYBURINDE, (6) 
COUMADIN;(7) LEVAQUIN (8) TRAZADONE;(9) NOTROGLYCERINE;” or “1. COUMADIN;2. 
SYNTHROID;3. PEPSID;4. CARDIZEM;5. XYLOCAINE;6. LIDOCAINE;7. HEPARIN;”. 
A final consideration specific to the TREATMENT field involved the presence of 
semicolons.  In some cases, different treatments were identified using the semicolon as a 
divider.  However, semicolons may not be present between treatments, e.g., “(3) 
CLONIDINE;(4) NORVASC, (5)GLYBURINDE, (6) COUMADIN” or may signify line breaks, e.g., 




CATOPRIL 25 MG THREE TIMES;PER DAY.”  Parsing this last example using semicolons as the 
divider would lead to the unintended result of three treatments assigned to the patient: i.e., 
1. VANCOMYCIN AND GENTAMYCIN AFTER INSERTION OF NEW, 2. GRAFT. ACE INHIBITOR: 
CATOPRIL 25 MG THREE TIMES, and 3. PER DAY. 
For purposes of the current research, the TREATMENT field was not utilized.  Thus, 
once its structure was understood, further consideration of this field was not pursued.  
However, for analyses necessitating the use of this data, the TREATMENT field is probably best 
evaluated through the application of text-based tools, for example finding records that 
match the name of a particular medication or therapy of interest. 
5.2.4 Text File 
The Text file encompasses information describing the adverse event and the 
manufacturer’s evaluation of returned devices.  The Text file contained more than twice the 
number of records present in the Master file.  This occurred for three reasons.  First, there 
were n=Master file NUMBER PATIENT IN EVENT Text file records for each MDR REPORT KEY.  
Fortunately, unlike the Patient file data, each Text file record was specific to the referenced 
PATIENT SEQUENCE NUMBER and did not reflect a concatenation of information across patients.  
Fewer than 0.1% of MAUDE reports had Text file records relating to multiple patients, and 
the text for a given TEXT TYPE CODE was typically the same or very similar across patient 
records sharing a common MDR REPORT KEY.  Second, MDR REPORT KEYs were repeated within 
the Text file, reflecting the submission of supplemental or additional information for 




The third, and most influential factor contributing to the much larger number of Text 
file records was that this file is populated from three separate MedWatch Form 3500 fields, 
with each comprising a separate record identified by its TEXT TYPE CODE (Table 5.7).  Thus, Text 
file data is uniquely identified by the MDR TEXT KEY field or the combination of MDR REPORT KEY, 
PATIENT SEQUENCE NUMBER and TEXT TYPE CODE. 
Table 5.7: Types of Text Information Included in the MAUDE Text File. 
A copy of the MedWatch 3500 form is included in Appendix A. 
Text Type 
Code MedWatch Field N (%) 
D B5 = Adverse event description 3,305,898 (50.6%) 
E H3 = Manufacturer’s device evaluation information 7,227 (0.1%) 




In practical terms, as shown in Table 5.7, few records were associated with the H3 
field, and information from this field is not provided in the detailed report obtained through 
the MAUDE online search interfaces.  Even when populated, text in the H3 field typically 
pointed back to information in the H10 field or indicated only that an investigation was 
pending or in process.  The analyses in subsequent chapters utilized information contained 
in the adverse event description field corresponding to MedWatch field B5. 
The work in this project entailed text mining the MAUDE database, and it would 
have been highly useful to be able to easily order narrative data about a particularly 
product problem sequentially by time.  However, across all produccts DATE REPORT was 
missing for 75% of Text file records and when populated contained a small number of 
records with illogical dates extending back to 1900.  In addition, although one might surmise 




relating to a particular report, examining the narrative data shows this is not always the 
case as demonstrated in Table 5.8. 
Table 5.8: MDR Text Key Does Not Provide Time Sequential Ordering. 
This example illustrates that MDR Text Key is not a viable candidate for sequentially 











2280212 11975421 Missing D ADDITIONAL INFORMATION INDICATES THAT 
ADDITIONAL PRODUCT TROUBLESHOOTING WAS 
PERFORMED DURING A REVISION PROCEDURE AND A 
1.1 JOULE COMMANDED SHOCK WAS DELIVERED 
AND AN OPEN CIRCUIT ERROR MESSAGE WAS 
DISPLAYED. SUBSEQUENTLY, THIS PATIENT'S RV LEAD 
WAS SURGICALLY CAPPED AND THIS CRT-D WAS 
EXPLANTED AND REPLACED DUE TO THE REPORTED 
PRODUCT PERFORMANCE ISSUE. 
2280212 12745131 Missing D BOSTON SCIENTIFIC RECEIVED INFORMATION THAT 
THIS RIGHT VENTRICULAR (RV) LEAD HAD EXHIBITED 
AN ACUTE INCREASE IN SHOCKING IMPEDANCES 
GREATER THAN 125 OHMS. THE SYSTEM WAS TESTED 
IN ALL CONFIGURATIONS AND ALL MEASUREMENTS 
WERE OUT OF RANGE. THERE WAS NO NOISE ON THE 
SHOCK EGRAM AND THERE WERE NO EVENTS WITH 
THERAPY IN THE LOGBOOK SINCE IMPLANT. PRIOR TO 
THE THIS FINDING THE IMPEDANCES HAD BEEN 
CONSISTENTLY IN THE 40'S. BOSTON SCIENTIFIC 
TECHNICAL SERVICES (TS) DISCUSSED 
TROUBLESHOOTING. NO ADVERSE PATIENT EFFECTS 
HAVE BEEN REPORTED. 
2280212 13467791 Missing D ADDITIONAL INFORMATION INDICATES THAT AN X-
RAY WAS PERFORMED AND NO FRACTURE WAS 
OBSERVED. THE CAUSE FOR THE HIGH IMPEDANCE 
MEASUREMENTS ARE UNKNOWN AT THIS TIME. THE 
PATIENT WAS TO UNDERGO A REPLACEMENT 






Since determination of a sequential ordering was not practical, as discussed in 
Section 5.all Text file records relating to the same MAUDE report were concatenated.  As 
discussed in Section 5.3.1, given the preponderance of missing report dates in the Text file, 
when the Text data was combined with the other MAUDE files, information contained in the 
Master file’s DATE RECEIVED field was used to identify the date of a Text file entry.  As a result, 
it is possible that portions of the concatenated adverse event text descriptions were 
actually received subsequent to the assigned report date (DATE RECEIVED). 
5.2.5 Device Problems and Problem Code Descriptions Files 
Device problem codes are reported in section F of the MedWatch Form 3500 and 
are included in the Device Problems and Problem Code Descriptions file (see Appendix 
Tables C.5 and C.6).  As shown in Figure 5.3, the Device Problems file links a MAUDE report 
to one or more DEVICE PROBLEM CODEs, and the Problem Code Description file maps the DEVICE 
PROBLEM CODE to a short, text description.  When reported, in the MAUDE data downloaded 
for this research, the number of device problems associated with a device ranged from 1 to 
18 (mean=1.4).  Linking multiple DEVICE PROBLEM CODEs with the associated adverse event 
report required transposing the Device Problems file in order to obtain a dataset having a 
single row corresponding to each MDR REPORT KEY.  Once this was accomplished, individual 







Figure 5.3: Device Problem and Problem Code Description File Mapping. 
In this example the codes associated with the first MDR REPORT KEY (169409) refer to an 
implantable cardioverter defibrillator device, and those associated to the second MDR 
REPORT KEY (184584) pertain to a saline breast prosthesis. 
 
The Problem Code Descriptions file was structured as a SAS format file (basically, a 
labeling file) and linked to the codes in the Device Problems file using standard SAS format 
statements.  Six percent of the DEVICE PROBLEM CODEs did not map to a provided PROBLEM 
DESCRIPTION, the majority of which were resolved by adding component and patient codes 
(229) to the Problem Code Descriptions format file.  However, plans to further evaluate the 
DEVICE PROBLEM CODE field – for example, comparing the structured device problem 
information to the unstructured adverse event narrative descriptions – were ultimately 
dropped after determining that DEVICE PROBLEM CODEs were reported for only one-third of the 
MAUDE reports, and even when provided were not useful (e.g., coded as “no information”, 




5.2.6 File Relationship Summary 
Many research inquiries including those of this dissertation project require use of 
two or more of the individual MAUDE files discussed above.  For example, to answer a 
question involving the number of events (as distinct from the number of reports), one must 
incorporate the Master file EVENT KEY information, even if the main parameters of interest 
are contained solely in the Device, Patient, Text or Device Problems files.  Similarly, to 
address the question of “How many medical device adverse event reports for product ‘X’ 
were associated with patient hospitalization?” necessitates use of the Master, Device, and 
Patient files. 
In order to combine files appropriately, one must appreciate the data structures 
underlying the files.  A key finding of my work with the raw MAUDE data files is that the 
information provided on the MAUDE website is often inadequate, and sometimes errant.  
These factors added significant time to this project and likely limit others’ use of these files.  
In addition, an individual who proceeds without understanding the structural nuances of 
the different MAUDE file types could easily obtain misleading results.  There are more than 
twice as many Text file observations as MAUDE reports, and perhaps less obvious because 
the raw numbers are closer, there are more Patient and Device file records than adverse 
events; outcomes and treatments are replicated across linked patients; and adverse event 
reports may be associated with multiple patients or products.  If not recognized, these and 




5.3 Cohort Selection 
This project relied primarily on information contained in the Master, Device and Text 
files.  Patient file data was also included in order to provide summaries of patient outcomes 
and to ensure duplicate text information was handled appropriately.  It was my initial 
intention to combine the MAUDE files prior to creating a subset of records specific to the 
time period and products of interest in this study; however even after compressing the 
individual datasets, I found that the size of the files, and particularly the Text dataset, 
prevented this approach.  As a result, using the Master and Device files, the subsets of 
records associated with this study’s analysis cohorts were identified first.  This information 
was then used to identify the corresponding Patient and Text file records.  Finally, the 
individual file subsets were combined into a unified dataset.  The results of these processes 
are discussed below.  Section 5.3.1 details the steps undertaken to identify and merge the 
ICD lead-specific files (Cohort 1), while Section 5.3.2 summarizes the results obtained 
applying these steps to create the AED, IAB, and MoM THR files from which Cohorts 2, 3 and 
4 were drawn.  The SAS programs used to merge the MAUDE files are available in a GitHub 
repository. (226) 
5.3.1 Cohort 1 ICD Lead Selection 
The data necessary for identifying the products and time period associated with a 
MAUDE adverse event report were contained in the Master and Device files.  However 





MDR REPORT KEY.  This was accomplished using the SAS FIRST.VARIABLE function on a dataset 
sorted by MDR REPORT KEY and DRPC.  This simplification was appropriate for the analyses in 
this research, as otherwise duplicate adverse event descriptions would have been 
propagated once the Text data file was incorporated.  Once this single record per MDR REPORT 
KEY Device file was formed, it was merged with the Master file, keeping only those records 
with matching MDR REPORT KEYs.  This process eliminated 67 unmatched Master file and 79 
Device file records, resulting in a Master/Device file total n=3,216,276. 
Figure 5.4 depicts the distribution of the classifiable Master/Device file records by 
time and product area, using the review panel associated with a DRPC to classify records. (2)  
The time period in which the MAUDE report was received was grouped as prior to (pre-June 
2001) or within (June 2001 – 2013) the study period, as determined from the DATE RECEIVED 
and DEVICE DATE OF MANUFACTURE entries.  As discussed in Chapter 1 and also seen in Figure 
5.4, the vast majority of reports (n=2,705,699, 84%) occurred between June 2001 and 2013, 
consistent with the exponential rise of adverse event reporting over the past decade. 
Among 690,423 cardiovascular medical device adverse event records received since 
June 2001, 10% (n=68,524) were associated with an ICD lead product.  This represents a 
statistically significant increase (Chi-square p < 0.001) compared to the prior time period 
where 8% of adverse event reports pertained to these medical devices.  Figure 5.5 details 







Figure 5.4: Master/Device MAUDE Reports by Reported Product Area and Date. 
The distribution of MAUDE reports by product area and date, based on information 
contained in the combined Master/Device dataset.  “Other’” includes Hematology, Dental, 
Ear Nose and Throat (each comprising 1% of the total records) and Microbiology, 
Immunology, Clinial Toxicology and Pathology (each at < 1%).  Of the 5,074 records not 
included in this chart, 3,218 (64%) had a missing, unknown or not applicable product code, 
11 had no reported date, and the remaining records had a code that could not be identified, 
likely due to data entry error. 
 
Once the subset of Master/Device ICD lead records was identified, the MDR REPORT KEY 
field from this file was used to extract corresponding data from the Patient file.  This ICD 
lead Patient file was then examined to determine whether any adverse event reports were 
associated with multiple patient records (PATIENT SEQUENCE NO > 1).  Only five such records 
were identified, none of which included OUTCOME data.  Accordingly, these five records were 
dropped and the resulting ICD lead Patient file was comprised of 68,524 records, each 






Figure 5.5: Distribution of ICD Lead Reports by Report Year and Device Reported Product 
Code. 
The distribution of the 68,524 MAUDE adverse event reports having an ICD lead product 
code (NVY), or an ICD product code (MRM, NIK, LWS) where the product name contains the 
word “lead” or “electrode”. 
Table 5.9: ICD Lead Patient File Outcome Events. 
This table summarizes the outcome events for the 64,429 ICD lead Patient file records with 
non-missing outcome data. 
Outcome N % 
Death 3,798 5.9% 
Life-Threatening 6,025 9.4% 
Disability 91 0.1% 
Hospitalization 12,761 19.8% 






The MDR REPORT KEY field from the Master/Device ICD lead-specific dataset was also 
used to select the subset of product-specific Text file observations, an activity which made 
practicable subsequent file merging.  After eliminating records associated with MedWatch 
fields H3 and H10 (see Section 5.2.4), the resulting ICD lead Text file included n=67,299 
records.  Further evaluation of this dataset supported the removal of n=293 duplicate 
reports and n=5,811 records with missing, non-informative or punctuation-only data in the 
TEXT field (Table 5.10). 
Table 5.10: ICD Lead Text File Records with Missing or Non-Informative Text. 
This table shows the contents and count of the ICD lead Text file records that were removed 
as non-informative.  NI = No Information; ASKU = Asked, but unanswered; (B)(4) references 
the (previous) MedWatch “Date of this Report” field. 
Text Entry N  Text Entry N  Text Entry N 
Missing 4,253  ASKU. 26  ----- 5 
ASKU 740  (B)(4). 23  ------ 4 
-- 534  NI 16  == 2 
(B) (4) 61  (B)(4) 10  .. 1 
I 48  (B) (4). 8  NINI 1 
- - 35  - 7  ___ 1 
--- 30  ---- 6    
 
 
Finally, the ICD lead Text file was examined for multiple (different) adverse event 
descriptions associated with a single MDR REPORT KEY, an occurrence observed for 6.9% of the 
ICD lead-specific Text file records (mean: 1.1; range: 1 - 7).  These various descriptions 
generally occurred when a Manufacturer provided an updated adverse event report 
containing additional data not available when an earlier version of the report was 
submitted.  Since 91% of the ICD lead Text file records were missing a REPORT DATE, this 
behavior was primarily ascertained by reviewing the Text file records associated with the 




Table 5.11: Example of Multiple Text Entries for the Same Adverse Event Report. 
As illustrated in this example, when multiple Text records are associated with the same MDR 
REPORT KEY, the reports generally represent updated information.  Information may, but is 
not necessarily, repeated in related reports. 
First Entry Second Entry Third Entry 
IT WAS REPORTED THAT THE 
RV COIL IMPEDANCE WAS 
VARYING BETWEEN 50 AND 
188 OHMS, AND THE SVC 
COIL IMPEDANCE WAS 
VARYING BETWEEN 37 AND 
184 OHMS. A REVISION WAS 
PLANNED. NO PATIENT 
COMPLICATIONS HAVE BEEN 
REPORTED AS A RESULT OF 
THIS EVENT. 
IT WAS REPORTED THAT THE 
RV COIL IMPEDANCE WAS 
VARYING BETWEEN 50 AND 
188 OHMS, AND THE SVC 
COIL IMPEDANCE WAS 
VARYING BETWEEN 37 AND 
184 OHMS. A REVISION WAS 
PLANNED. NO PATIENT 
COMPLICATIONS HAVE BEEN 
REPORTED AS A RESULT OF 
THIS EVENT. ADDITIONAL 
INFORMATION WAS 
RECEIVED REPORTING THERE 
WAS OVERSENSING, NOISE 
ON EGMS, AND AN 
APPARENT LEAD FRACTURE. 
IT WAS REPORTED THAT THE 
RV COIL IMPEDANCE WAS 
VARYING BETWEEN 50 AND 
188 OHMS, AND THE SVC 
COIL IMPEDANCE WAS 
VARYING BETWEEN 37 AND 
184 OHMS. A REVISION WAS 
PLANNED. IT WAS FURTHER 
REPORTED THAT THERE WAS 
OVERSENSING, NOISE, HIGH 
IMPEDANCE, AND A LEAD 
FRACTURE. THE LEAD WAS 
EXPLANTED AND REPLACED. 
NO PATIENT COMPLICATIONS 
HAVE BEEN REPORTED AS A 
RESULT OF THIS EVENT. 
 
When multiple adverse event descriptions were associated with the same MDR 
REPORT KEY, they were simply concatenated into a single text string.  As depicted in the above 
table, a portion of the supplemental reports typically included the same, or similar text to 
previously submitted reports.  While this could impact text modeling activities that utilize 
word counts, as discussed in Section 4.5.2 the text classifiers used in this research were 
based solely on the presence or absence of attributes.  The resulting ICD lead Text file 
included 56,766 reports. 
At this point, the 68,524 Master/Device, 68,524 Patient and 56,766 Text ICD lead 
files were ready to be combined.  Because subsequent analyses were based upon the 




having an MDR REPORT KEY corresponding to the Text file were retained, resulting in a merged 
dataset with 56,766 records.  After merging the files, another check for duplicate entries 
was performed, this time reviewing the combined ICD lead dataset for duplicate text 
reports linked to the same EVENT KEY.  This process removed an additional 562 observations, 
resulting in a combined cohort 1 ICD lead dataset containing 56,204 reports. 
55.3.2 Cohorts 2 (AED), 3 (IAB) and 4 (MoM THR) Selection 
While Cohort 1 included reports associated with both recalled and non-recalled ICD 
leads, Cohorts 2 through 4 were limited to recalled medical devices only.  Identifying the 
subset of recalled records necessitated first labeling each observation as Recalled/Not 
Recalled, a process discussed in the following Chapter.  However, to facilitate this process, 
AED, IAB and MoM THR datasets representing both recalled and non-recalled medical 
devices were created at this juncture, using the same methodology described to select the 
ICD lead-specific records. 
The AED and IAB records were selected from the 690,423 cardiovascular medical 
device adverse event reports received since June 2001, and the MoM THR records 
comprised a subset of the 295,621 orthopedic reports received over the same time period.  
After processing the individual Master, Device, Patient and Text files and then combining 
them together, the resulting datasets contained n=56,484 AED records, n=6,035 IAB 
records, and 63,902 MoM THR records.  A random sample of the records in these three 





I greatly underestimated the difficulties of working with the MAUDE data files and 
the time required to understand the structural complexities of the various files types.  
Knowing what I know now, parts of the process could have been greatly simplified or 
eliminated.  For example: among the product cohorts used in this study, the issue discussed 
in Section 5.2.3 of sequentially concatenated outcomes when multiple patient records were 
linked to a single adverse event report did not occur; and information in the Device Problem 
Codes file turned out to be so limited that the various efforts to associate multiple codes to 
a single device record and to augment the code descriptions with additional values were, in 
the end, unrewarded.  On the other hand, through this process I developed and 
documented a much deeper understanding of the MAUDE data and its limitations, and I am 
confident that the resulting analysis data files accurately reflect the source data and a 
purpose-driven structure appropriate to the subsequent analyses. 
Once the files were successfully imported in SAS, identification and selection of 
cohort records was fairly straightforward.  The largest impediment proved to be the size of 
the files, which necessitated identification of the subset of records pertaining to the cohorts 
of interest in this study before merging the files together.  With these files in place, Chapter 







PREPARE ANALYSIS DATA 
 
The previous chapter discussed the first of these, creating the analysis datasets.  
Once these datasets were in place and prior to building and evaluating the text classification 
models, the data had to be prepared for analyses.  This chapter discusses the results of this 
second step of the project.  This step entailed labeling each MAUDE record with a 
standardized manufacturer name, normalized product identifier, recall status classifier, and 
censoring indicator as discussed in Section 6.1.  Then, as discussed in Section 6.2, the 
adverse event text field was prepared for subsequent text classification modeling by 
anonymizing specific manufacturer and product information, replacing numbers with 
context-specific generic labels, removing punctuation, and generating feature vectors for 
the matrix of variance reduction techniques discussed in Chapter 4. 
6.1 Label MAUDE Product, Recall and Censoring Information 
The text classification models used in this project required that each record be 
labeled with a recalled indicator (yes/no); however, within the MAUDE database, there is no 
single field identifying the medical device associated with a reported adverse event.  
Instead, this information is typically found in one or more of the free-entry manufacturer, 
brand name (MedWatch and Baseline Reporting), and model number (MedWatch and 
Baseline Reporting) fields as shown in Figure 6.1.  In order to systematically identify those 
records associated with a recalled medical device, it was necessary to first assign a 




each record.  This information could then be compared to the FDA Recall database to 
determine the recall status for each product through supervised learning (Section 6.1.3).  
Censoring indicators were then applied to identify those records included in the analyses 





Figure 6.1: Example of Original MAUDE Manufacturer and Product Information. 
As shown in this picture, manufacturer and product information is typically found in one or 
more of the free-entry Manufacturer, Brand Name and Model MAUDE fields.  In this 
example, the solid orange lines illustrate manufacturer name variants entered for 
Medtronic and St. Jude Medical.  The dashed purple box shows three variations entered for 





6.1.1 Assign Standardized Manufacturer Names 
Standardized manufacturer names (MFR_STD) were assigned to each Cohort 1 record 
using information provided in the MAUDE database manufacturer and, if manufacturer 
information was not provided, brand name fields.  Company acquisitions were grouped 
under the label of the current primary management company.  For example, Cardiac 
Pacemakers, Inc. (CPI) and Guidant Corporation were both grouped under the standardized 
manufacturer label of Boston Scientific.  Perl regular expression matching was utilized to 
associate various related company names, along with company name spellings and 
abbreviations, into a single label.  Table 6.1 depicts the 44 St. Jude Medical variations found 
in the ICD lead MAUDE cohort when matching on Perl regular expressions of ‘JUDE’ and 
‘SJM’ in the Manufacturer field, all of which were standardized to ‘ST. JUDE MEDICAL.’  
Table 6.2 shows the standardized manufacturer names assigned to the Cohort 1 records.  Of 
the 56,204 ICD lead cohort records, six records were ultimately excluded due to a missing or 
unidentifiable information regarding the ICD lead manufacturer. 
In Cohorts 2-4, the FDA Recall database was first was reviewed to identify those 
manufacturers having a recalled product during the timeframe of interest.  Standardized 
manufacturer names were then assigned to the subset of SAS records corresponding to the 
manufacturers having one or more product recalls.  The remaining SAS records were either 
associated with a company having no recalls during the time period of interest or had 





Table 6.1: Name Variations in MAUDE ICD Records Identifying St. Jude Medical as the 
Manufacturer. 
 
Manufacturer Name Provided in the MAUDE Record Frequency 
SJM 1 
ST JUDE 10 
ST JUDE CARDIOLOGY 1 
ST JUDE MED 1 
ST JUDE MEDICAL 25 
ST JUDE MEDICAL - NEUROMODULATION 2 
ST JUDE MEDICAL - NEUROMODULATION DIVISION 1 
ST JUDE MEDICAL CARDIAC RHYTHM 1 
ST JUDE MEDICAL CARDIAC RHYTHM MANAGEMENT DIVISION 17,270 
ST JUDE MEDICAL INC 1 
ST JUDE MEDICAL, CARDIAC RHYTHM MANAGMENT DIVISION 1 
ST JUDE MEDICAL, CARDIAC RHYTHM MGMT 1 
ST JUDE MEDICAL, GLOBAL HEADQUARTERS 1 
ST JUDE MEDICAL, INC. 2 
ST JUDE MEDICAL, INC., CRMD 3 
ST JUDE MILTON 2 
ST JUDE'S 1 
ST JUDE'S SLYMAR 1 
ST. JUDE 8 
ST. JUDE MEDICAL 85 
ST. JUDE MEDICAL - CARDIAC RHYTHM MANAGEMENT DIVISION 1 
ST. JUDE MEDICAL - NEUROMODULATION 11 
ST. JUDE MEDICAL CARDIAC RHYTHM 9 
ST. JUDE MEDICAL CARDIAC RHYTHM MANAGEMENT DIVISION 1 
ST. JUDE MEDICAL INC. 1 
ST. JUDE MEDICAL INC., CRMD 9 
ST. JUDE MEDICAL INC.,CRMD 1 
ST. JUDE MEDICAL, CARDIAC RHYTHM MANAGEMENT DIVISION 1 
ST. JUDE MEDICAL, CRMD 3 
ST. JUDE MEDICAL, INC CRMD. 1 
ST. JUDE MEDICAL, INC, CRMD 2 
ST. JUDE MEDICAL, INC. 38 
ST. JUDE MEDICAL, INC. (CRMD) 1 
ST. JUDE MEDICAL, INC. CRMD 124 
ST. JUDE MEDICAL, INC., (CRMD) 1 
ST. JUDE MEDICAL, INC., CRM 1 
ST. JUDE MEDICAL, INC., CRMB 1 
ST. JUDE MEDICAL, INC., CRMD 2,959 
ST. JUDE MEDICAL, INC.,CRMD 4 
ST. JUDE MEDICAL, INC.. CRMD 1 
ST. JUDE MEDICAL, INC.CMRD 2 
ST. JUDE MEDICAL, INC.CRMD 7 
ST. JUDE MEDICAL., INC., CRMD 1 









Manufacturer Name Frequency 
Percent 
within Cohort 
1 – ICD Leads MEDTRONIC 20,752 36.9 
 ST. JUDE MEDICAL 20,608 36.7 
 BOSTON SCIENTIFIC 12,053 21.4 
 BIOTRONIK 2,607 4.6 
 SORIN GROUP 131 0.2 
 CAMERON HEALTH 47 0.1 
 Missing/Unidentifiable* 6 < 0.1 
    
 Total Cohort 1 56,204 100.0 
Total Excluding Missing/Unidentifiable 56,198 > 99.9 
    
2 – AEDs ZOLL MEDICAL 27,418 48.5 
 PHILIPS/LAERDAL 19,942 35.3 
 PHYSIO-CONTROL/MEDTRONIC 4,987 8.8 
 WELCH ALLYN 1,497 2.7 
 CARDIAC SCIENCE 195 0.3 
 DEFIBTECH 135 0.2 
 LEONHARD LANG GMBH 2 < 0.1 
 Non-Recalled/Missing* 2,308 4.1 
    
 Total Cohort 2 56,484 100.0 
Total Excluding Non-Recalled/Missing 54,176 95.9 
    
3 – IABs ARROW/TELEFLEX 5,086 84.3 
 MAQUET/DATASCOPE 902 14.9 
 Non-Recalled/Missing* 47 0.8 
    
 Total Cohort 3 6,035 100.0 
Total Excluding Non-Recalled/Missing 5,988 99.2 
    
4 – MoM THR DEPUY 54,082 84.6 
 BIOMET 4,444 7.0 
 ZIMMER 3,110 4.9 
 WRIGHT MEDICAL 1,685 2.6 
 Non-Recalled/Missing* 581 0.9 
    
 Total Cohort 4 63,902 100.0 
Total Excluding Non-Recalled/Missing 63,321 99.1 




6.1.2 Determine Product Identifiers 
Once the standardized manufacturer label was assigned, standardized product 
identifiers (PRODUCT_STD) were determined by reviewing product information published by 
manufacturers, regulatory agencies and scientific journals and applying this information to 
the cohort datasets.  Specifically, within a standardized manufacturer name subset, the 
free-entry text information entered for model number fields (primarily) and brand name 
fields (secondarily) were searched using Perl regular expressions, and a standardized 
product identifier was assigned to each matching record.  In the main analysis group 
(Cohort 1), a specific standardized product label was assigned to each record as shown in 
Table 6.3.  (Appendix E provides a complete list of MAUDE-referenced brand names and 
model numbers included within each ICD lead standardized product label.)  For example, 
within the group of Cohort 1 records in which Medtronic was identified as the 
manufacturer, Perl regular expressions matching ‘6930’, ‘6931’, ‘6948’, ‘6949’ and ‘FIDELIS’ 
were standardized to ‘SPRINT FIDELIS.’  
Although the majority (> 90%) of standardized product identifiers within Cohort 1 
were matched to ICD leads, in some cases, insufficient information was provided in order to 
identify the reported product, or the reported product matched a different lead type (e.g., 
subcutaneous, pace-sense lead, etc.).  With input from Dr. Varosy, an additional Lead Type 
identifier (LEAD_TYPE: ICD, Subcutaneous, Defibrillator Coil Only, Pace-Sense, Epicardial 
Patch, Adaptor, NA, Unknown) was assigned to each record.  Records where LEAD_TYPE = ICD 
were included in subsequent analyses.  Table 6.3 presents a tabulation of results for Cohort 




Table 6.3: Standardized Product Identifiers and Lead Type Indicators – Cohort 1. 
LV = Left ventricular lead; ICD = Transvenous high-voltage defibrillation lead. 
 
Standardized 







MEDTRONIC SPRINT QUATTRO SECURE  ICD 10,564 50.9 18.8 
SPRINT FIDELIS  ICD 6,346 30.6 11.3 
SPRINT QUATTRO  ICD 1,689 8.1 3.0 
SPRINT QUATTRO SECURE MRI  ICD 993 4.8 1.8 
SPRINT  ICD 591 2.8 1.1 
SUB-Q  Subcutaneous* 103 0.5 0.2 
TRANSVENE  Defibrillator Coil Only* 104 0.5 0.2 
SVC  Defibrillator Coil Only* 64 0.3 0.1 
SELECTSECURE  Pace-Sense* 98 0.5 0.2 
CAPSURE  Pace-Sense* 41 0.2 0.1 
ATTAIN  Pace-Sense* 13 0.1 <0.1 
Model 6721  Epicardial Patch* 58 0.3 0.1 
LEAD ADAPTORS  Adaptors* 8 <0.1 <0.1 
Non Lead  NA* 22 0.1 <0.1 
Unknown Unknown* 58 0.3 0.1 
 
Overall Total within Manufacturer 20,752 100.0 36.9 
ICD Lead Total within Manufacturer 20,183 97.3 38.2 
 
ST. JUDE MEDICAL  RIATA  ICD 8,811 42.8 15.7 
 DURATA  ICD 6,577 31.9 11.7 
 RIATA ST  ICD 2,593 12.6 4.6 
 RIATA ST OPTIM ICD 902 4.4 1.6 
 TVL-ADX  ICD 157 0.8 0.3 
 SPL  ICD 72 0.3 0.1 
 TVL  ICD 42 0.2 0.1 
 QUICKFLEX u  Pace-Sense* 691 3.4 1.2 
 QUICKFLEX  Pace-Sense* 470 2.3 0.8 
 QUICKSITE  Pace-Sense* 256 1.2 0.5 
 TENDRIL  Pace-Sense* 9 <0.1 <0.1 
 AESCULA  Pace-Sense* 1 <0.1 <0.1 
 Non Lead  NA* 19 0.1 <0.1 
 Unknown Unknown* 8 <0.1 <0.1 
      
 Overall Total within Manufacturer 20,608 100.0 36.7 
 ICD Lead Total within Manufacturer 19,154 92.9 36.2 
      
BOSTON 
SCIENTIFIC  
ENDOTAK RELIANCE  ICD 9,618 79.8 17.1 
ENDOTAK ENDURANCE  ICD 548 4.5 1.0 
 ENDOTAK DSP  ICD 529 4.4 0.9 
 ENDOTAK  ICD 284 2.3 0.5 
 EASYTRAK  Pace-Sense* 338 2.8 0.6 
 EASYTRAK 2  Pace-Sense* 276 2.3 0.5 
 SELUTE  Pace-Sense* 86 0.7 0.2 
 INTERVENE  Pace-Sense* 45 0.4 0.1 
 EASYTRAK 3  Pace-Sense* 34 0.3 0.1 
 FLEXTEND 2  Pace-Sense* 27 0.2 <0.1 
 Models 0010-0020  Pace-Sense* 22 0.2 <0.1 
 Models 4047,4312,4316  Pace-Sense* 15 0.1 <0.1 
 FINELINE II  Pace-Sense* 6 <0.1 <0.1 
 SWEET TIP  Pace-Sense* 6 <0.1 <0.1 




















2 <0.1 <0.1 
 SWEET PICOTIP  Pace-Sense* 2 <0.1 <0.1 
 TACHY LEAD EPI-PATCH  Epicardial Patch* 83 0.7 0.1 
 ENDOTAK SQ  Subcutaneous* 36 0.3 0.1 
 LEAD ADAPTORS  Adaptors* 2 <0.1 <0.1 
 Unknown Unknown* 86 0.7 0.2 
      
 Overall Total within Manufacturer 12,053 100.0 21.4 
 ICD Lead Total within Manufacturer 10,979 91.1 20.8 
      
BIOTRONIK  LINOX  ICD 1,586 60.8 2.8 
 LINOX SMART  ICD 490 18.8 0.9 
 KENTROX STEROID  ICD 191 7.3 0.3 
 LINOX SMART PROMRI  ICD 79 3.0 0.1 
 KAINOX  ICD 54 2.1 0.1 
 KENTROX  ICD 46 1.8 0.1 
 VIGILA 1  ICD 16 0.6 <0.1 
 VIGILA 2  ICD 9 0.3 <0.1 
 COROX OTW  Pace-Sense* 53 2.0 0.1 
 SELOX  Pace-Sense* 33 1.3 0.1 
 SETROX  Pace-Sense* 15 0.6 <0.1 
 AROX  Pace-Sense* 6 0.2 <0.1 
 ELOX  Pace-Sense* 3 0.1 <0.1 
 TILDA R  Pace-Sense* 3 0.1 <0.1 
 DEXTRUS  Pace-Sense* 2 0.1 <0.1 
 Non Lead  NA* 17 0.7 <0.1 
 Unknown Unknown* 4 0.2 <0.1 
      
 Overall Total within Manufacturer 2,607 100.0 4.6 
 ICD Lead Total within Manufacturer 2,471 94.8 4.7 
      
SORIN GROUP ISOLINE  ICD 108 82.4 0.2 
 ANGEPASS  ICD 7 5.3 <0.1 
 ANGEFLEX  ICD 1 0.8 <0.1 
 SITUS  Pace-Sense* 8 6.1 <0.1 
 STELID II  Pace-Sense* 4 3.1 <0.1 
 STELIX II  Pace-Sense* 2 1.5 <0.1 
 Unknown Unknown* 1 0.8 <0.1 
      
 Overall Total within Manufacturer 131 100.0 0.2 
 ICD Lead Total within Manufacturer 116 88.5 0.2 
      
CAMERON HEALTH  Q-TRAK  Subcutaneous 47 100.0 0.1 
Unknown Mfr   6 100.0 <0.1 
      
 Cohort 1 Total 56,204  100.0 
 Cohort 1 ICD Lead Total 52,903  94.1 




Product-specific information was not utilized in Cohorts 2-4, thus records in these 
groups were assigned either a generic, manufacturer-specific recalled product label or 
‘Other’ for records associated with non-recalled products as shown in Table 6.4.  For 
example, among Cohort 2 records in which Welch Allyn was the identified manufacturer, 
Perl regular expressions matching recalled products ‘MRL’ or variations of ‘AED 10’ were 
standardized to PRODUCT_STD = ‘WELCH ALLYN Recalled AED,’ while records associated with 
non-recalled WELCH ALLYN products were labeled as ‘Other’.  In Cohorts 2-4, only those 
records associated with a recalled product (PRODUCT_STD  not equal to ‘Other’) were included 
in subsequent analyses.  Half of Cohort 2 (49%) and Cohort 4 (53%) MAUDE records met this 
criteria, while a smaller proportion of Cohort 3 (10%) were associated with a recalled 
product. 
6.1.3 Identify Recall Status 
Once a standardized product identifier was assigned to each of the MAUDE records, this 
identifier was compared to the FDA Recall database (Appendix D) to determine the recall 
status and classification for each product.  As shown in Table 6.5, MAUDE ICD lead records 
with an assigned product identifier matching the FDA Recall database were labeled as 
recalled (LEAD_RECALL = yes) and assigned a recall class (RECALL_CLASS: 0=Not Recalled, 1=Class 
I Recall, 2=Class II Recall, 3=Class III Recall).  Of the 52,903 MAUDE ICD lead records, 17,750 
(33.6%) were associated with a Class I recall: 36% with the Medtronic Sprint Fidelis recall, 
and the remaining with the SJM Riata/Riata ST recall.  There were two Class II ICD lead 




lead and one for Medtronic’s Sprint Quattro Secure ICD lead, the latter involving a sizeable 
proportion (10%) of MAUDE ICD lead records. 
Table 6.4: Standardized Product Identifiers – Cohorts 2-4. 
This table summarizes the standardized product identifier assigned to MAUDE Records.  
AED = automated external defibrillator; IAB = intra-aortic balloon; MoM THR = metal-on-
metal total hip replacement. 
Standardized 







Cohort 2 – AEDs 
ZOLL MEDICAL ZOLL MEDICAL Recalled AED 6,572 24.0 12.1 
 Other* 20,846 76.0 38.5 
PHILIPS/LAERDAL PHILIPS/LAERDAL Recalled AED 17,783 89.2 32.8 
 Other* 2,159 10.8 4.0 
PHYSIO-CONTROL 
/MEDTRONIC 
PHYSIO-CONTROL/MEDTRONIC Recalled AED 1,681 33.7 3.1 
 Other* 3,306 66.3 6.1 
WELCH ALLYN WELCH ALLYN Recalled AED 457 30.5 0.8 
 Other* 1,040 69.5 1.9 
CARDIAC SCIENCE CARDIAC SCIENCE Recalled AED 147 75.4 0.3 
 Other* 48 24.6 0.1 
DEFIBTECH DEFIBTECH Recalled AED 4 3.0 < 0.1 
 Other* 131 97.0 0.2 
     
Total AED Products 54,176  100 
Total Recalled AED Products 26,644  49.2 
Cohort 3 – IABs 
ARROW /TELEFLEX ARROW Recalled IAB 61 1.2 1.0 
 Other* 5,025 98.8 83.9 
MAQUET MAQUET/DATASCOPE Recalled IAB 539 59.8 9.0 
/DATASCOPE Other* 363 40.2 6.1 
     
Total IAB Products 5,988  100 
Total Recalled IAB Products 600  10.0 
Cohort 4 – MoM THRs 
DEPUY DEPUY Recalled MoM THR  31,319 57.9 49.5 
 Other* 22,763 42.1 35.9 
BIOMET BIOMET Recalled MoM THR  10 0.2 < 0.1 
 Other* 4,434 99.8 7.0 
ZIMMER ZIMMER Recalled MoM THR  1,919 61.7 3.0 
 Other* 1,191 38.3 1.9 
WRIGHT MEDICAL WRIGHT MEDICAL Recalled MoM THR  35 2.1 0.1 
 Other* 1,650 97.9 2.6 
     
Total MoM THR Products 63,361  100 
Total Recalled MoM THR Products 33,283  52.5 




Table 6.5: Cohort 1 Recalled Class Assignment. 
 
Standardized 








Cohort 1 – ICD Leads      
BIOTRONIK  KAINOX  0 54 2.2 0.1 
KENTROX  0 46 1.9 0.1 
KENTROX STEROID  0 191 7.7 0.4 
LINOX  0 1,586 64.2 3.0 
LINOX SMART  0 490 19.8 0.9 
LINOX SMART PROMRI  0 79 3.2 0.1 
VIGILA 1  0 16 0.6 0.0 
VIGILA 2  0 9 0.4 0.0 
BOSTON SCIENTIFIC  ENDOTAK  0 284 2.6 0.5 
ENDOTAK DSP  0 529 4.8 1.0 
ENDOTAK ENDURANCE  0 548 5.0 1.0 
ENDOTAK RELIANCE  0 9,618 87.6 18.2 
MEDTRONIC  SPRINT  0 591 2.9 1.1 
SPRINT FIDELIS  1 6,346 31.4 12.0 
Uncensored Class I Recalled 1,068   
SPRINT QUATTRO  0 1,689 8.4 3.2 
SPRINT QUATTRO SECURE  2 10,564 52.3 20.0 
Uncensored Class II Recalled 3,201   
SPRINT QUATTRO SECURE MRI  0 993 4.9 1.9 
SORIN GROUP  ANGEFLEX  0 1 0.9 0.0 
ANGEPASS  0 7 6.0 0.0 
ISOLINE  2 108 93.1 0.2 
 Uncensored Class II Recalled 106   
ST. JUDE MEDICAL  DURATA  0 6,577 34.3 12.4 
RIATA  1 8,811 46.0 16.7 
Uncensored Class I Recalled 3,231   
RIATA ST  1 2,593 13.5 4.9 
Uncensored Class I Recalled 1,077   
RIATA ST OPTIM 0 902 4.7 1.7 
SPL  0 72 0.4 0.1 
TVL  0 42 0.2 0.1 
TVL-ADX  0 157 0.8 0.3 
     
Total ICD Lead Products 52,903  100 
Non-Recalled + Uncensored Class I Recalled 40,529  76.6 






Table 6.6 presents similar recall classification information for Cohorts 2 through 4.  
In these groups all included MAUDE records are associated with recalled products, and as a 
result there are no records assigned a RECALL_CLASS = 0.  The majority of recalls for these 
cohorts were Class II recalls:  Cohorts 2 and 3 had just one Class I recall each, and all of the 
recalls involving MoM THR systems during the study period were Class II recalls. 
6.1.4 Designate Censoring Indicators 
As discussed in Section 4.5.1, in order to minimize the impact that product recall 
knowledge may have had on the information reported in the MAUDE database, a Class I 
recall censored indicator (CENSOR_1: included/not included) was assigned to each recalled 
record by comparing the date the MAUDE report was received to the date of the recall 
notification.  Tables 6.5 (Cohort 1) and 6.6 (Cohorts 2-4) above indicate the number of 
uncensored records for each recalled product. 
Unsurprisingly, given the public nature of a Class I recall and the timing of the recalls, 
the majority of reports submitted to the MAUDE database for Class I recalled ICD leads 
were received after FDA recall notification.  As shown in Table 6.5, of the 18,651 MAUDE 
records associated with Class I recalled ICD leads, 1,068 (17%) of the 6,346 Medtronic Sprint 
Fidelis ICD leads and 4,860 (39%) of the 11,404 SJM Riata and Riata ST ICD leads were 
received before FDA notification of the product’s recall (uncensored).  The greater 
proportion of uncensored SJM Riata/Riata ST ICD leads as compared to the Medtronic 
Sprint Fidelis ICD leads (p < 0.001) likely reflects longer availability of the product as well as 

















Cohort 2 – AEDs      
ZOLL MEDICAL  ZOLL MEDICAL Recalled AED 4,152 2,420 6,572 24.7 
 Uncensored 2,367 350 2,717  
PHILIPS/LAERDAL PHILIPS/LAERDAL Recalled AED 0 17,783 17,783 66.7 













WELCH ALLYN WELCH ALLYN Recalled AED 0 457 457 1.7 
 Uncensored  137 137  







DEFIBTECH DEFIBTECH Recalled AED 0 4 4 < 0.1 
 Uncensored  4 4  
      
 Total Recalled AED Products 4,152 24,277 26,644 100 
 Uncensored Total 2,367 2,312 4,679 17.6 
Cohort 3 IABs      
ARROW/ 
TELEFLEX  











0 539 539 89.8 
 Uncensored  258 258  
      
 Total Recalled IAB Products 61 539 600 100 
 Uncensored Total 25 258 283 47.2 
Cohort 4 – MoM THRs     
DEPUY  DEPUY Recalled MoM THR 0 31,319 31,319 94.1 
 Uncensored  3,457 3,457  
BIOMET BIOMET Recalled MoM THR 0 10 10 < 0.1 
 Uncensored  4 4  
ZIMMER ZIMMER Recalled MoM THR  1,919 1,919 5.8 
 Uncensored  304 304  
WRIGHT 
MEDICAL 
WRIGHT MEDICAL Recalled 
MoM THR 
0 35 35 < 0.1 
 Uncensored  35 35  
      
Total Recalled MoM THR Products 0 33,283 33,283 100 








Figure 6.2: Cumulative Distribution of Censored and Uncensored Sprint Fidelis and 
Riata/Riata ST MAUDE Reports. 
This graph shows the cumulative distribution of the 6,346 Medtronic Sprint Fidelis (light and 
dark purple solid bars) and the 11,404 St. Jude Medical Riata and Riata ST ICD lead (light and 
dark green patterned bars) MAUDE reports. Records received after FDA recall notification 
(October 15, 2007 for Sprint Fidelis (dark purple) and November 28, 2011 for Riata/Riata ST 
(dark green)) ICD leads are censored. 
 
The relative proportion of uncensored recalled records was relatively similar for 
Cohorts 2 and 4 (Table 6.6).  However, the proportion of uncensored recalled records in 




variance due to the relatively smaller number of records in this group, or different reporting 
practices by the manufacturers in this cohort. 
6.2 Pre-Process the Adverse Event Text Description 
Certain information present in the adverse event description, such as manufacturer 
and product names, were masked prior to modeling to ensure they didn’t act as a surrogate 
for recall status and thus bias the study’s results.  Other information, such as numbers and 
punctuation, were masked or removed to reduce extraneous noise in the model.  This 
section discusses the results of anonymizing manufacturer names, product names, and 
model numbers (Section 6.2.1); replacing numbers and removing punctuation (Section 
6.2.2); the removal of legal text that inferred a recall (Section 6.2.3), and generating feature 
vectors (Section 6.2.4) utilizing a variety of variance reduction techniques discussed in 
Chapter 4.  The SAS programs used to label and preprocess the MAUDE files are available in 
a GitHub repository. (226) 
6.2.1 De-identify Manufacturer and Product-specific Information 
Table 6.7 depicts examples of adverse event narrative descriptions that include 
specific manufacturer and product information.  To identify and substitute this detailed 
data with anonymized or de-identified information, Perl regular expression matching was 
used to replace specific mentions of manufacturer names and product names and model 
numbers with generic placeholder text (MFRREF or MODREF, respectively).  As discussed in 
Chapter 4, this de-identification was performed to remove information that might 





Table 6.7: Adverse Event Narratives that Include Specific Manufacturer and Product 
Information. 
 
Reference Substitution Reference Substitution 
Manufacturers MFRREF Model Number/Name MODREF 
Example Before Recoding Example After Recoding 
THE PT UNDERWENT A BIVENTRICULAR ICD IMPLANTATION 
IN 2007. HE DID WELL UNTIL ABOUT 3 MONTHS LATER, 
WHEN HE RECEIVED AN INAPPROPRIATE ICD SHOCK. HE HAD 
AN ECHOCARDIOGRAM AND A CT SCAN WHICH SHOWED 
THAT THE VENTRICULAR ICD LEAD PENETRATED THE RIGHT 
VENTRICLE. THE PT WAS TAKEN TO THE OPERATING ROOM, 
THE VENTRICULAR ICD ELECTRODE WAS REMOVED UNDER 
TEE GUIDANCE AND A NEW ELECTRODE WAS PLACED IN THE 
HIGH SEPTUM. THE VENTRICULAR ELECTRODE WAS A RIATA 
ST FROM ST JUDE MEDICAL. DIAGNOSIS OR REASON FOR 
USE: HEART FAILURE. EVENT ABATED AFTER USE STOPPED 
OR DOSE REDUCED: YES. 
THE PT UNDERWENT A BIVENTRICULAR ICD IMPLANTATION 
IN DATEREF HE DID WELL UNTIL ABOUT TIMEREF LATER 
WHEN HE RECEIVED AN INAPPROPRIATE ICD SHOCK HE HAD 
AN ECHOCARDIOGRAM AND A CT SCAN WHICH SHOWED 
THAT THE VENTRICULAR ICD LEAD PENETRATED THE RIGHT 
VENTRICLE THE PT WAS TAKEN TO THE OPERATING ROOM 
THE VENTRICULAR ICD ELECTRODE WAS REMOVED UNDER 
TEE GUIDANCE AND A NEW ELECTRODE WAS PLACED IN THE 
HIGH SEPTUM THE VENTRICULAR ELECTRODE WAS A 
MODREF FROM MFRREF DIAGNOSIS OR REASON FOR USE 
HEART FAILURE EVENT ABATED AFTER USE STOPPED OR 
DOSE REDUCED YES 
PATIENT IS A MAN WITH A HISTORY OF A NONISCHEMIC 
CARDIOMYOPATHY WHO UNDER WENT IMPLANT OF AN ICD 
SYSTEM 2004. MEDTRONIC MODEL 7230CX ICD, MEDTRONIC 
6949 FIDELIS LEAD. HE PRESENTED 2007 WITH MULTIPLE 
SHOCKS FROM HIS ICD. INTERROGATION REVEALED NOISE 
ON THE ELECTROGRAMS AND VARYING LEAD IMPEDANCE 
CONSISTENT WITH A LEAD FRACTURE. 
PATIENT IS A MAN WITH A HISTORY OF A NONISCHEMIC 
CARDIOMYOPATHY WHO UNDER WENT IMPLANT OF AN ICD 
SYSTEM DATEREF MFRREF MODEL MODREF ICD MFRREF 
MODREF MODREF LEAD HE PRESENTED DATEREF WITH 
MULTIPLE SHOCKS FROM HIS ICD INTERROGATION 
REVEALED NOISE ON THE ELECTROGRAMS AND VARYING 
LEAD IMPEDANCE CONSISTENT WITH A LEAD FRACTURE 
PATIENT DEVELOPED MULTIPLE ICD DISCHARGES DUE TO 
NOISE OVERSENSING. LEAD MALFUNCTION CONFIRMED AT 
OPERATION. PRE EXISTING HISTORY OF SAME PROBLEMS 
WITH THIS TYPE OF LEAD (MEDTRONIC SPRINT FIDEUS - 
ACTIVE FIXATION). 
PATIENT DEVELOPED MULTIPLE ICD DISCHARGES DUE TO 
NOISE OVERSENSING LEAD MALFUNCTION CONFIRMED AT 
OPERATION PRE EXISTING HISTORY OF SAME PROBLEMS 




Tables 6.8 (Manufacturer) and 6.9 (Model Name/Number) provide a cohort-specific 
summary of the number of records that required at least one name substitution.  As shown 
in these tables, the distribution of string substitutions across cohorts was significantly 
different for each type of de-identifier.  For example, MAUDE MoM THR records were less 
likely to mention a Manufacturer by name, but more likely to mention a product model 
name or number within the adverse event description as compared to the other cohorts, 





Table 6.8: Distribution of De-Identified Manufacturer (MFRREF) Coding by Cohort. 
 
Cohort # Uncensored 
Records in Cohort 
# Records (% in Cohort) 
Requiring MFRREF Anonymization 
Chi-square P-
value 
1 - ICD Leads 40,529 11,582 (28.6) 
< 0.0001 
2 – AEDs 1,000 115 (11.5) 
3 – IABs 283 37 (13.1) 
4 – MoM THR 1,000 34 (  3.4) 
 
 
Table 6.9: Distribution of De-Identified Model (MODREF) Coding by Cohort. 
 
Cohort # Uncensored 
Records in Cohort 
# Records (% in Cohort) 
Requiring MODREF Anonymization 
Chi-square P-
value 
1 - ICD Leads 40,529 937 (2.2) 
< 0.0001 
2 – AEDs 1,000 27 (2.7) 
3 – IABs 283 9 (3.2) 
4 – MoM THR 1,000 179 (17.9) 
 
6.2.2 Replace Numbers and Removing Punctuation 
In addition to anonymizing specific manufacturer names and product names/model 
numbers, other numbers were replaced with context-specific place-holders as illustrated in 
Table 6.10.  Approximately half of the MAUDE ICD Lead (48%) and IAB (41%) records and 
one-quarter of the AED (28%) and MoM THR (24%) records included one or more field 
substitutions. 
Punctuation removal was performed in SAS to allow more exact specification of 
whether to compress the removed punctuation or to replace with a space.  For example, 
when removing the apostrophe in “WASN’T”, compression results in a single, interpretable 
token, “WASNT”, whereas the same process used for the text 




latter case, replacing the equal sign with a blank space yields a more desirable outcome of 
two interpretable tokens, “IMPRESSION” and “LEAD.”  The Example After Recoding columns 
in Figures 6.3 and 6.4 illustrate the results of punctuation removal. 
6.2.3 Remove Records with Legal Terms 
During the process of anonymizing data, records were observed that contained legal 
terminology that implied knowledge of a product recall, e.g., “ATTORNEY ALLEGES THAT 
THE PLAINTIFF HAS SUSTAINED AND WILL CONTINUE TO SUSTAIN SEVERE PHYSICAL 
INJURIES AND/OR DEATH, AND SEVERE EMOTIONAL DISTRESS RELATED TO THE LEAD.”  All 
records subsequent to the date of recall were censored as discussed in Section 6.1.4; 
however, as discussed in Chapter 5.2.4, the lack of information allowing Text file data to be 
sequentially ordered can result in some records containing data that was actually received 
subsequent to the date assigned to the report.  Reports containing legal phrases were 
reviewed and all reports (n=208) with the terms: “PLAINTIFF”, “LAWSUIT”, “ATTORNEY”, 
“LITIGATION”, “ANGUISH”, or “SEVERE EMOTIONAL DISTRESS” were removed, leaving a 
total across all cohorts of 42,812 records.  Although this approach may have resulted in the 
loss of records that might contain legal phrases used outside of the context of a recall and 
thus be informative, as shown in Table 6.11, only a very small number of non-recalled 
(Recall Class = 0) records were omitted.  Table 6.12 presents the final number of records 





Table 6.10: Adverse Event Narrative Field Substitutions with Highlighted Examples. 
 
Reference Substitution Reference Substitution Reference Substitution 
Manufacturers MFRREF MDR Numbers MDRREF Ohms OHMREF  
Model Number/Name MODREF MedWatch Form MWREF Joules JOULEREF  
Dates DATEREF MedWatch B fields BFIELDREF  Beats per Minute BPMREF  
Times TIMEREF Serial or Lot Numbers SLNREF  Other, non-specific NUMREF  
Example Before Recoding Example After Recoding 
ADDITIONAL INFORMATION WAS RECEIVED THAT THE 
PRODUCT STATUS UPDATE FIELD WAS SET PRIOR TO THE LAST 
MDR REPORT SUBMITTED AND DUE TO SYSTEM INTERFACE 
TIMING THE IMPLANT DATE, (B)(6) 2012, WAS MISSING FROM 
THE 3500A BATCH INITIAL REPORT. SUPPLEMENTAL 
CORRECTION REPORT WILL BE SUBMITTED WITH THIS 
CORRECTED INFORMATION. BOSTON SCIENTIFIC RECEIVED 
INFORMATION THAT DURING A ROUTINE POST-OPERATIVE 
CHECK-UP, THE RIGHT VENTRICULAR (RV) LEAD SENSING 
EVENTS CORRELATED WITH THE P-WAVE ON THE ECG. 
SENSING R WAVES HAD DIMINISHED TO 1.7 MV. VVI PACING 
RESULTED IN ATRIAL CAPTURE. THE TACHYCARDIA THERAPIES 
WERE DISABLED AND REPROGRAMMED TO AAI 30. NO 
INAPPROPRIATE THERAPY HAD BEEN DELIVERED. THE PATIENT 
IS SCHEDULED FOR A RIGHT VENTRICULAR (RV) LEAD 
REPOSITIONING PROCEDURE IN THE FUTURE. 
ADDITIONAL INFORMATION WAS RECEIVED THAT THE 
PRODUCT STATUS UPDATE FIELD WAS SET PRIOR TO THE 
LAST MDR REPORT SUBMITTED AND DUE TO SYSTEM 
INTERFACE TIMING THE IMPLANT DATE BFIELDREF 
DATEREF WAS MISSING FROM THE MWREF BATCH INITIAL 
REPORT SUPPLEMENTAL CORRECTION REPORT WILL BE 
SUBMITTED WITH THIS CORRECTED INFORMATION 
MFRREF RECEIVED INFORMATION THAT DURING A 
ROUTINE POST OPERATIVE CHECK UP THE RIGHT 
VENTRICULAR RV LEAD SENSING EVENTS CORRELATED 
WITH THE P WAVE ON THE ECG SENSING R WAVES HAD 
DIMINISHED TO NUMREF MV VVI PACING RESULTED IN 
ATRIAL CAPTURE THE TACHYCARDIA THERAPIES WERE 
DISABLED AND REPROGRAMMED TO AAI NUMREF NO 
INAPPROPRIATE THERAPY HAD BEEN DELIVERED THE 
PATIENT IS SCHEDULED FOR A RIGHT VENTRICULAR RV 
LEAD REPOSITIONING PROCEDURE IN THE FUTURE 
AN INTERNAL REVIEW REVEALED TATH THIS PRODUCT WAS 
REMOVED FOR INFECTION AND DISCARDED BY THE HOSPITAL. 
THIS DEVICE WAS PART OF A SYSTEM REMOVED FOR 
INFECTION. PLEASE REFERENCE LEXOS DR-T, SN: 79843136, 
MDR# 05-0111 FOR ADDITIONAL INFORMATION. 
AN INTERNAL REVIEW REVEALED TATH THIS PRODUCT 
WAS REMOVED FOR INFECTION AND DISCARDED BY THE 
HOSPITAL THIS DEVICE WAS PART OF A SYSTEM 
REMOVED FOR INFECTION PLEASE REFERENCE MODREF 
SLNREF MDRREF FOR ADDITIONAL INFORMATION 
BOSTON SCIENTIFIC RECEIVED INFORMATION THAT THIS 
PATIENT WITH THIS IMPLANTABLE CARDIOVERTER 
DEFIBRILLATOR (ICD) PRESENTED TO THE EMERGENCY ROOM 
AFTER EXPERIENCING A LOSS OF CONSCIOUSNESS. THE 
PATIENT REMEMBERS ONE OTHER EPISODE WHERE THEY FELL 
ABOUT THREE MONTHS AGO. THE DEVICE WAS 
INTERROGATED BY A BOSTON SCIENTIFIC FIELD 
REPRESENTATIVE AND FOUND PACING IMPEDANCE 
MEASUREMENTS ABOVE 2,000 OHMS ON THIS RIGHT 
VENTRICULAR (RV) LEAD. THERE WERE NON-SUSTAINED 
VENTRICULAR TACHYCARDIA (VT) EVENTS WHICH WERE 
CAUSED BY THE OVERSENSING OF NOISE ON THE RV LEAD. 
THESE EVENTS WERE NOT TREATED WITH SHOCKS. THE FIELD 
REPRESENTATIVE NOTED THAT THE PATIENT IS NOT PACER 
DEPENDANT AND HAS AN INTRINSIC RHYTHM OF SIXTY BEATS 
PER MINUTE, SO THERE WAS NO ASYSTOLE NOTED. THE 
DEVICE WAS REEVALUATED THREE DAYS AFTER THE EVENT. 
NON-INVASIVE PROGRAMMED STIMULATION (NIPS) WAS 
PERFORMED WAS SUCCESSFUL WITH A 21J SHOCK. PACE 
IMPEDANCES MEASUREMENTS CONTINUE TO BE OVER 2000 
OHMS BUT THERE ARE NO NEW EPISODES OF NOISE AND 
OVERSENSING. THE PHYSICIAN ELECTED TO CONTINUE TO 
MONITOR THE ICD AND RV LEAD AT THIS TIME. NO 
ADDITIONAL ADVERSE PATIENT EFFECTS WERE REPORTED. 
MFRREF RECEIVED INFORMATION THAT THIS PATIENT 
WITH THIS IMPLANTABLE CARDIOVERTER DEFIBRILLATOR 
ICD PRESENTED TO THE EMERGENCY ROOM AFTER 
EXPERIENCING A LOSS OF CONSCIOUSNESS THE PATIENT 
REMEMBERS NUMREF OTHER EPISODE WHERE THEY FELL 
ABOUT TIMEREF AGO THE DEVICE WAS INTERROGATED 
BY A MFRREF FIELD REPRESENTATIVE AND FOUND 
PACING IMPEDANCE MEASUREMENTS ABOVE OHMREF 
ON THIS RIGHT VENTRICULAR RV LEAD THERE WERE NON 
SUSTAINED VENTRICULAR TACHYCARDIA VT EVENTS 
WHICH WERE CAUSED BY THE OVERSENSING OF NOISE 
ON THE RV LEAD THESE EVENTS WERE NOT TREATED 
WITH SHOCKS THE FIELD REPRESENTATIVE NOTED THAT 
THE PATIENT IS NOT PACER DEPENDANT AND HAS AN 
INTRINSIC RHYTHM OF BPMREF SO THERE WAS NO 
ASYSTOLE NOTED THE DEVICE WAS REEVALUATED 
TIMEREF AFTER THE EVENT NON INVASIVE 
PROGRAMMED STIMULATION NIPS WAS PERFORMED 
WAS SUCCESSFUL WITH A JOULEREF SHOCK PACE 
IMPEDANCES MEASUREMENTS CONTINUE TO BE OVER 
OHMREF BUT THERE ARE NO NEW EPISODES OF NOISE 
AND OVERSENSING THE PHYSICIAN ELECTED TO 
CONTINUE TO MONITOR THE ICD AND RV LEAD AT THIS 









Total 0 1 2 
1 – ICD Leads 11 118 27 156 
2 – AEDs 0 0 0 0 
3 – IABs 0 0 0 0 
4 – MoM THR 0 0 52 52 
Total 11 118 79 208 
 




Total 0 1 2 
1 – ICD Leads 24,470 5,258 10,645 40,373 
Training 15,805 3,869 7,009 26,916 
Testing 7,764 1,941 3,636 13,341 
2 – AEDs 0 493 507 1,000 
3 – IABs 0 25 258 283 
4 – MoM THR 0 0 948 948 
Total 24,470 5,776 12,358 42,604 
 
6.2.4 Generate Adverse Event Description Feature Vectors 
As discussed in Chapter 4, a combination of stemming, stop words and feature 
reduction was used to reduce variance once the adverse event text was converted to a 
vector of features (words/tokens).  Preliminary models demonstrated that a variance 
reduction matrix with all possible combination was unnecessarily complex without adding 
demonstrable value.  Thus a simpler structure (Table 4.4) was adopted in which only one 
filtering parameter was varied at a time, and including both the null (no) and complete (all) 
feature filtering approaches.  These attribute filtering combinations were also more in 
keeping with algorithm testing in related published literature. (111, 144, 183)  Table 6.13 




combination of feature reduction methods.  As discussed in Chapter 4, since the word 
bigram and trigram datasets included lower-level n-grams, stemming was employed to 
reduce the total number of features.  However, as this still resulted in a computationally 
unmanageable number of attributes, feature reduction was also utilized to reduce the 
number of features to a more manageable size. 
Table 6.13: ICD Lead Training Cohorts - Number of Features. 
 





No No No Unigrams 8,407 
Yes No No Unigrams 4,743 
No Yes No Unigrams 7,986 
No No Yes Unigrams 1,489 
Yes Yes Yes Unigrams 690 
 
Yes No No Bigrams 96,443 
Yes No Yes Bigrams 5,340 
 
Yes No No Trigrams 375,119 
Yes No Yes Trigrams 12,685 
 
Finally, additional datasets representing over- and under-sampling were generated.  
As outlined in Section 4.6.4, a variety of class imbalance approaches were explored, 
including under-sampling which decreases the total size of the training population, and 
over-sampling which increases the total.  Cost adjustment reweights the classes, but 
doesn’t impact the size of the training dataset.  Under-sampling to achieve equal number of 
cases by class reduced the total number of records.  Over-sampling by SMOTE increased the 
total number of training records by adding to the number of minority (ICD Lead recall) 
records, where SMOTE2 doubles the class, SMOTE3 triples this class, and so forth.  Table 




Table 6.14: ICD Lead Training Dataset Sample Sizes. 
Cost2 models double the cost of false negatives, Cost3 models triple the cost, and so forth 
(see Table 4.6).  SMOTE2 doubles the minority (ICD Lead recall) class, SMOTE3 triples this 
class, etc. 
Class Imbalance Adjustment Model 






None, Cost2, Cost3, Balanced Class 3,505 23,411 26,916 
Under-sampling 3,505 3,505 7,010 
Over-sampling    
SMOTE2 7,010 23,411 30,421 
SMOTE3,  
w/wo bigrams/trigrams 
10,515 23,411 33,926 
SMOTE4 14,020 23,411 37,431 
SMOTE5,  
w/wo bigrams/trigrams 
17,525 23,411 40,936 
Class Imbalance Combinations    
SMOTE2 + Under-sampling, 
w/wo bigrams/trigrams 
7,010 7,010 14,020 
SMOTE3 + Under-sampling, 
w/wo bigrams/trigrams 
10,515 10,515 21,030 
 
6.3 Summary 
As discussed by Witten, the process of readying the analysis database “usually 
consumes the bulk of the effort invested in the entire data mining process.” (80)  These pre-
processing tasks included the supervised learning of the ICD lead recalled outcome with 
which subsequent models were trained, and the preparation of the adverse event narrative 
for use in the text classification models.  The text classification modeling results discussed in 






MACHINE LEARNING AND SIGNAL DETECTION MODELING RESULTS 
 
The previous two chapters discussed creating the analysis datasets and preparing 
the data for analysis.  This chapter discusses the results of model training, tuning and 
selection (Section 7.1), hypothesis testing (Section 7.2) and sensitivity analyses (Section 7.3). 
7.1 Model Training and Testing 
As discussed in Chapter 4, three classification approaches and their parameter 
settings were evaluated: decision trees, Naïve Bayes and SVMs (linear and quadratic).  
Within each approach, five class imbalance adjustment methods were also assessed: none, 
cost adjustment, under-sampling, over-sampling and hybrid approaches.  This section 
begins by presenting the cross-validation training results for each classifier (Sections 7.1.1-
7.1.4).  The best models within each approach are then compared to select the model used 
to generate final model performance characteristics using the held-out test data (Section 
7.1.5).  This model is then used for hypothesis testing and sensitivity analyses as discussed 
in the remainder of the chapter. 
7.1.1 Cross-Validation Training Results – All Classification Models 
Of the 40,373 eligible ICD lead records, two-thirds (n=26,916) were used for training.  
Class I ICD lead recalls accounted for 13.0% of both the training and testing populations.  
The training steps are graphically represented in Figure 7.1 using Weka’s Knowledge Flow 
interface, with Table 7.1 providing a description of the individual components.  All training 






Figure 7.1: Graphical Depiction of the Cross-Validation Training Process. 
 
 
Table 7.1: Text Classifier Training Knowledge Flow Component Descriptions. 
 
Process Explanation 
Arff Loader Loads the training dataset as an attribute relation file format 
(ARFF) file used by Weka. 
Class Assigner Specifies the variable (Class I Recall Indicator) used as the 
classification variable. 
Cross Validation Fold 
Maker 
Splits the data into 10 cross-validation folds – for each run, nine of 
the ten folds are used for training and one for testing. 
Naïve Bayes This example shows selection of a Naïve Bayes classifier.  Decision 
tree (J48) and SVM (SMO) components were also utilized. 
Model Performance 
Chart 
Produces threshold curves (e.g., ROC, PRC) which can be saved as 
Weka ARFF files. 
Text Viewer After the modeling is complete, allows display of the formatted 
results. 
Text Saver Saves the unformatted results into a text file. 
 
A total of 210 cross-validation training models were run to evaluate the best 
combination of attributes, complexity parameter and class imbalance adjustment 




specific sections below.  F1 scores, which balance the contribution of precision and recall, 
are emphasized in this research.  However, detailed result tables include both F0.5 scores 
which emphasize precision over recall, and F2 scores which give more emphasis to recall 
over precision, to facilitate evaluation under alternative weighting plans.  Area under 
receiver operating characteristic (ROC) curves and precision-recall curves (PRC) are 
provided.  Because ROC curves can present an overly optimistic view of an algorithm’s 
performance when there is a large skew in the class distribution, emphasis is given to PRC 
results in this research. (230)  Model comparison and selection within each text classifier 
approach considered F1 scores, PRC area and model run time. 
For all classification models, the best performance generally occurred when feature 
reduction was utilized, but without stemming or use of stop words.  Cost2 models generally 
outperformed Cost3 models.  As a result, higher cost weighting assignments were not 
typically pursued, although for completeness, balanced class cost-adjusted models were 
evaluated and did not perform as well as their Cost2 counterparts.  Under-sampling, over-
sampling and combination (hybrid) approaches all tended to improve F1 scores and PRC 
estimates.  The best-performing hybrid approaches used a sequential combination of over-
sampling (SMOTE) to increase representation of the lead recall class, followed by under-
sampling to achieve balanced representation of the recalled and non-recalled examples. 
Models using bigram and trigram features were evaluated for most of the 
classification approaches.  While bigram models generally provided higher F1 scores 
compared to their unigram counterparts, they typically took 5-10 times longer to run.  




SVMs).  Trigram models typically took 15-40 times longer to run than their unigram 
counterparts, and performed only marginally better than, or not as well as, their bigram 
equivalents. 
The tables of cross-validation training results in Sections 7.1.2-7.1.4 are grouped by 
class imbalance adjustment approach.  The feature combinations shown in Table 6.11 were 
evaluated for each classifier and are shown in the tabular results provided in each section.  
Results for models requiring parameter tuning (decision tree and SVM classifiers) are also 
grouped by attribute selection combination.  Yellow highlighted rows in the tables 
emphasize the unigram model with the best balance of performance characteristics within 
each class imbalance adjustment group.  The row in blue highlights the model providing the 
highest F1 score overall.  Figures in Section 7.1.2-7.1.4 graphically compare the precision, 
recall, F1 score, PRC area estimate and computational run time for the subset of best-in-
group performers for each text classification method. 
7.1.2 Cross-Validation Training – Naïve Bayes Results 
Naïve Bayes models were generated first as they tend to provide good baseline 
values and rapid computational times.  Table 7.2 provides the results of the 44 Naïve Bayes 
cross-validation training models.  Unlike the other text classification methods, cost-
adjustment added little or no performance benefit for Naïve Bayes models; however, 






The highest Naïve Bayes model F1 score (0.841) was achieved with a 5x over-
sampling (SMOTE5) model evaluating bigram features.  However, an under-sampling 
approach provided the best combination of performance and efficiency, yielding an F1 score 
of 0.807 and the highest PRC value (0.848).  Balancing precision, recall, F1 score, PRC area 
and run time for the subset of best-in-group performers (Figure 7.2), the under-sampling 
approach was selected to represent the best Naïve Bayes classifier for the model 
comparisons discussed in Section 7.1.5. 
 
 
Figure 7.2: Comparison of Naïve Bayes Cross-Validation Training Model Performance 
Characteristics for Selected Class Imbalance Adjustment Approaches. 
The starred, under-sampling approach, is used to represent the best Naïve Bayes classifier 






Table 7.2: Naïve Bayes Cross-Validation Training Results. 
Yellow highlighted rows emphasize the unigram models deemed to have the best balance of performance characteristics within each 
class imbalance adjustment group.  The row in blue highlights the model providing the highest F1 score overall.  FP = False Positive; 
MCC = Matthews correlation coefficient; ROC = receiver operating characteristic area under the curve; PRC = precision-recall curve 

















No Class Balance Adjustment 
No No Unigrams No None 0.207 0.392 0.789 0.524 0.471 0.590 0.450 0.873 0.505 79.2% 8.3 
Yes No Unigrams No None 0.211 0.383 0.774 0.512 0.461 0.577 0.435 0.864 0.486 78.6% 4.0 
No Yes Unigrams No None 0.198 0.396 0.763 0.521 0.472 0.583 0.444 0.870 0.517 79.7% 6.6 
No No Unigrams Yes None 0.208 0.392 0.789 0.524 0.471 0.590 0.450 0.873 0.506 79.2% 0.7 
Yes Yes Unigrams Yes None 0.203 0.391 0.769 0.519 0.468 0.582 0.441 0.865 0.509 79.3% 0.4 
Cost Adjustment 
No No Unigrams No Cost2 0.215 0.388 0.803 0.524 0.469 0.592 0.452 0.873 0.505 78.8% 7.6 
Yes No Unigrams No Cost2 0.221 0.378 0.791 0.512 0.458 0.580 0.437 0.864 0.486 78.1% 5.1 
No Yes Unigrams No Cost2 0.222 0.378 0.796 0.513 0.458 0.582 0.439 0.870 0.517 78.1% 6.9 
No No Unigrams Yes Cost2 0.215 0.388 0.804 0.524 0.469 0.592 0.452 0.873 0.506 78.8% 0.9 
Yes Yes Unigrams Yes Cost2 0.220 0.380 0.794 0.514 0.460 0.582 0.440 0.865 0.509 78.2% 0.5 
No No Unigrams No Cost3 0.219 0.386 0.810 0.522 0.468 0.593 0.452 0.873 0.505 78.5% 8.1 
Yes No Unigrams No Cost3 0.224 0.377 0.800 0.513 0.458 0.582 0.439 0.864 0.486 77.9% 5.3 
No Yes Unigrams No Cost3 0.236 0.369 0.813 0.508 0.451 0.580 0.436 0.870 0.517 77.1% 7.2 
No No Unigrams Yes Cost3 0.220 0.385 0.811 0.522 0.467 0.592 0.452 0.873 0.506 78.5% 0.9 
Yes Yes Unigrams Yes Cost3 0.230 0.373 0.807 0.511 0.454 0.581 0.438 0.865 0.509 77.6% 0.8 
No No Unigrams No Balanced Class 0.226 0.381 0.820 0.520 0.464 0.592 0.451 0.873 0.505 78.1% 9.3 
Yes No Unigrams No Balanced Class 0.234 0.372 0.816 0.511 0.454 0.584 0.44 0.864 0.486 77.3% 6.0 
No Yes Unigrams No Balanced Class 0.257 0.357 0.839 0.501 0.442 0.579 0.433 0.870 0.517 75.7% 7.7 
No No Unigrams Yes Balanced Class 0.226 0.381 0.820 0.520 0.464 0.592 0.451 0.873 0.506 78.1% 1.4 
Yes Yes Unigrams Yes Balanced Class 0.248 0.361 0.826 0.502 0.444 0.578 0.432 0.865 0.509 76.3% 0.5 


















No No Unigrams No Under-sampling 0.216 0.792 0.821 0.806 0.801 0.811 0.606 0.876 0.848 80.3% 1.2 
Yes No Unigrams No Under-sampling 0.225 0.783 0.814 0.798 0.793 0.803 0.589 0.867 0.837 79.4% 0.8 
No Yes Unigrams No Under-sampling 0.245 0.774 0.838 0.805 0.794 0.816 0.595 0.875 0.852 79.7% 1.1 
No No Unigrams Yes Under-sampling 0.216 0.792 0.822 0.807 0.802 0.812 0.607 0.877 0.848 80.3% 0.2 
Yes Yes Unigrams Yes Under-sampling 0.242 0.774 0.830 0.801 0.792 0.810 0.589 0.869 0.846 79.4% 0.1 
Over-sampling 
No No Unigrams Yes SMOTE2 0.233 0.541 0.809 0.648 0.608 0.694 0.516 0.839 0.545 77.8% 0.8 
No No Unigrams Yes SMOTE3 0.264 0.614 0.824 0.704 0.671 0.740 0.533 0.822 0.605 76.6% 0.8 
No No Unigrams Yes SMOTE4 0.280 0.675 0.859 0.756 0.727 0.787 0.569 0.822 0.670 77.6% 1.1 
No No Unigrams Yes SMOTE5 0.302 0.711 0.879 0.786 0.759 0.815 0.580 0.821 0.716 78.1% 1.2 
Yes No Bigrams Yes SMOTE3 0.196 0.686 0.841 0.756 0.731 0.782 0.619 0.857 0.667 81.6% 6.8 
Yes No Bigrams Yes SMOTE4 0.210 0.738 0.869 0.798 0.777 0.820 0.648 0.857 0.722 82.2% 7.9 
Yes No Bigrams Yes SMOTE5 0.223 0.771 0.888 0.826 0.806 0.845 0.664 0.855 0.758 82.8% 7.5 
Yes No Trigrams Yes SMOTE3 0.116 0.763 0.736 0.749 0.754 0.745 0.625 0.834 0.678 83.4% 14.5 






















No No Unigrams Yes 
SMOTE5 +  
Cost2 
0.303 0.711 0.879 0.786 0.759 0.815 0.580 0.821 0.716 78.1% 1.1 
No No Unigrams Yes 
SMOTE5 +  
Cost3 
0.303 0.711 0.879 0.786 0.759 0.815 0.579 0.821 0.716 78.0% 1.1 
No No Unigrams Yes 
SMOTE3 +  
Under-sampling 
0.260 0.760 0.822 0.790 0.780 0.800 0.564 0.823 0.751 78.1% 0.5 
No No Unigrams Yes 
SMOTE4 +  
Under-sampling 
0.278 0.756 0.861 0.805 0.788 0.823 0.589 0.824 0.752 79.2% 0.6 
No No Unigrams Yes 
SMOTE5 +  
Under-sampling 
0.302 0.744 0.878 0.805 0.784 0.828 0.585 0.821 0.748 78.8% 0.9 
Yes No Bigrams Yes 
SMOTE2 +  
Under-sampling 
0.162 0.828 0.777 0.801 0.810 0.793 0.616 0.859 0.803 80.8% 1.7 
Yes No Bigrams Yes 
SMOTE3 +  
Under-sampling 
0.197 0.810 0.839 0.824 0.819 0.829 0.643 0.856 0.792 82.1% 2.5 
Yes No Bigrams Yes 
SMOTE4 +  
Under-sampling 
0.208 0.807 0.868 0.836 0.826 0.847 0.662 0.858 0.792 83.0% 6.1 
Yes No Bigrams Yes 
SMOTE5 +  
Under-sampling 
0.222 0.800 0.886 0.841 0.827 0.855 0.668 0.855 0.786 83.2% 5.4 
Yes No Trigrams Yes 
SMOTE3 +  
Under-sampling 






7.1.3 Cross-Validation Training – Decision Tree Results 
Table 7.3 provides the detailed results of the 72 decision tree cross-validation 
training results.  The chosen model in the No Class Balance Adjustment group had a slightly 
lower F1 score, but a higher PRC area and much lower computational time compared to two 
other unadjusted models that produced slightly higher F1 scores.  Cost2-adjusted models 
outperformed their unadjusted model counterparts.  A complexity parameter of c=0.01 
tended to provide the best performance where stemming was employed, and otherwise a 
complexity parameter value of c=0.1 generally provided the highest Cost2 model F1 scores.   
Given that it was not feasible to evaluate all models with all parameter values, the 
complexity parameter for the Cost3, balanced class, and under-sampling approaches used 
the value of the parameter found to work best for each Cost2 model attribute combination.  
For example, a complexity parameter of c=0.01 provided the best Cost2 model performance 
where no stemming, no stop words and no feature selection was performed; thus, the 
Cost3, balanced class, and under-sampling models having this same combination of 
attributes were all evaluated using c=0.01.  Whereas, when stop words were used, without 
stemming or feature selection, c=0.1 provided the best Cost2 model performance; thereby 
for the evaluation of the Cost3, balanced class, and under-sampling models using stop 
words but not stemming or feature selection, the complexity parameter was assigned a 






Table 7.3: Decision Tree Cross-Validation Training Results. 
Yellow highlighted rows emphasize the unigram models deemed to have the best balance of performance characteristics within each 
class imbalance adjustment group.  The row in blue highlights the model providing the highest F1 score overall.  FP = False Positive; 
MCC = Matthews correlation coefficient; ROC = receiver operating characteristic area under the curve; PRC = precision-recall curve 




















No Class Balance Adjustment 
0.5 No No Unigrams No None 0.065 0.596 0.562 0.578 0.584 0.573 0.510 0.793 0.484 88.1% 200.1 
0.25 No No Unigrams No None 0.059 0.623 0.572 0.596 0.605 0.588 0.532 0.831 0.514 88.8% 294.1 
0.1 No No Unigrams No None 0.044 0.668 0.528 0.590 0.614 0.568 0.534 0.864 0.542 89.4% 308.7 
0.01 No No Unigrams No None 0.034 0.699 0.466 0.559 0.599 0.524 0.514 0.860 0.556 89.3% 306.3 
0.5 Yes No Unigrams No None 0.068 0.578 0.552 0.565 0.569 0.560 0.493 0.791 0.475 87.7% 124.7 
0.25 Yes No Unigrams No None 0.060 0.606 0.547 0.575 0.585 0.565 0.509 0.826 0.496 88.3% 136.0 
0.1 Yes No Unigrams No None 0.047 0.644 0.505 0.566 0.590 0.544 0.507 0.865 0.531 88.8% 134.3 
0.01 Yes No Unigrams No None 0.032 0.681 0.408 0.511 0.557 0.471 0.470 0.822 0.510 88.6% 132.8 
0.5 No Yes Unigrams No None 0.065 0.585 0.544 0.564 0.571 0.557 0.494 0.816 0.491 87.8% 172.0 
0.25 No Yes Unigrams No None 0.061 0.609 0.557 0.582 0.591 0.573 0.515 0.852 0.516 88.4% 259.4 
0.1 No Yes Unigrams No None 0.047 0.648 0.505 0.568 0.592 0.545 0.51 0.880 0.542 88.9% 256.0 
0.5 No No Unigrams Yes None 0.066 0.593 0.568 0.580 0.584 0.576 0.511 0.801 0.493 88.1% 18.8 
0.25 No No Unigrams Yes None 0.058 0.623 0.567 0.593 0.603 0.585 0.529 0.841 0.530 88.7% 18.9 
0.1 No No Unigrams Yes None 0.043 0.674 0.519 0.586 0.613 0.562 0.532 0.873 0.562 89.4% 23.2 
0.01 No No Unigrams Yes None 0.035 0.693 0.462 0.554 0.594 0.520 0.509 0.858 0.555 89.2% 23.2 
0.5 No No Unigrams Yes None 0.535 0.065 0.584 0.535 0.567 0.550 0.488 0.811 0.482 87.7% 15.5 
0.25 Yes Yes Unigrams Yes None 0.059 0.610 0.539 0.572 0.584 0.561 0.506 0.842 0.507 88.3% 13.9 
0.1 Yes Yes Unigrams Yes None 0.047 0.642 0.497 0.561 0.585 0.537 0.502 0.874 0.531 88.7% 14.3 


























0.25 No No Unigrams No Cost2 0.087 0.565 0.663 0.610 0.594 0.627 0.540 0.800 0.490 87.7% 204.5 
0.1 No No Unigrams No Cost2 0.087 0.573 0.685 0.624 0.606 0.643 0.556 0.828 0.522 88.0% 206.5 
0.01 No No Unigrams No Cost2 0.090 0.572 0.705 0.632 0.610 0.654 0.566 0.880 0.557 88.1% 242.7 
0.005 No No Unigrams No Cost2 0.089 0.572 0.701 0.630 0.609 0.652 0.564 0.881 0.560 88.1% 259.7 
0.25 Yes No Unigrams No Cost2 0.090 0.553 0.661 0.602 0.585 0.621 0.531 0.794 0.479 87.3% 92.2 
0.1 Yes No Unigrams No Cost2 0.090 0.560 0.676 0.613 0.594 0.632 0.543 0.825 0.500 87.6% 80.5 
0.01 Yes No Unigrams No Cost2 0.090 0.564 0.690 0.621 0.601 0.642 0.553 0.879 0.555 87.8% 81.6 
0.005 Yes No Unigrams No Cost2 0.091 0.563 0.691 0.620 0.600 0.642 0.552 0.884 0.557 87.7% 116.0 
0.25 No Yes Unigrams No Cost2 0.088 0.569 0.685 0.622 0.603 0.641 0.554 0.830 0.526 87.9% 155.0 
0.1 No Yes Unigrams No Cost2 0.086 0.578 0.697 0.632 0.613 0.652 0.566 0.857 0.554 88.2% 194.8 
0.01 No Yes Unigrams No Cost2 0.092 0.567 0.709 0.630 0.608 0.654 0.564 0.890 0.583 87.9% 196.9 
0.25 No No Unigrams Yes Cost2 0.085 0.577 0.679 0.624 0.607 0.641 0.556 0.821 0.522 88.1% 31.8 
0.1 No No Unigrams Yes Cost2 0.087 0.580 0.708 0.637 0.617 0.659 0.572 0.854 0.551 88.3% 32.3 
0.01 No No Unigrams Yes Cost2 0.091 0.571 0.715 0.635 0.612 0.660 0.570 0.889 0.574 88.1% 20.4 
0.25 Yes Yes Unigrams Yes Cost2 0.094 0.547 0.667 0.601 0.582 0.622 0.529 0.823 0.509 87.2% 10.7 
0.1 Yes Yes Unigrams Yes Cost2 0.096 0.553 0.696 0.616 0.594 0.641 0.547 0.849 0.525 87.4% 11.8 
0.01 Yes Yes Unigrams Yes Cost2 0.099 0.552 0.716 0.623 0.598 0.651 0.556 0.886 0.564 87.4% 12.1 
0.005 Yes Yes Unigrams Yes Cost2 0.100 0.547 0.715 0.620 0.593 0.649 0.552 0.888 0.561 87.3% 13.7 
0.01 No No Unigrams No Cost3 0.128 0.520 0.815 0.635 0.591 0.685 0.578 0.873 0.527 86.4% 183.1 
0.01 Yes No Unigrams No Cost3 0.145 0.486 0.811 0.608 0.561 0.663 0.547 0.852 0.469 84.8% 101.3 
0.1 No Yes Unigrams No Cost3 0.102 0.542 0.715 0.617 0.590 0.646 0.548 0.797 0.494 87.1% 146.1 
0.1 No No Unigrams Yes Cost3 0.103 0.551 0.743 0.632 0.603 0.666 0.568 0.821 0.493 87.5% 20.5 
0.01 Yes Yes Unigrams Yes Cost3 0.134 0.506 0.807 0.622 0.578 0.673 0.562 0.880 0.544 85.8% 10.0 
0.01 No No Unigrams No Balanced Class 0.179 0.460 0.896 0.607 0.549 0.681 0.179 0.460 0.896 0.607 0.179 
0.01 Yes No Unigrams No Balanced Class 0.188 0.445 0.888 0.593 0.534 0.667 0.543 0.848 0.441 82.3% 93.1 
0.1 No Yes Unigrams No Balanced Class 0.149 0.484 0.823 0.610 0.561 0.667 0.551 0.846 0.493 84.7% 136.9 
0.1 No No Unigrams Yes Balanced Class 0.146 0.494 0.840 0.622 0.573 0.681 0.567 0.852 0.498 85.2% 17.3 


























0.01 No No Unigrams No Under-sampling 0.187 0.827 0.896 0.860 0.849 0.872 0.711 0.876 0.813 85.4% 27.7 
0.01 Yes No Unigrams No Under-sampling 0.236 0.797 0.928 0.858 0.836 0.880 0.702 0.871 0.802 84.6% 22.1 
0.1 No Yes Unigrams No Under-sampling 0.202 0.818 0.912 0.862 0.847 0.878 0.714 0.874 0.802 85.5% 30.4 
0.1 No No Unigrams Yes Under-sampling 0.185 0.830 0.902 0.864 0.853 0.877 0.719 0.880 0.818 85.8% 3.7 
0.01 Yes Yes Unigrams Yes Under-sampling 0.222 0.807 0.928 0.863 0.844 0.884 0.714 0.876 0.813 85.3% 2.8 
Over-sampling 
0.1 No No Unigrams Yes SMOTE2 0.068 0.795 0.776 0.785 0.789 0.782 0.714 0.920 0.814 89.3% 25.8 
0.1 No No Unigrams Yes SMOTE3 0.075 0.852 0.852 0.852 0.852 0.852 0.777 0.935 0.866 90.0% 34.6 
0.1 No No Unigrams Yes SMOTE4 0.083 0.880 0.898 0.889 0.886 0.892 0.813 0.940 0.893 90.9% 42.8 
0.1 No No Unigrams Yes SMOTE5 0.088 0.899 0.919 0.909 0.906 0.912 0.830 0.945 0.909 91.5% 89.5 
0.1 Yes No Bigrams Yes SMOTE3 0.082 0.844 0.867 0.855 0.852 0.859 0.780 0.932 0.843 90.1% 344.7 
0.1 Yes No Bigrams Yes SMOTE4 0.086 0.877 0.901 0.889 0.885 0.893 0.812 0.938 0.860 90.9% 453.3 
0.1 Yes No Bigrams Yes SMOTE5 0.088 0.900 0.926 0.913 0.909 0.917 0.837 0.944 0.891 91.9% 717.3 
0.1 Yes No Trigrams Yes SMOTE3 0.074 0.856 0.861 0.859 0.858 0.859 0.786 0.928 0.849 90.4% 961.0 


























0.1 No No Unigrams Yes 
SMOTE4 + 
Cost2 
0.131 0.829 0.939 0.881 0.863 0.899 0.796 0.930 0.855 89.7% 77.8 
0.1 No No Unigrams Yes 
SMOTE5 + 
Cost2 
0.131 0.860 0.950 0.903 0.888 0.918 0.816 0.937 0.889 90.6% 117.8 
0.1 No No Unigrams Yes 
SMOTE2 + 
Under-sampling 
0.149 0.860 0.916 0.887 0.878 0.897 0.769 0.911 0.858 88.3% 10.2 
0.1 No No Unigrams Yes 
SMOTE3 + 
Under-sampling 
0.132 0.875 0.922 0.897 0.890 0.906 0.790 0.924 0.875 89.5% 17.2 
0.1 No No Unigrams Yes 
SMOTE4 + 
Under-sampling 
0.115 0.889 0.925 0.907 0.901 0.913 0.811 0.931 0.896 90.5% 37.4 
0.1 No No Unigrams Yes 
SMOTE5 + 
Under-sampling 
0.099 0.904 0.931 0.917 0.913 0.922 0.832 0.940 0.910 91.6% 54.7 
0.1 Yes No Bigrams Yes 
SMOTE2 + 
Under-sampling 
0.155 0.857 0.928 0.891 0.879 0.903 0.776 0.909 0.847 88.6% 107.0 
0.1 Yes No Bigrams Yes 
SMOTE3 + 
Under-sampling 
0.125 0.881 0.924 0.902 0.895 0.909 0.800 0.926 0.875 89.9% 177.7 
0.1 Yes No Bigrams Yes 
SMOTE4 + 
Under-sampling 
0.110 0.895 0.930 0.912 0.906 0.918 0.821 0.933 0.883 91.0% 385.2 
0.1 Yes No Bigrams Yes 
SMOTE5 + 
Under-sampling 
0.096 0.906 0.931 0.918 0.914 0.923 0.835 0.940 0.896 91.7% 627.1 
0.1 Yes No Trigrams Yes 
SMOTE3 + 
Under-sampling 




A comparison of performance characteristics for the subset of best-in-group decision 
tree models is shown in Figure 7.3.  The sequential approach of 5x over-sampling (SMOTE5) 
followed by under-sampling applied to bigram features, provided the highest F1 score 
(0.918).  This hybrid combination also yielded the best unigram F1 score (0.917, not shown 
graphically), but still required almost an hour to run.  Therefore, for the model comparisons 
discussed in Section 7.1.5, SMOTE3 with under-sampling applied to unigram features was 
selected to represent the best decision tree classifier, as it provided good model 
performance (F1 score = 0.897) and executed in 17.2 minutes. 
 
Figure 7.3: Comparison of Decision Tree Cross-Validation Training Model Performance 
Characteristics for Selected Class Imbalance Adjustment Approaches. 
The starred, hybrid approach of SMOTE3 followed by under-sampling, represents the best 




7.1.4 Cross-Validation Training – SVM Results 
SVM models were trained using linear (56 models) and quadratic (38 models) 
kernels.  Gaussian and text kernel models were also attempted, but failed to execute the 
first of the planned 10 fold iterations after 400 hours and were terminated as being 
computationally unfeasible. 
As Cost2 models outperformed unadjusted models for decision tree algorithms, 
these models were explored first for the linear SVM classifiers, and then the best 
complexity parameter within each attribute selection combination was compared to its 
unadjusted, Cost3 and balanced class equivalent models.  Evaluations of over-sampling and 
hybrid approach models were all based on the combination (complexity parameter c=0.05 
with feature selection, but no stemming or stop words) that provided the best performance 
for the cost-adjusted and under-sampling approaches. 
Table 7.4 provides the detailed results of the linear SVM cross-validation training 
results, and Figure 7.4 graphically compares the performance of the best-in-group models.  
Although the sequential combination of 3x over-sampling (SMOTE3) followed by under-
sampling applied to bigram features achieved the highest F1 score (0.912), this model took 
over 2.5 hours to run.  As such, the same modeling approach applied to unigram features 
which ran in 15.7 minutes and yield an F1 score = 0.887 was selected to represent the best 
linear SVM model for model comparisons (Section 7.1.5).  If maximizing computational 
speed is a priority, then an under-sampling approach which executed in less than a minute 





Table 7.4: Linear SVM Cross-Validation Training Results. 
Yellow highlighted rows emphasize the unigram models deemed to have the best balance of performance characteristics within each 
class imbalance adjustment group.  The row in blue highlights the model providing the highest F1 score overall.  FP = False Positive; 
MCC = Matthews correlation coefficient; ROC = receiver operating characteristic area under the curve; PRC = precision-recall curve 




















No Class Balance Adjustment 
0.05 No No Unigrams No None 0.042 0.693 0.561 0.620 0.643 0.599 0.568 0.929 0.679 90.0% 5.5 
0.05 Yes No Unigrams No None 0.039 0.690 0.515 0.590 0.620 0.563 0.539 0.919 0.657 89.6% 3.9 
0.1 No Yes Unigrams No None 0.042 0.677 0.517 0.586 0.614 0.561 0.533 0.917 0.649 89.4% 6.8 
0.5 No No Unigrams Yes None 0.042 0.691 0.549 0.612 0.636 0.589 0.560 0.929 0.674 89.9% 43.0 
0.5 Yes Yes Unigrams Yes None 0.039 0.672 0.466 0.550 0.586 0.519 0.501 0.909 0.630 89.0% 30.4 
Cost Adjustment 
0.01 No No Unigrams No Cost2 0.087 0.588 0.727 0.650 0.628 0.674 0.588 0.820 0.467 88.6% 1.8 
0.05 No No Unigrams No Cost2 0.076 0.611 0.705 0.655 0.639 0.671 0.593 0.933 0.673 89.2% 7.3 
0.1 No No Unigrams No Cost2 0.082 0.599 0.721 0.654 0.635 0.675 0.593 0.819 0.472 89.0% 10.9 
0.01 Yes No Unigrams No Cost2 0.086 0.581 0.700 0.635 0.616 0.655 0.570 0.807 0.450 88.3% 1.6 
0.05 Yes No Unigrams No Cost2 0.085 0.588 0.718 0.646 0.626 0.669 0.584 0.816 0.463 88.6% 6.5 
0.1 Yes No Unigrams No Cost2 0.086 0.586 0.715 0.644 0.623 0.666 0.581 0.815 0.461 88.6% 10.2 
0.05 No Yes Unigrams No Cost2 0.088 0.578 0.713 0.638 0.617 0.661 0.574 0.812 0.454 88.3% 3.8 
0.1 No Yes Unigrams No Cost2 0.088 0.579 0.713 0.639 0.618 0.662 0.575 0.812 0.454 88.3% 6.1 
0.5 No Yes Unigrams No Cost2 0.088 0.574 0.697 0.630 0.610 0.651 0.563 0.805 0.444 88.1% 34.2 
0.01 No No Unigrams Yes Cost2 0.088 0.582 0.720 0.644 0.622 0.667 0.580 0.816 0.460 88.4% 0.6 
0.05 No No Unigrams Yes Cost2 0.078 0.605 0.709 0.653 0.636 0.671 0.591 0.932 0.670 89.1% 2.9 
0.1 No No Unigrams Yes Cost2 0.084 0.595 0.730 0.656 0.634 0.679 0.594 0.823 0.473 88.9% 5.3 
0.5 No No Unigrams Yes Cost2 0.078 0.607 0.713 0.655 0.639 0.674 0.594 0.932 0.670 89.1% 31.2 
1 No No Unigrams Yes Cost2 0.079 0.603 0.712 0.653 0.635 0.672 0.591 0.932 0.668 89.0% 60.8 
0.05 Yes Yes Unigrams Yes Cost2 0.097 0.555 0.716 0.625 0.600 0.653 0.558 0.809 0.438 87.5% 2.1 
0.1 Yes Yes Unigrams Yes Cost2 0.098 0.555 0.724 0.628 0.602 0.657 0.563 0.813 0.442 87.6% 6.3 
0.5 Yes Yes Unigrams Yes Cost2 0.099 0.556 0.730 0.631 0.604 0.661 0.566 0.816 0.445 87.6% 17.9 

























Cost Adjustment (Continued) 
0.05 No No Unigrams No Cost3 0.116 0.543 0.813 0.651 0.611 0.697 0.595 0.848 0.469 87.4% 8.8 
0.05 Yes No Unigrams No Cost3 0.121 0.529 0.804 0.638 0.597 0.685 0.580 0.841 0.454 86.8% 7.9 
0.1 No Yes Unigrams No Cost3 0.117 0.532 0.789 0.636 0.597 0.680 0.575 0.836 0.451 86.9% 9.6 
0.1 No No Unigrams Yes Cost3 0.109 0.553 0.796 0.653 0.616 0.694 0.595 0.931 0.658 87.7% 4.7 
0.5 Yes Yes Unigrams Yes Cost3 0.119 0.526 0.776 0.627 0.589 0.670 0.564 0.916 0.613 86.6% 30.1 
0.05 No No Unigrams No Balanced Class 0.149 0.499 0.876 0.635 0.583 0.700 0.587 0.930 0.639 85.4% 6.1 
0.05 Yes No Unigrams No Balanced Class 0.162 0.477 0.869 0.616 0.561 0.682 0.565 0.922 0.612 84.3% 5.5 
0.1 No Yes Unigrams No Balanced Class 0.159 0.477 0.854 0.612 0.559 0.676 0.559 0.920 0.604 84.3% 7.8 
0.05 No No Unigrams Yes Balanced Class 0.166 0.478 0.894 0.623 0.566 0.693 0.577 0.929 0.637 84.3% 4.7 
0.5 Yes Yes Unigrams Yes Balanced Class 0.172 0.463 0.872 0.605 0.549 0.674 0.553 0.915 0.590 83.5% 27.1 
Under-sampling 
0.05 No No Unigrams No Under-sampling 0.162 0.847 0.894 0.870 0.862 0.878 0.733 0.929 0.901 86.6% 1.0 
0.05 Yes No Unigrams No Under-sampling 0.172 0.838 0.889 0.862 0.854 0.871 0.718 0.923 0.895 85.8% 0.7 
0.1 No Yes Unigrams No Under-sampling 0.173 0.835 0.879 0.857 0.849 0.864 0.707 0.920 0.890 85.3% 0.8 
0.05 No No Unigrams Yes Under-sampling 0.165 0.845 0.903 0.873 0.863 0.883 0.739 0.928 0.903 86.9% 0.4 
0.5 Yes Yes Unigrams Yes Under-sampling 0.175 0.834 0.879 0.856 0.848 0.863 0.704 0.915 0.885 85.2% 3.3 
Over-sampling 
0.05 No No Unigrams Yes SMOTE2 0.085 0.754 0.770 0.762 0.759 0.765 0.681 0.843 0.639 87.8% 15.7 
0.05 No No Unigrams Yes SMOTE3 0.106 0.801 0.839 0.819 0.813 0.826 0.725 0.942 0.856 87.5% 28.2 
0.05 No No Unigrams Yes SMOTE4 0.141 0.815 0.916 0.862 0.846 0.880 0.763 0.887 0.780 88.2% 47.4 
0.05 No No Unigrams Yes SMOTE5 0.160 0.833 0.942 0.884 0.866 0.903 0.780 0.891 0.811 88.7% 67.9 


























0.05 No No Unigrams Yes 
SMOTE2 + 
Cost2 
0.149 0.673 0.904 0.772 0.736 0.811 0.693 0.878 0.633 86.5% 19.6 
0.05 No No Unigrams Yes 
SMOTE3 + 
Cost2 
0.157 0.750 0.926 0.829 0.801 0.859 0.738 0.941 0.844 87.1% 28.9 
0.05 No No Unigrams Yes 
SMOTE3 + 
Cost3 
0.185 0.725 0.956 0.824 0.789 0.864 0.734 0.939 0.837 86.3% 28.7 
0.05 No No Unigrams Yes 
SMOTE4 + 
Cost2 
0.198 0.768 0.969 0.857 0.825 0.891 0.757 0.885 0.757 87.0% 39.6 
0.05 No No Unigrams Yes 
SMOTE4 + 
Cost3 
0.228 0.745 0.982 0.847 0.810 0.888 0.742 0.877 0.739 85.7% 43.1 
0.05 No No Unigrams Yes 
SMOTE5 + 
Cost2 
0.211 0.798 0.978 0.879 0.850 0.910 0.771 0.884 0.790 87.6% 61.3 
0.05 No No Unigrams Yes 
SMOTE3 + 
Under-sampling 
0.160 0.853 0.924 0.887 0.875 0.899 0.767 0.939 0.911 88.2% 15.7 
0.05 No No Unigrams Yes 
SMOTE4 + 
Under-sampling 
0.156 0.856 0.931 0.892 0.880 0.905 0.777 0.941 0.913 88.7% 43.0 
0.05 No No Unigrams Yes 
SMOTE5 + 
Under-sampling 
0.152 0.860 0.934 0.895 0.883 0.908 0.785 0.943 0.916 89.1% 64.7 
0.05 Yes No Bigrams Yes 
SMOTE3 + 
Under-sampling 
0.128 0.881 0.946 0.912 0.902 0.923 0.820 0.955 0.931 90.9% 159.0 
0.05 Yes No Bigrams Yes 
SMOTE4 + 
Under-sampling 
0.121 0.887 0.953 0.919 0.908 0.930 0.958 0.935 91.6% 314.4 0.958 
0.05 Yes No Bigrams Yes 
SMOTE5 + 
Under-sampling 
0.117 0.891 0.957 0.923 0.912 0.934 0.842 0.960 0.937 92.0% 467.5 
0.05 Yes No Trigrams Yes 
SMOTE3 + 
Under-sampling 





Figure 7.4: Comparison of Linear SVM Cross-Validation Training Model Performance 
Characteristics for Selected Class Imbalance Adjustment Approaches. 
The starred, hybrid approach of SMOTE3 followed by under-sampling, represents the best 
linear SVM classifier for model comparisons performed in Section 7.1.5. 
 
When training the quadratic SVM models, a similar approach was taken to that used 
for the linear SVM models with the exception that a reduced cohort of unadjusted and 
Cost3 and balanced class cost adjusted models were evaluated.  For the quadratic SVM 
models, parameter tuning was accomplished using the Cost2 models, and then only the 
best Cost2 model combination of characteristics (complexity parameter c=0.005, no 
stemming, no stop words, with feature reduction) was evaluated for the unadjusted, Cost3 
and balanced class groups.  This was due to the increased computational time required for 




outperform unadjusted, Cost3 and balanced class cost-adjustment models for both linear 
SVM and decision tree classification algorithms. 
Table 7.5 provides the detailed results of the quadratic SVM cross-validation training 
results.  Extrapolating the time comparison of bigram versus trigram models for Naïve 
Bayes, decision tree and linear SVM results, execution of quadratic SVM trigram models 
would have likely required several days.  Furthermore, the trigram models for the other 
classification approaches generally yielded little to no performance improvement compared 
to their bigram counterparts.  Thus, it was deemed impractical to generate trigram results 
for the quadratic SVM classifier.  A bigram model was evaluated and, similar to the other 
classification algorithms, provided the highest overall F1 score (0.936).  However, this model 
required nearly 20 hours of computational time to complete. 
Figure 7.5 graphically compares the performance of the best-in-group models.  
Model run time became an important criterion for comparing the best-in-group quadratic 
SVM models.  The unigram counterpart to the bigram model discussed above, with a 
sequential combination of SMOTE3 followed by under-sampling, provided the next highest 
F1 score (0.924).  However, this model still required several hours (4.0) to execute.  
Consequently, among the quadratic SVM models, an under-sampling only approach was 
chosen as providing the best balance of performance and efficiency, producing an F1 score = 
0.881 and a run-time of 5.8 minutes.  This model is compared to the selected models 





Table 7.5: Quadratic SVM Cross-Validation Training Results. 
Yellow highlighted rows emphasize the unigram models deemed to have the best balance of performance characteristics within each 
class imbalance adjustment group.  The row in blue highlights the model providing the highest F1 score overall.  FP = False Positive; 
MCC = Matthews correlation coefficient; ROC = receiver operating characteristic area under the curve; PRC = precision-recall curve 




















No Class Balance Adjustment 
0.005 No No Unigrams Yes None 0.047 0.701 0.646 0.672 0.682 0.663 0.62 0.942 0.711 90.9% 74.6 
Cost Adjustment 
0.0005 No No Unigrams No Cost2 0.077 0.626 0.765 0.689 0.666 0.712 0.634 0.844 0.513 90.0% 60.7 
0.001 No No Unigrams No Cost2 0.073 0.640 0.763 0.696 0.676 0.717 0.643 0.845 0.523 90.4% 66.4 
0.005 No No Unigrams No Cost2 0.064 0.656 0.725 0.689 0.677 0.700 0.634 0.830 0.515 90.5% 81.7 
0.01 No No Unigrams No Cost2 0.065 0.647 0.696 0.670 0.663 0.679 0.613 0.816 0.494 90.1% 106.9 
0.05 No No Unigrams No Cost2 0.066 0.625 0.645 0.635 0.632 0.638 0.572 0.790 0.454 89.2% 169.5 
0.1 No No Unigrams No Cost2 0.068 0.612 0.629 0.620 0.618 0.623 0.555 0.780 0.438 88.8% 229.6 
0.0005 Yes No Unigrams No Cost2 0.076 0.624 0.745 0.679 0.660 0.700 0.623 0.834 0.502 89.8% 65.0 
0.001 Yes No Unigrams No Cost2 0.074 0.632 0.746 0.685 0.666 0.704 0.629 0.836 0.509 90.0% 77.1 
0.005 Yes No Unigrams No Cost2 0.067 0.641 0.708 0.672 0.662 0.684 0.615 0.820 0.496 90.0% 93.1 
0.01 Yes No Unigrams No Cost2 0.066 0.638 0.687 0.662 0.654 0.670 0.602 0.811 0.484 89.8% 113.4 
0.05 Yes No Unigrams No Cost2 0.067 0.620 0.644 0.632 0.628 0.636 0.568 0.788 0.451 89.1% 194.2 
0.1 Yes No Unigrams No Cost2 0.071 0.600 0.627 0.613 0.609 0.618 0.546 0.778 0.430 88.5% 255.1 
0.001 No Yes Unigrams No Cost2 0.080 0.611 0.742 0.670 0.649 0.693 0.612 0.831 0.491 89.4% 65.0 
0.005 No Yes Unigrams No Cost2 0.070 0.638 0.730 0.681 0.666 0.697 0.625 0.830 0.505 90.1% 70.3 
0.01 No Yes Unigrams No Cost2 0.067 0.643 0.710 0.675 0.664 0.686 0.617 0.822 0.498 90.1% 79.8 
0.05 No Yes Unigrams No Cost2 0.067 0.625 0.659 0.642 0.636 0.647 0.579 0.796 0.461 89.3% 101.7 
0.1 No Yes Unigrams No Cost2 0.068 0.612 0.633 0.622 0.619 0.626 0.557 0.783 0.441 88.9% 119.9 
0.001 No No Unigrams Yes Cost2 0.069 0.644 0.731 0.685 0.671 0.700 0.629 0.943 0.709 90.2% 63.5 
0.005 No No Unigrams Yes Cost2 0.062 0.659 0.711 0.684 0.675 0.693 0.629 0.944 0.709 90.5% 57.8 
0.01 No No Unigrams Yes Cost2 0.069 0.640 0.719 0.677 0.664 0.691 0.620 0.825 0.501 90.1% 103.9 
0.05 No No Unigrams Yes Cost2 0.069 0.616 0.656 0.635 0.629 0.642 0.572 0.793 0.454 89.1% 156.6 

























Cost Adjustment (Continued) 
0.001 Yes Yes Unigrams Yes Cost2 0.094 0.583 0.773 0.665 0.635 0.697 0.607 0.840 0.484 88.7% 62.6 
0.005 Yes Yes Unigrams Yes Cost2 0.082 0.609 0.757 0.675 0.651 0.700 0.618 0.837 0.496 89.4% 60.1 
0.01 Yes Yes Unigrams Yes Cost2 0.078 0.617 0.739 0.672 0.653 0.693 0.614 0.831 0.494 89.6% 63.6 
0.05 Yes Yes Unigrams Yes Cost2 0.074 0.610 0.685 0.645 0.633 0.658 0.582 0.805 0.463 89.1% 115.7 
0.1 Yes Yes Unigrams Yes Cost2 0.076 0.596 0.664 0.628 0.617 0.640 0.562 0.794 0.445 88.6% 123.2 
0.005 No No Unigrams Yes Cost3 0.062 0.659 0.711 0.684 0.675 0.693 0.629 0.944 0.709 90.5% 94.1 
0.005 No No Unigrams Yes Balanced Class 0.126 0.538 0.868 0.665 0.616 0.721 0.617 0.871 0.487 87.3% 91.0 
Under-sampling 
0.001 No No Unigrams No Under-sampling 0.145 0.861 0.898 0.879 0.873 0.885 0.754 0.941 0.918 87.7% 7.6 
0.001 Yes No Unigrams No Under-sampling 0.150 0.857 0.898 0.877 0.870 0.884 0.749 0.939 0.917 87.4% 8.6 
0.005 No Yes Unigrams No Under-sampling 0.138 0.866 0.889 0.877 0.874 0.881 0.751 0.938 0.915 87.6% 7.6 
0.005 No No Unigrams Yes Under-sampling 0.126 0.876 0.886 0.881 0.879 0.883 0.76 0.942 0.919 88.0% 5.8 
0.005 Yes Yes Unigrams Yes Under-sampling 0.148 0.859 0.907 0.882 0.879 0.890 0.759 0.938 0.915 87.9% 6.1 
Over-sampling 
0.005 No No Unigrams Yes SMOTE3 0.074 0.862 0.910 0.885 0.877 0.893 0.825 0.972 0.923 92.0% 466.2 
Hybrid Approach 
0.005 No No Unigrams Yes 
SMOTE3 + 
Under-sampling 0.101 0.903 0.945 0.924 0.917 0.931 0.845 0.967 0.950 92.2% 241.8 
0.005 Yes No Bigrams Yes 
SMOTE3 + 





Figure 7.5: Comparison of Quadratic SVM Cross-Validation Training Model Performance 
Characteristics for Selected Class Imbalance Adjustment Approaches. 
The starred, under-sampling approach, represents the best quadratic SVM classifier for 
model comparisons performed in Section 7.1.5. 
 
7.1.5 Final Model Selection and Testing 
In order to select a model to generate final test performance measures and to 
proceed with hypothesis testing (Section 7.2), the performance of the selected model 
within each classification approach was compared.  Table 7.6 summarizes the 
characteristics of the chosen Naïve Bayes, decision tree, linear SVM and quadratic SVM 
models.  Figure 7.6 shows a side-by-side comparison of the models’ precision, recall, F1 
score and run time, similar to the graphical presentations in the previous sections, while 











Adjustment Precision Recall F1 PRC Area 
Run Time 
(Minutes) 
Naïve Bayes NA Under-sampling 0.792 0.822 0.807 0.848 0.2 
Decision Tree 0.1 
SMOTE3 + 
Under-sampling 
0.875 0.922 0.897 0.875 17.2 
Linear SVM 0.05 
SMOTE3 + 
Under-sampling 
0.853 0.924 0.887 0.911 15.7 




Figure 7.6: Comparison of Best-of-Classifier Cross-Validation Training Model 
Performance Characteristics. 
The starred, quadratic SVM model with under-sampling, represents the best overall 









During the main model training and evaluation, all Riata leads (Riata, Riata ST and 
Riata ST Optim) were labeled as Class I recall = yes.  However, the Riata ST Optim leads, 
while similar in design to the Riata and Riata ST leads with the exception of the insulation 
used to coat the lead, were not included in the 2011 recall of the Riata and Riata ST leads 
and are considered separately in the subsequent sections.  The four modeling approaches 
compared in Table 7.6 and Figures 7.6 and 7.7 were retrained with the Riata ST Optim leads 
separately classified, with the results shown in Table 7.7 and Figures 7.8 and 7.9.  With the 
exception that the decision tree and linear SVM approaches required longer to run (as a 
result of increased number of attributes), the results are comparable  to those generated 




Table 7.7: Performance Characteristics of Selected Best-of-Classifier Cross-Validation 






Adjustment Precision Recall F1 PRC Area 
Run Time 
(Minutes) 
Naïve Bayes NA Under-sampling 0.768 0.809 0.788 0.834 0.2 
Decision Tree 0.1 
SMOTE3 + 
Under-sampling 0.872 0.902 0.887 0.883 31.3 
Linear SVM 0.05 
SMOTE3 + 
Under-sampling 0.846 0.922 0.882 0.901 21.5 




Figure 7.10: Comparison of Best-of-Classifier Cross-Validation Training Model 
Performance Characteristics – Updated Models. 
The starred, quadratic SVM model with under-sampling, represents the best overall 





Figure 7.8: Comparison of Best-of-Classifier Cross-Validation Training Model Precision-
Recall Curves  – Updated Models. 
 
As shown in Figures 7.2-7.5, decision tree and support vector machine models 
consistently out-performed Naïve Bayes models within the group of selected models, and 
also yielded better performance metrics across all of the class imbalance approaches 
evaluated, with the exception of model run time.  The ‘best’ choice among decision tree, 
linear SVM and quadratic SVM is subjective, and there are several tradeoffs to consider.  
Decision trees are more readily interpretable and provide the highest F1 score of the models 
in consideration.  However as illustrated in Figure 7.7 and 7.8, both linear and quadratic 




model provided the highest recall measure, and the quadratic SVM furnished the highest 
precision estimate.  Finally, the quadratic SVM classifier provided the highest PRC estimate 
and required just one-third of the time to train compared to the selected decision tree and 
linear SVM models. 
Weighing all of these factors and giving consideration to the number of planned 
subsequent sensitivity analyses requiring model re-execution, the quadratic SVM model 
having complexity parameter c=0.005 with feature selection, but no stemming or stop 
words was selected as providing the best combination of performance metrics for this 
project.  Thus, this model was applied to the held-out test data, yielding the results 
summarized in Table 7.8. 
Table 7.8: Performance Metrics and Confusion Matrix Obtained Applying the Quadratic 
SVM Classifier to the Held-out Test Data. 
 
Model Characteristics Model Performance Results 
Classifier SVM F1 score 0.622 
Kernel Quadratic Precision 0.488 
Stemming No Recall 0.859 
Stop Words No Precision-Recall Area 0.617 




ROC Area 0.933 
Accuracy 86.4% 
 
 Actual Classification 
Total 
Recalled Not Recalled 
Model Prediction 
Recalled 1,506 1,581 3,087 
Not Recalled 247 10,123 10,370 






Comparing model performance results from the training and testing cohorts, recall – 
that is, the proportion of actual recalls correctly predicted by the model - stays about the 
same (0.876 training versus 0.859 testing).  However, precision – the proportion of 
predicted recalls that are correct - drops substantially between training (0.886) and testing 
(0.488), with a corresponding decrease in F1 scores (0.881 training versus 0.622 testing).  
More will be said about this in the upcoming hypothesis and sensitivity analysis sections. 
7.1.6 Machine Learning Discussion 
Over 200 cross-validation training models were evaluated across a variety of 
algorithms, parameter settings, variance reduction techniques and class imbalance 
adjustment approaches.  Opportunities for improving the model include exploring other 
text classification algorithms, fine-tuning model parameter selection, and investigating 
other class imbalance approaches.  However given the findings by Chai, (111) a semi-
supervised approach to feature selection, rather than the automated feature selection 
process used in this study, may offer the best avenue for improving model performance.  
With such a process, the standard text classification training workflow would be iteratively 
refined to incorporate modifications based on investigation of misclassification errors. 
From among the large number of text classification models generated, I chose to 
proceed with a quadratic SVM model after factoring together model performance and 
efficiency.  It is quite likely that others would weigh the model characteristics differently 
and choose an alternative model with which to proceed with testing.  Additional  
comparisons, including contrasts between classifiers using the same modeling approach and 




provided in Appendix F.  However, as the top-performing machine learning models provided 
similar results, it is reasonable to assume that model choice did not have a large impact on 
overall findings and conclusions drawn from the hypothesis and sensitivity analyses 
presented in the next sections.  To an extent, the resilience of the model to different 
classification assignments was realized when performing the model training first with all 
Riata leads labeled as Class I recalls, and then with the Riata St Optim leads separately 
grouped as non-recalled leads, providing comparable model results.  As discussed in Section 
4.8, any model will incur labeling misclassifications, and thus this result suggests that such 
misclassifications do not undermine the overall model results.  
There are two approaches to making a classifier cost-sensitive: cost sensitive 
classification and cost-sensitive learning.  This project only examined cost-sensitive learning, 
a standard method for handling class-imbalanced data.  In this approach, training instances 
are re-weighted to adjust the probability of making (false negative) errors.  Cost-sensitive 
classification, in contrast, adjusts a classifier’s output by recalculating the probability 
thresholds as determined by an assigned cost matrix. 
The weighted assignments explored in this work were based only on maximizing 
precision and recall statistics for the Class I recall class; however, one could motivate model 
selection by actual monetary costs, if known.  While several groups have published 
estimates on various costs to the health system of product recalls, (231-234) to date, no 
published data was discovered that provided similar estimates for the cost of more rigorous 





7.2 Hypothesis Testing Results 
The main objective of this study was to investigate whether information present in 
MAUDE adverse event text descriptions provided an early signal of product problems in 
advance of Class I ICD lead recalls (Sections 7.2.1 and 7.2.2).  Two secondary hypotheses 
evaluating the model's predictive ability for: 1) recalled medical devices that are 
increasingly differentiated from ICD leads, and 2) less serious ICD lead recalls, were also 
evaluated with results presented in Sections 7.2.3 and 7.2.4, respectively. 
7.2.1 Primary Hypothesis of Early Prediction 
After selection and characterization of the quadratic SVM text classifier, this model 
was applied to the entire ICD lead analysis dataset.  The resulting predictions of Class I recall 
were then systematically evaluated using disproportionality analysis techniques to 
determine whether signals were evident in advance of the actual date of recall.  Figures 7.8-
7.10 present heat map results by individual quarter and ICD lead for the three standard 
disproportionality analysis (DPA) measures applied to this data: the lower bound confidence 
intervals of the Bayesian empirical Bayes gamma mean (EB05), the Bayesian confidence 
neural network (BCPNN025), and the frequentist proportional reporting ratio (PRR025).  
Corresponding detailed tabular results from which the heat maps were generated are 
provided in Appendix G.  With the exception of four lead models with no positive Class I 
recall predictions (AngeFlex, AngePass, Vigila 2, and Linox Smart ProMRI), all leads are 
represented in these tables and figures.  Cumulative results over time, results for combined 







Figure 7.9: Individual Quarter EB05 Heat Map - Discrete Leads. 




Figure 7.10: Individual Quarter BCPNN025 Heat Map - Discrete Leads.  






Figure 7.11: Individual Quarter PRR025 Heat Map - Discrete Leads. 
The Sprint Fidelis was recalled October 25,2007; the Riata/Riata ST November 28, 2011. 
 
The discussion here focuses on the EB05 results planned as the primary signal 
indicator.  However, all three signal detection metrics provide similar results.  Using the 
standard value of EB05 > 2 to identify a signal of disproportionality, a signal portending lead 
recall was consistently demonstrated for both the Riata and Riata ST leads by Q2.2010, 
approximately six months prior to removal of these leads from distribution and 18 months 
prior to their recall.  Assuming a less stringent signal value of EB05 > 1 as proposed by 
Harpaz (see Section 3.2), consistent signals for the Riata were observed by Q4.2007 and for 





A trend is also observed, but not as strongly for the Sprint Fidelis lead, with EB05 
values ranging from 1.03 to 1.93 during the entire time period before device recall.  There 
are at least two potential explanations for the weaker Sprint Fidelis signal.  Due to the 
timing of the Sprint Fidelis and Riata product distributions and recalls, the majority of 
training records belong to the Riata lead groups.  Thus, the weaker Sprint Fidelis signal may 
reflect sensitivity of the model to individual lead and the smaller number of Sprint Fidelis 
examples, a topic explored in more detail in Section 7.3.1 which details the results of the 
planned sensitivity analysis by lead.  Alternatively, there are a large number of lead models 
that incorporate “Sprint” into the model name (Sprint, Sprint Fidelis, Sprint Quattro, Sprint 
Quattro Secure and Sprint Quattro Secure MRI), with only one of these (Sprint Fidelis) 
subject to the Class I recall.  Although both model number and names were used to group 
leads by model, the weaker Sprint Fidelis signal may reflect a greater level of product 
misclassification when the adverse event report was initially submitted due to the wide-
spread “Sprint” naming convention.  This could also explain the signals seen for the Sprint, 
Sprint Quattro and Sprint Quattro Secure leads.  Although modest signals for these other 
“Sprint” leads were detected prior to 2006, since that time the EB05 statistics for these 
leads have been well below an EB05 threshold of one, and these leads are generally 
considered to be safe and effective. (235, 236) 
Finally, all of the DPA measures showed a strong signal for the non-recalled Durata 
and Riata ST Optim leads.  That is, although the model was trained with these leads labeled 
as “non-recalled”, the DPA measures consistently indicated a signal consistent with a lead 




Optim leads were approved in 2006 and in January 2008, SJM submitted a PMA tradename 
change to label all of the Riata ST Optim model numbers as Durata. (237)  Thus, although 
both model number and names were used to group leads as Riata, Riata ST, Rata ST Optim 
or Durata, it is possible that the Durata and Riata ST Optim signals are partially the result of 
product misclassification at the time the adverse event report was submitted to MAUDE.  
However, in contrast to the potential carry-over signal effects seen for the non-recalled 
“Sprint” leads, the Durata and Riata ST Optim signals are much stronger, consistent and 
enduring. 
Another possible explanation for the Durata signal is that as knowledge of the Riata 
and Riata ST lead problems surfaced, issues with Durata and Riata ST Optim leads – which 
are also manufactured by SJM - were more likely to be reported.  Given limitations with SRS 
databases, it is not possible to determine the rate of reporting for any particular lead.  
However, the negative press surrounding the Riata/Riata ST recall coupled with the striking 
similarity of the Durata and Riata ST Optim leads to the Riata ST certainly raises this 
possibility.  In fact, the Riata ST Optim EB05 signal (7.19) was highest in Q2.2012, 
approximately five months after the Rita/Riata ST recall, and the Durata signal in Q4.2012 
(6.27).  On the other hand, strong signals for both of these leads were first evidenced by the 
second quarter of 2010, about six months prior to SJM’s Dear Doctor letter communicating 
information about the potential insulation abrasion issue with the Riata and Riata ST leads. 
Finally, the goal of the text mining based signal detection is to identify potential 
reports that are similar to those of recalled leads, thereby identifying other leads that may 




made of silicone and polyurethane but is otherwise similar in design to the Riata ST leads.” 
(77)  Swerdlow reported conductor cable migration in the Durata lead, an issue also seen in 
the recalled Riata lead groups. (238)  And Durata and ST Optim lead failures have been 
attributed to both insulation abrasion (132, 238, 239) and fatigue fractures in the IS-1 
connector leg, (135) both of which have been found in the recalled Riata and Riata ST leads.  
Analysts have also raised concerns about a pending Durata recall, (240, 241) and in August 
2012 the FDA issued an order requiring SJM to augment its postmarket surveillance efforts 
to include study of the Durata and Riata St Optim leads based on concerns about insulation 
failure. (242-244)  As such, it is possible that the observed Durata DPA results represent a 
legitimate signal of a potential product problem worth monitoring. 
7.2.2 Additional Disproportionality Analyses 
Signal algorithms were also evaluated on cumulative quarterly data, in a manner 
similar to the approach used by Duggirala. (93)  As shown in Appendix G, similar results 
were obtained as when evaluated on individual quarters, with the cumulative quarterly 
results delivering stronger signals for the three recalled leads, but also less discrimination 
(i.e., more ICD leads showing a potential signal) across the other ICD lead products. 
One potential limitation with analyzing data cumulatively results from the approach 
used to censor data at the time of recall.  Censoring is appropriate while training the model 
in order to avoid learning from adverse event reports that were described with knowledge 
of the product’s recall.  However, for the cumulative disproportionality analyses, this 
censoring effectively holds the total number of records static after the date of recall, where 




database.  As a result, after a lead is censored, an artificially stronger cumulative signal may 
result for the other, non-recalled ICD leads.  In fact, the cumulative results did indeed 
appear to demonstrate signal increases among the non-recalled ICD leads following a recall.  
Because the relative number of Sprint Fidelis records were fairly small, the impact of 
censoring the Sprint Fidelis lead did not appear to be large.  However, a larger rise in the 
DPA measures was seen after removal of the recalled Riata lead groups, and as such the 
cumulative quarter results are truncated at 2011, after the Riata/Riata ST recalls. 
A more appropriate cumulative analysis may result by applying the text classification 
model to the entire, uncensored MAUDE ICD lead cohort.  While this would likely 
demonstrate a strong and uninformative recall signal subsequent to the date of recall, it 
may provide a better assessment of the true potential signal strength among the remaining 
leads if one were most interested in a cumulative analysis.  Because the cumulative results 
appeared to be less specific than the those achieved when evaluating individual quarter 
data and as additional analyses would require significant work to accomplish the necessary 
text pre-processing for the group of censored lead records, further work along these lines 
were not pursued, but could provide an interesting avenue of subsequent exploration. 
In addition to evaluating DPA measures across cumulative quarters, DPA statistics 
were also generated for combined lead groups.  In Duggirala’s ICD lead DPA, brand names 
were grouped using ‘custom terms’. (93)  A similar approach was evaluated in this study 
with the DPA applied to composite groups by lead name, e.g., a Vigila Group comprised of 
both Vigila 1 and Vigila 2; a Riata Group including both the Riata and Riata ST leads, a 




results and conclusions drawn from the composite brand groups used in the current 
analysis draw the same conclusions as did the analyses by individual ICD lead brand name.  
It is likely a matter of preference as to whether to group, or not, lead names together.  
Because details describing the makeup of the custom groups used by Duggirala were not 
provided, the groupings used in the current study are likely similar to, but not necessarily 
the same as, those reported in Duggirala’s paper.  As such, the grouped results from the 
current study are provided in Appendix G, with results provided for both individual and 
cumulative quarters. 
Finally, in the primary DPA discussed in Section 7.2.1, the main text classification 
model was re-applied to the entire ICD lead cohort, rather than using predictions from the 
held-out test cohort only.  While this approach mirrors the methodology as it would likely 
be applied in the real world, it raises the potential question of whether the DPA results 
were unduly biased given that the model was trained using two-thirds of the data to which 
it was subsequently applied.  Therefore, additional analyses were conducted in which the 
DPA measures were generated for just the held-out test data.  Figure 7.12 shows the 
resulting EB05 heat map  
Comparing Figure 7.12 to Figure 7.9, the DPA results from the held-out test data are 
quite consistent with those obtained using the entire data cohort.  First detection of strong 
signal responses occurs at the same time points.  Due to the smaller sample size of the test 
dataset, the number of modest signals (EB05 greater than 1 but less than 2) are more 
limited as compared to the analysis using the entire database; otherwise, the main 




maps were generated are provided in Appendix G, as are graphical and tabular results for 
the BCPNN025 and PRR025 results, both of which provide similar results to those generated 
in the primary analysis. 
 
 
Figure 7.12: Individual Quarter EB05 Heat Map - Discrete Leads, Held-Out Test Data. 
The Sprint Fidelis was recalled October 25,2007; the Riata/Riata ST November 28, 2011.  ICD 
leads with no Class I recall predictions and are not included in this Figure. 
 
7.2.3 Secondary Hypothesis 1 of Model Performance across Non-ICD Lead Medical 
Devices 
Cohorts 2-4 were selected to represent an increasing order of expected 
differentiation from the ICD lead data comprising Cohort 1.  It was hypothesized that the 
model’s performance would deteriorate by cohort.  Since Cohorts 2-4 consist only of 
recalled products, recall score (sensitivity) is the logical measure of comparison as precision 




As shown in Figure 7.13, within the cohorts representing cardiovascular products, 
the trend was as expected with the model sensitivity decreasing as products became more 
differentiated from ICD leads.  However, the sensitivity of the model was surprisingly good 
for MoM THRs, even outperforming that of the model applied to the ICD lead cohort.  As a 
result, the Spearman’s rank-correlation coefficient (ρ=0.2) evaluating the model’s sensitivity 
across increasingly differentiated products was not statistically significant (p=0.8). 
 
 
Figure 7.13: Model Sensitivity Scores by Cohort. 
 
Generally speaking, the model performed well across all cohorts.  Although the 
sample cohorts from the other device types were relatively small, these results give some 
indication that use of a text-mining based approach to identifying recalled products may 
work well across a wide spectrum of products.  These results, albeit across a very limited 
number of records and products, may also suggest that a universal, rather than device-




needed, but it would be highly advantageous and much more expedient if a collective 
approach were found to be successful. 
7.2.4 Secondary Hypothesis 2 of Model Performance for Class I Versus Class II Recalls 
It was also hypothesized that the model’s performance (sensitivity) would be higher 
for the group of Class I recalled ICD leads upon which it was trained, than for less serious 
Class II recalls.  Using the subset of recalled ICD leads in the held-out test data, a significant 
difference (p < 0.001) was observed when comparing the model’s sensitivity for Class I and 
Class II recalled ICD leads (Table 7.9).  Thus, the trained quadratic SVM text classifier 
appeared to provide good differentiation between more and less serious product recalls.  
The ability of the model to isolate the more serious Class I recalls from less serious Class II 
recalls was desirable in the current work.  However, this finding also implies that if one were 
interested in predicting any recall within the group of ICD leads, it would be important to 
include both Class I and Class II recall examples during the model training.  Since there were 
no ICD lead Class III recalls during the study period, further work would be needed to 
determine whether the pattern continues to this group and to determine if the behavior 
holds true for other types of medical devices. 
Table 7.9: Model Sensitivity for Class I vs Class II Recalled ICD Leads. 
As only recalled ICD leads are included in this analysis, predictions were either accurate 




Prediction Sensitivity P-Value 
Class I Recalled Leads 1753 1506 85.9% 
< 0.001 




7.3 Sensitivity Analyses 
Sensitivity analyses were conducted to explore the influence of reports for specific 
ICD lead brands (Section 7.3.1).  Additionally, models were trained and tested using 
cumulative yearly cohorts to evaluate their sensitivity over time (Section7.3.2).  For both 
analyses, the machine learning approach that was selected as providing the best overall 
model performance (under-sampled quadratic SVM model having complexity parameter 
c=0.005 with feature selection, but no stemming or stop words) was used to train and test 
the sensitivity analysis models.  That is, these analyses did not independently determine the 
best algorithmic model for a particular lead or time subset.  However, ten-fold cross-
validation was used for the training of all models. 
7.3.1 Sensitivity Analyses by ICD Lead 
To explore the influence of records pertaining to a particular ICD lead, sensitivity 
analyses were conducted in which models were trained using the full training dataset, less 
those records specific to each designated lead.  The resulting models were then applied to 
the full held-out testing data, including records for the ICD lead that was removed during 
training.  For example, the text classifier was trained using all records except those reported 
for the Kainox ICD lead, and the resulting model was then applied to the full held-out 
testing dataset including the Kainox lead records.  Table 7.10 shows the characteristics of 
the training datasets in which with each lead product was successively removed.  Due to 
sample sizes, the groups of AngePass, AngeFlex, Vigila 1 and Vigila 2 leads were excluded. 
Table 7.11 displays the training and testing results obtained for each ‘leave one ICD 




robust to the influence of any particular ICD lead product, i.e., the results obtained when 
training the model leaving out a designated lead were very similar to those achieved when 
model training was performed using the entire (all ICD leads) dataset.  The most notable 
difference occurred when the model was trained excluding both the Riata and Riata ST 
leads, and then applied to the entire testing cohort including both Riata lead models (F1 
score = 0.216 versus 0.622 obtained for the primary analysis model). 
Table 7.10: Sensitivity Analysis Training Dataset Characteristics After ICD Lead Removal. 
 
 
ICD Lead Removed During Training # Features 
Class I 
Recalls 
N After  
Under-sampling 













s SPRINT FIDELIS  1,384 2,888 5,776 
RIATA  817 1,335 2,670 
RIATA ST  1,322 2,787 5,574 


















ENDOTAK  1,484 
ENDOTAK DSP  1,484 
ENDOTAK ENDURANCE  1,466 
ENDOTAK RELIANCE  798 
ISOLINE 1,487 
KAINOX  1,488 
KENTROX  1,490 
KENTROX STEROID  1,487 
LINOX  1,485 
LINOX SMART  1,484 
LINOX SMART PROMRI  1,490 
RIATA ST OPTIM 1,507 
SPL  1,492 
SPRINT  1,488 
SPRINT QUATTRO  1,481 
SPRINT QUATTRO SECURE  1,065 
SPRINT QUATTRO SECURE MRI  1,471 
TVL  1,488 
TVL-ADX  1,493 






Table 7.11: Sensitivity Analysis Training and Testing Results after ICD Lead Removal. 
Each lead (row) was systematically removed from the training dataset.  Ten-fold cross 
validation model training was accomplished with each ‘leave one ICD lead out’ group, and 
the resulting model then applied to the entire testing dataset including all ICD leads. 
 
ICD Lead Removed 
Training Results  Testing Results 
 Precision Recall F1 PRC  Precision Recall F1 PRC 
 None (Primary 
Model) 














SPRINT FIDELIS 0.890 0.880 0.885 0.929  0.501 0.725 0.592 0.585 
RIATA 0.829 0.816 0.823 0.884  0.450 0.852 0.589 0.549 
RIATA ST 0.859 0.862 0.861 0.914  0.490 0.850 0.622 0.633 
Both RIATA & RIATA 
ST 













DURATA 0.923 0.933 0.928 0.949  0.371 0.943 0.533 0.501 
ENDOTAK 0.858 0.859 0.858 0.906  0.479 0.877 0.620 0.634 
ENDOTAK DSP 0.856 0.862 0.859 0.91  0.482 0.87 0.621 0.633 
ENDOTAK 
ENDURANCE 
0.858 0.876 0.867 0.915  0.474 0.871 0.614 0.628 
ENDOTAK RELIANCE 0.833 0.851 0.842 0.896  0.502 0.855 0.632 0.644 
ISOLINE 0.855 0.867 0.861 0.905  0.483 0.877 0.623 0.632 
KAINOX 0.860 0.870 0.865 0.918  0.482 0.883 0.623 0.632 
KENTROX 0.864 0.880 0.872 0.918  0.487 0.878 0.627 0.630 
KENTROX STEROID 0.854 0.866 0.860 0.912  0.495 0.878 0.633 0.637 
LINOX 0.857 0.869 0.863 0.907  0.486 0.865 0.622 0.625 
LINOX SMART 0.854 0.864 0.859 0.909  0.483 0.861 0.619 0.624 
LINOX SMART 
PROMRI 
0.860 0.863 0.861 0.921  0.487 0.860 0.622 0.641 
RIATA ST OPTIM 0.875 0.874 0.875 0.921  0.482 0.88 0.623 0.616 
SPL 0.864 0.869 0.866 0.915  0.486 0.869 0.624 0.625 
SPRINT 0.866 0.868 0.867 0.918  0.489 0.864 0.625 0.624 
SPRINT QUATTRO 0.864 0.869 0.867 0.915  0.479 0.867 0.617 0.631 
SPRINT QUATTRO 
SECURE 
0.845 0.855 0.850 0.903  0.485 0.929 0.638 0.662 
SPRINT QUATTRO 
SECURE MRI 
0.861 0.862 0.861 0.910  0.492 0.871 0.629 0.622 
TVL 0.859 0.871 0.865 0.907  0.476 0.871 0.616 0.613 
TVL-ADX 0.865 0.869 0.867 0.922  0.489 0.875 0.628 0.640 
VIGILA 1 0.858 0.869 0.863 0.914  0.489 0.867 0.625 0.630 
Both DURATA & 
RIATA ST OPTIM 





The drop in the model’s accuracy predictions when both the Riata and Riata ST leads 
were excluded during training potentially indicated a larger lead-specific effect than was 
apparent examining the model performance as a whole.  That is, lead-specific differences 
might be largely hidden when aggregating results.  To investigate this further, Table 7.12 
presents the proportion of accurate predictions (true positives for recalled leads or true 
negatives for non-recalled leads) by ICD lead.   
The results shown in Table 7.12 demonstrate that the overall findings did mask 
important lead-specific differences.  When excluding either the Riata or Riata ST leads from 
training, the testing results across all three recalled leads remained fairly stable and 
consistent compared to the primary analysis model results.  However, the primary model 
prediction accuracy for the Riata and Riata ST leads together (89.8%) deteriorated 
substantially when both of these leads were removed from training.  That is, when training 
was performed using only Sprint Fidelis lead recall examples, the predication accuracy in the 
held-out test data was just 3.9% for the Riata and 3.3% for the Riata ST leads.  Thus, while 
training accomplished using only the Riata lead still yielded good performance for the Riata 
ST lead and vice versa, models trained using only the Sprint Fidelis records as examples of 
Class I recalled leads performed quite poorly when applied to either the Riata or Riata ST 
leads.  Similarly, when the model training excluded the Sprint Fidelis lead records, the 
prediction accuracy dropped appreciably when then applied to these leads (69.3% primary 






Table 7.12: Detailed Sensitivity Analysis Testing Results – Percentage Correct Predictions after ICD Lead Removal. 
Yellow highlighted columns show the primary model’s accuracy, evaluated by ICD lead.  The remaining columns provide the results 
when the model was trained on a ‘leave one ICD lead out’ dataset and then tested on all leads.  Grey highlighted cells emphasize the 














Sensitivity Analysis Model Results - Correct Prediction % 
Class I Recall = Yes Class I Recall = No 
N RIATA RIATA ST 
SPRINT 


















s RIATA 1059 92.5% 86.7% 81.3% 84.5% 54.2% 99.1% 100% 99.5% 99.8% 81.4% 72.2% 69.2% 
RIATA ST 359 81.9% 92.3% 78.0% 69.6% 59.8% 98.1% 99.4% 98.9% 99.7% 79.1% 83.3% 69.2% 
Both RIATA & 
RIATA ST 
1418 89.8% 3.9% 3.3% 82.4% 98.7% 99.1% 100% 99.5% 97.8% 97.7% 77.8% 84.6% 
SPRINT 
FIDELIS 














Sensitivity Analysis Model Results - Correct Prediction % 


























s RIATA 1059 92.5% 88.9% 90.8% 93.5% 35.8% 19.2% 70.4% 81.7% 90.9% 98.8% 36.4% 13.0% 
RIATA ST 359 81.9% 85.2% 91.4% 96.5% 31.8% 11.5% 81.6% 87.1% 94.5% 99.7% 0% 3.7% 
Both RIATA & 
RIATA ST 
1418 89.8% 87.0% 91.0% 97.6% 98.0% 92.3% 54.2% 71.3% 83.3% 96.2% 90.9% 94.4% 
SPRINT 
FIDELIS 



















Sensitivity Analysis Model Results - Correct Prediction % 
Class I Recall = Yes Class I Recall = No 
N RIATA RIATA ST 
SPRINT 



















DURATA 2155 56.9% 98.6% 99.2% 75.5% 6.2% 99.1% 100% 100% 99.6% 79.1% 83.3% 76.9% 
ENDOTAK 108 99.1% 93.2% 85.2% 73.3% 54.2% 99.1% 100% 100% 99.7% 95.3% 77.8% 69.2% 
ENDOTAK DSP 171 100% 93.1% 86.4% 68.4% 56.3% 99.1% 100% 99.5% 99.8% 86.0% 77.8% 69.2% 
ENDOTAK 
ENDURANCE 
189 100% 93.2% 84.1% 71.0% 54.5% 99.1% 98.8% 100% 99.8% 81.4% 83.3% 69.2% 
ENDOTAK 
RELIANCE 
3183 99.7% 90.3% 82.5% 73.7% 62.9% 97.2% 98.8% 97.4% 99.0% 90.7% 77.8% 69.2% 
ISOLINE 43 79.1% 93.6% 86.4% 70.4% 56.5% 99.1% 99.4% 99.5% 99.7% 74.4% 77.8% 69.2% 
KAINOX 18 83.3% 94.0% 84.4% 74.6% 55.7% 99.1% 100% 99.5% 99.8% 93.0% 83.3% 61.5% 



















Sensitivity Analysis Model Results - Correct Prediction % 



























DURATA 2155 56.9% 85.2% 92.5% 95.3% 7.1% 3.8% 79.3% 86.5% 94.1% 100% 0% 0% 
ENDOTAK 108 99.1% 87.0% 91.6% 95.3% 28.7% 15.4% 80.4% 87.8% 94.3% 98.8% 0% 9.3% 
ENDOTAK DSP 171 100% 90.7% 90.6% 94.7% 30.1% 7.7% 78.8% 87.2% 94.4% 98.8% 0% 3.7% 
ENDOTAK 
ENDURANCE 
189 100% 81.5% 89.5% 94.7% 27.7% 7.7% 78.2% 87.6% 94.4% 99.1% 0% 3.7% 
ENDOTAK 
RELIANCE 
3183 99.7% 87.0% 93.2% 97.1% 34.5% 15.4% 81.0% 87.2% 94.4% 99.1% 0% 5.6% 
ISOLINE 43 79.1% 85.2% 90.8% 94.1% 26.0% 15.4% 81.0% 87.8% 94.3% 99.4% 9.1% 1.9% 
KAINOX 18 83.3% 92.6% 90.8% 94.7% 30.7% 7.7% 79.3% 86.3% 93.9% 99.4% 0% 1.9% 



















Sensitivity Analysis Model Results - Correct Prediction % 
Class I Recall = Yes Class I Recall = No 
N RIATA RIATA ST 
SPRINT 





















54 88.9% 92.9% 86.4% 64.1% 58.2% 98.1% 99.4% 99.4% 99.7% 90.7% 88.9% 76.9% 
LINOX 545 93.0% 91.8% 82.2% 74.6% 59.8% 98.1% 100% 100% 99.8% 69.8% 77.8% 69.2% 
LINOX SMART 170 94.7% 92.7% 82.5% 69.3% 57.4% 99.1% 100% 99.5% 99.8% 83.7% 83.3% 76.9% 
RIATA ST 
OPTIM 
296 30.4% 93.8% 85.2% 72.5% 55.3% 99.1% 100% 100% 99.7% 79.1% 83.3% 76.9% 
SPL 26 11.5% 93.0% 83.0% 71.9% 58.7% 98.1% 99.4% 99.4% 99.7% 83.7% 83.3% 69.2% 
SPRINT 179 83.2% 92.1% 83.0% 77.2% 59.1% 98.1% 99.4% 97.9% 99.6% 88.4% 77.8% 69.2% 
SPRINT 
QUATTRO 








339 99.7% 92.7% 83.3% 73.4% 58.4% 98.1% 99.4% 99.5% 99.7% 90.7% 77.8% 84.6% 
TVL 11 0% 93.0% 86.1% 69.3% 54.4% 99.1% 99.4% 99.5% 99.7% 86.0% 72.2% 84.6% 
TVL-ADX 54 5.6% 93.1% 85.0% 72.2% 57.8% 99.1% 99.4% 98.9% 99.7% 86.0% 83.3% 69.2% 
Both DURATA 
& RIATA ST 
OPTIM 



















Sensitivity Analysis Model Results - Correct Prediction % 














SECURE MRI TVL TVL-ADX 
KENTROX 
STEROID 
54 88.9% 81.5% 93.6% 95.9% 30.7% 11.5% 80.4% 87.2% 94.4% 99.1% 0% 7.4% 
LINOX 545 93.0% 75.9% 86.4% 91.2% 33.1% 7.7% 77.7% 87.2% 94.1% 99.4% 0% 1.9% 
LINOX SMART 170 94.7% 85.2% 91.0% 94.7% 30.7% 15.4% 77.1% 86.7% 94.2% 99.4% 9.1% 1.9% 
RIATA ST 
OPTIM 
296 30.4% 85.2% 92.8% 94.7% 30.7% 11.5% 79.3% 87.2% 94.1% 99.4% 0% 1.9% 
SPL 26 11.5% 85.2% 91.2% 93.5% 29.7% 15.4% 76.5% 86.0% 94.1% 98.8% 9.1% 5.6% 
SPRINT 179 83.2% 92.6% 96.3% 98.8% 33.8% 15.4% 77.7% 99.3% 99.5% 100% 0% 9.3% 
SPRINT 
QUATTRO 








339 99.7% 88.9% 93.0% 96.5% 32.8% 7.7% 77.7% 86.9% 94.1% 100% 0% 3.7% 
TVL 11 0% 90.7% 93.2% 94.7% 26.7% 7.7% 78.8% 87.9% 94.2% 99.7% 0% 
TVL-ADX 54 5.6% 87.0% 91.6% 95.3% 29.4% 15.4% 77.7% 88.5% 94.3% 99.4% 0% 3.7% 
Both DURATA 
& RIATA ST 
OPTIM 
















The poor ability of the Sprint Fidelis leads to predict Riata or Riata ST lead recall and 
vice versa may appear disappointing at first as this may suggest that the trained model may 
be product-dependent, and therefore have limited ability to detect potential problems for 
future ICD leads.  On the other hand, the failure mechanism for the Sprint Fidelis lead 
(conductor fracture) differs from that of the Riata and Riata ST leads (insulation failure), 
(236, 245) and thus it may not be surprising that predictions for one don’t translate well to 
the other.  Indeed, it is possible that the model will be better able to predict future failures 
than if the training examples had only included one or the other of the recalled leads, but 
this has not yet been borne out.  However, in light of this, the results for the Durata and 
Riata ST Optim leads shown in Table 7.12 are of interest. 
Recall that the DPA heat maps demonstrated strong signals for the Durata and Riata 
ST Optim leads (Figures 7.8-7.10), despite the fact that the model was trained with these 
labeled as non-Class I recalled products (Section 7.2.1).  Table 7.12 reveals that the primary 
model’s overall estimated accuracy was 56.9% for the Durata and 30.4% for the Riata ST 
Optim leads – that it, the model predicted a Class I recall for nearly half of the Durata 
reports and two-thirds of the Riata ST Optim records.  Similar results were obtained when 
the model was trained excluding, individually, the Sprint Fidelis, Riata or Riata ST leads.  
However, when both the Riata and Riata ST leads were excluded in combination, the 
model’s performance against the leads removed during training improved dramatically 
(98.7% for the Durata and 98.0% for the Riata ST Optim lead).  Correspondingly, when the 
model was trained on all but the Durata leads, the resulting model, when applied to the 




were Class I recalled products, i.e., a correct prediction = 6.2%.  When both the Durata and 
Riata ST Optim groups were excluded from the training dataset, virtually all (99.0%) of the 
records in these group were predicted as Class I recalls when the model was applied to the 
held-out test set included these models.  At the same time, when either or both of the 
Durata and Riata ST Optim leads were excluded from model training, the prediction 
accuracy for the Riata and Riata ST leads improved, with that for the Riata ST exhibiting the 
most dramatic improvement, from 81.9% accuracy for the primary analysis to 99.4%, when 
both the Durata and Riata ST Optim leads were excluded from model training.  At the same 
time, there was little effect on the Sprint Fidelis results when excluding any, but this specific 
lead from training, suggesting a tight coupling of the model results for the Riata, Riata ST, 
Riata ST Optim and Durata leads (see also Section 7.2.1).  Only time will tell whether the 
Durata and Riata ST Optim signals are accurate with regard to a prediction of a recall, but 
given that the Durata and Riata ST Optim leads were recently put under mandatory 
postmarket surveillance, the results from this study may indicate the model’s successful 
ability to detect, in advance, evidence of a potential ICD lead problem similar to one 
previously encountered. 
7.3.2 Sensitivity Analyses Across Time 
Sensitivity analyses were also conducted to explore the impact of training the model 
using records spanning the entire study period versus an approach that would be more 
similar to how this program might be applied in practice once initiated, in which training 
and testing would be accomplished using data available up to a particular time point.  These 




training and testing the model on these time-based subsets.  The approach used for this 
analysis differed from a true ‘real-world’ scenario in one critical way – ICD lead 
classifications were assigned assuming knowledge of both the Sprint Fidelis recall in 2007 
and the Riata/Riata ST recall in 2011.  However, a program such as the one envisioned in 
this research would, by necessity, only make sense if past product recalls were available 
with which to train a prediction model, and thus the assumed knowledge of the Sprint 
Fidelis and Riata/Riata ST Class I recalls was made knowingly, and model training based only 
on the first (Sprint Fidelis) of the ICD lead recalls was previously discussed in Section 7.3.1. 
The cumulative time subsets were created using the original training and testing 
datasets.  The 2004 cohort included all records received through the end of 2004, the 2005 
cohort added to the 2004 cohort those MAUDE reports received in 2005, and so forth.  
Table 7.13 shows the characteristics of the training and held-out testing datasets 
accumulated across time. 
Table 7.13: Sensitivity Analysis Training and Testing Dataset Characteristics by 
Cumulative Time Cohorts. 
 
# ICD Lead Records 
Thru 
Training Data Testing Data 
# Features Class I Recalls 
N After  
Under-sampling N 
None (Primary Model) 1,489 3,505 7010 13,457 
2004 237 104 208 395 
2005 177 187 374 594 
2006 403 730 1,460 1,122 
2007 482 1,139 2,278 1,443 
2008 496 1,508 3,016 1,829 
2009 560 2,036 4,072 2,605 
2010 758 2,623 5,246 5,038 
2011 996 3,505 7,010 8,517 





Table 7.14 presents the cross validation training and final model testing results 
applied to the cumulative datasets over time.  While these results indicated that the overall 
evaluations over time were quite consistent, there was some evidence of model 
performance degradation beginning in 2008.  Therefore, similar to the previous section, 
Table 7.15 presents details of the model predictions by ICD lead for each of the cumulative 
time datasets, with results obtained by the primary analysis model again provided for 
comparison. 
Table 7.14: Sensitivity Analysis Training and Testing Results by Cumulative Time Cohorts. 
Ten-fold cross validation model training was accomplished for each cumulative dataset and 
the resulting model was then applied to the held-out testing cohort consisting of records 
through the same time period. 
Cumulative ICD Lead 
Records Thru 
Training Results  Testing Results 
Precision Recall F1 PRC  Precision Recall F1 PRC 
None (Primary Model) 0.852 0.861 0.857 0.910  0.488 0.859 0.622 0.617 
2004 0.875 0.875 0.875 0.893  0.541 0.870 0.667 0.577 
2005 0.783 0.829 0.805 0.896  0.317 0.769 0.449 0.570 
2006 0.853 0.884 0.868 0.925  0.749 0.896 0.816 0.836 
2007 0.842 0.878 0.859 0.891  0.777 0.880 0.825 0.854 
2008 0.808 0.877 0.841 0.864  0.743 0.856 0.795 0.812 
2009 0.780 0.821 0.800 0.841  0.691 0.809 0.745 0.755 
2010 0.816 0.846 0.831 0.887  0.630 0.838 0.719 0.730 
2011 0.849 0.877 0.863 0.903  0.588 0.870 0.702 0.712 
2012 0.861 0.878 0.870 0.912  0.538 0.877 0.667 0.657 
 
As shown in Table 7.15, with the exception of the Durata, Riata ST and Riata ST 
Optim leads, no obvious temporal trends were apparent among those leads having a 
sizeable count (N > 100 overall), and as expected, all of the predictions converged towards 
the results from the primary model with increasing passage of time.  Upon introduction of 




Table 7.15: Detailed Sensitivity Analysis Testing Results - Percentage Correct Predictions 




Primary Model Correct Prediction % for ICD Lead Records Thru 
 














RIATA 1059 92.5% 87.0% 76.3% 94.5% 93.8% 91.7% 91.7% 94.0% 95.4% 93.9% 
RIATA ST 359 81.9%   100% 90.5% 89.3% 87.3% 86.2% 87.2% 85.8% 
SPRINT 
FIDELIS 













DURATA 2155 56.9%     9.3% 33.3% 38.8% 44.1% 49.0% 
ENDOTAK 108 99.1% 100% 100% 100% 100% 100% 100% 100% 96.5% 97.9% 
ENDOTAK 
DSP 
171 100% 100% 100% 98.6% 100% 100% 100% 100% 100% 100% 
ENDOTAK 
ENDURANCE 
189 100% 100% 100% 100% 100% 100% 100% 98.7% 100% 99.4% 
ENDOTAK 
RELIANCE 
3183 99.7% 100% 100% 99.7% 100% 99.7% 99.8% 99.6% 99.5% 99.8% 
ISOLINE 43 79.1%      100% 95.7% 90.9% 82.9% 
KAINOX 18 83.3%    50.0% 83.3% 90.9% 91.7% 76.9% 82.4% 
KENTROX 13 61.5%   50.0% 50.0% 100% 100% 77.8% 61.5% 76.9% 
KENTROX 
STEROID 
54 88.9%   50.0% 66.7% 91.7% 94.4% 83.3% 77.4% 88.4% 
LINOX 545 93.0%   100% 80.0% 100% 99.2% 97.6% 92.9% 94.2% 
LINOX SMART 170 94.7%       100% 96.3% 95.0% 
RIATA ST 
OPTIM 
296 30.4%     1.9% 22.6% 24.1% 23.1% 24.1% 
SPL 26 11.5% 50.0% 50.0% 20.0% 40.0% 33.3% 9.1% 0% 0% 5.0% 
SPRINT 179 83.2% 90.9% 66.7% 73.1% 63.0% 75.0% 70.2% 79.6% 75.6% 82.7% 
SPRINT 
QUATTRO 








339 99.7%        100% 100% 
TVL 11 0% 25.0% 25.0% 12.5% 0% 11.1% 11.1% 0 0% 0% 






the records in these groups were Class I recalls (i.e., accuracy percentages of 9.7% and 
1.,9%, respectively).  These results are only tempered with the accumulation of additional 
training examples labeled as ‘not recalled’.  At the same time, as additional negative 
examples of the Durata and Riata ST Optim lead were encountered, the model’s predicted 
accuracy for Riata ST lead decreased from 100% in 2006 to 85.8% in 2012.  Thus, similar to 
the conclusions drawn from the sensitivity analysis by ICD lead in Section 7.3.1, these 
results also suggest a tight coupling of the Durata, Riata ST and Riata ST Optim results. 
7.4 Summary 
After creating (Chapter 5) and readying the database for analysis (Chapter 6), this 
chapter detailed the results of applying text mining techniques to predict Class I ICD lead 
recalls and then applying DPA techniques to these machine learning results to 
systematically assess trends in the resulting predictions.  This combined methodological 
approach revealed modest to strong signals months to years in advance of the Sprint Fidelis 
and Riata and Riata ST Class I recalls, demonstrating the overall feasibility of this 
methodology. 
This study also raised several questions that merit future research.  There were 
‘only’ two Class I ICD lead recalls during the time period encompassed in this study.  Work 
on other products with a greater number of recalls (see Chapter 8) could corroborate the 
methodology developed in this study, determine if the specificity of the model to recall 
seriousness that was shown for ICD leads is present for other products, and allow a better 




This study showed a strong correspondence of results between the Riata, Riata ST, 
Riata ST Optim and Durata leads, but not the Sprint Fidelis leads.  While this might seem 
surprising in light of the secondary hypothesis results demonstrating good model 
performance across a wide spectrum of products (Section 7.2.3), consider that the lead-
specific findings were not initially apparent.  That is, the overall model performed well when 
the ICD leads were evaluated as a whole (see for example, Figure 7.13), and it is certainly 
possible that if one were to detail results for individual AEDs, IABs or MoM THRs devices, 
the model’s performance might also demonstrate varying product-specific performance 
similar to that observed within the group of ICD leads.  This study did not explore the nature 
of the similarities and differences within the ICD leads.  Future investigations could explore 
these relationships, perhaps providing a better understanding of the resulting predictions.  
Such insights may even provide guidance on how to incorporate information on known 
failure modes for which there are not, as of yet, concrete training examples. 
Finally, the text classification predictions generated by the model developed in this 
study were principally lead-specific.  The model’s lead specificity might just be an indication 
that the model was quite good at learning something - Class I ICD lead recall of the Sprint 
Fidelis and Riata/Riata ST leads – that we already know, thereby limiting its future utility.  
However, because the mechanisms of failure are different for the Sprint Fidelis and 
Riata/Riata ST leads, this lead specificity could also suggest that the model will be better 
able to predict either type of failure in the future.  If so, the model’s predictive ability over a 
wider range of problems should improve as future recalls occur and are incorporated into 




model for the currently non-recalled Riata ST Optim and Durata leads.  But even if these 
leads are never recalled, detection of the Riata ST Optim and Durata signals could still be 
considered a ‘success.’  Disproportionality signals should never be considered proof of a 
problem, only that there is some indication that a product might be worth heightened 
evaluation, and the Durata signals observed in this study were evident 2.5 years in advance 






CONTRIBUTIONS, RECOMMENDATIONS AND FUTURE DIRECTIONS 
 
This project developed an innovative, sequential combination of text and data 
mining methodologies to automate a data-driven early warning system that successfully 
predicted ICD lead recalls from text-based adverse event information in the MAUDE 
database.  Strong signals of the Riata and Riata ST lead recalls were observed eighteen 
months in advance of formal product recall and 6 months in advance of removal of these 
products from the market.  Modest signals were detected two and a half years prior to the 
Sprint Fidelis recall and four years in advance of the Riata and Riata ST leads recalls.  Signals 
were also observed for the Durata lead which, although not recalled, is similar to the Riata 
leads and has been put under additional scrutiny due to reported insulation failures.  In 
addition to these findings, this research provided insights into the opportunities and 
challenges of applying this methodology more broadly, and laid the groundwork for future 
work. 
8.1 Contributions of this Research 
In the last decade there has been an alarming rise both in the reporting of medical 
device problems and in recalls of medical devices that were found to have a significant risk 
of causing serious injury or death in patients.  Given the need to identify issues amongst 
intermittent text-based reports that may span years or even decades of a product’s history, 




After conducting a comprehensive literature review, I believe this is the first study to 
use data or text mining methods to predict ICD lead or other medical product recall using 
information contained in a spontaneous reporting system database.  The application of text 
mining to SRS or recall databases is at its earliest stages, with only eight papers reporting 
this usage, and only one of these applied to MAUDE.  In addition, while text mining and data 
mining each, individually have a rich background, this is likely the first research to use 
disproportionality analysis techniques to systematically assess temporal trends in 
predictions made from a text classification algorithm.  This combination, while utilized to 
determine whether text mining predictions signaled potential product problems in advance 
of Class I ICD lead recalls, could easily be adopted to other types of text mining predictions, 
providing an excellent framework for interpreting text classification predictions. 
8.2 Economic Impact of the Study Findings 
ICDs are designed to prevent sudden cardiac death due to ventricular arrhythmias, a 
problem attributed to several hundred thousand deaths per year in the United States, and 4 
to 5 million deaths per year worldwide.  Nearly 12,000 ICD devices and 26,000 ICD leads 
were implanted per month in 2011. (62)  Early recognition of ICD lead problems could have 
a profound impact on patients who experience inappropriate shocks, loss of pacing, failure 
of defibrillation, or even deaths due to ICD lead failure. 
While it is difficult to put a price on these quality of life issues, two studies have 
assessed the financial implication of the Sprint Fidelis ICD lead recall.  Bashir estimated that 
proactive Sprint Fidelis ICD lead removal versus a monitoring strategy saved $12,779 per 




Schwartz estimated a total of 116 extra out-patient visits in 82 patients with a Sprint Fidelis 
lead. (234)  Though Schwartz did not separately catalogue costs for ICD versus ICD leads, a 
prorated estimate suggests an added cost of approximately 1,200 € per patient.  Thus, it is 
clear that early detection of problematic ICD leads could afford a large potential savings 
depending upon the number of ICD leads concerned. 
Although the denominator underlying MAUDE reports is generally not known, based 
on product performance reports published by St. Jude Medical, we have some awareness of 
the impact that early signal detection of the Riata/Riata ST ICD lead problem could have. 
Between April and November 2010, corresponding to the time when a strong 
disproportionality signal was observed for the Riata and Riata ST leads, 889 Riata ICD leads 
that were eventually part of the Class I recall were registered in the United States. (246, 
247)  From November 2007 to November 2010 spanning the period when a more modest, 
but continuous signal was observed, 33,142 eventually recalled ICD leads were registered. 
(247, 248)  Given that these numbers only account for US usage and that registration 
numbers likely underreport actual implants, we can appreciate that earlier recognition of 
the Riata/Riata ST issue could have prevented use of a large number of leads.  Considering 
the signals shown for the Riata ST Optim and Durata ICD leads, it is worth noting that SJM 
product performance reports indicate that from 2011 to 2015 approximately 2,200-3,200 of 
these leads were registered in the US per month. (249-253) 
8.3 MAUDE Recommendations 
This study demonstrates the feasibility of using a sequential combination of text 




question is whether expanding the approach taken in this study to a broader group of 
devices is practicable? 
The biggest hurdles faced in this research involved working with the MAUDE 
database.  Firstly, the contents and file linking mechanics were poorly, and at times 
incorrectly, described.  While the process of developing an understanding of MAUDE’s 
structure, content, file interrelationships and limitations was exceedingly time-consuming, 
having gone through and thoroughly documented this process, (254) this part of a larger 
project would be much more manageable. 
Not so readily overcome, however, are limitations of the data itself.  Codes 
identifying products are not structured in a hierarchical manner.  As a result, in this project, 
and I suspect more globally for a product involving multiple components, one may find 
records pertaining to a particular product of interest classified under several related codes.  
For example, 57% of records determined for this project were coded with an ICD, rather 
than ICD lead-specific code.  While naïve use of a specific product code could result in 
missing a fairly substantial number of records that pertain to a question of interest, this 
issue can be largely surmounted with some general investigation of records in potentially 
related product categories.  Alternatively, this issue could be addressed at the database 
level, with product codes structured in a hierarchical manner so that one could easily select 
umbrella terms that would include related products to better ensure that a selected group 
of reports includes all records of interest. 
On the other hand, all of the MAUDE fields relating to the identification of a product 




and other identifying number) allow open (unconstrained) text entry.  This project, and any 
research using MAUDE that requires analysis by product, necessitates generation of a 
standardized product identifier.  As an example, there were 44 variations relating to St Jude 
Medical in the data used in this analysis, all of which had to be coalesced into a single 
entity, which could then be used to sort through an even larger number of product names 
and model numbers, many of which were provided in different fields (for example, model 
numbers provided in brand name fields, or vice versa.)  In order to apply the methodology 
used in the project to other device types, one would need to work through a similar process 
for each product of interest, generating a standardized product identifier for each record. 
It is astonishing to think of the number of hours that have been spent by 
independent groups each generating their own custom product identifier to accomplish 
work using MAUDE.  The FDA recently established a unique device identifier (UDI) system 
which will be phased in over the next several years and which should greatly facilitate the 
identification of medical devices. (217, 255)  With modern databases, it should be fairly 
routine to enable smart lists or other structured data mechanisms for entering device codes 
and product problems, or at a minimum to verify that free-text entered information 
matches a valid device product or problem code.  Incorporation of the UDI into MedWatch 
forms and the MAUDE database, coupled with mechanisms to ensure valid UDI entry, would 
save researchers a vast amount of time.  It should also better ensure that results obtained 





Finally, because manufacturer or product names could act as a surrogate for recall 
status, the adverse event descriptive text was pre-processed to mask use of these words 
and their variants during model training.  Unlike the product identifying fields, the adverse 
event description must, by definition, allow free text entry.  Given that details of a product 
in question are provided in other field, could one simply instruct users to omit such details 
from the adverse event description?  While this might seem plausible upon first glance, one 
quickly appreciates that such a rule would be difficult to enforce. (256)  More importantly, 
the descriptive adverse event report often provides important information such as other 
products related to the event or that were used to replace a problematic device.  As such, in 
the foreseeable future application of the proposed approach would still require pre-
processing the adverse event descriptive information.  While entailing a significant amount 
of work, once such pre-processing rules were put into place, keeping them up to date as 
new products came on to the market would be a fairly straightforward task. 
In summary, there are several MAUDE modifications that would facilitate the 
approach used in this research.  These include: 
1. Correct and provide more clarity to the information about field contents and 
file linking on the MAUDE website. 
2. Incorporate UDI information into MedWatch forms and the MAUDE database. 
3. Enable structured entry of product type and problem codes or verify the 
validity of free-entered codes on submission. 
4. Filter the list of problem code fields to the specific product or product group.  




to entry of an inaccurate product code if they were to see a list of problem 
codes that were unrelated to the product they intended to select. 
8.4 Future Work 
A number of potential text mining opportunities were identified while working with 
the MAUDE database.  For example, while coded device problems are provided in MAUDE, 
at the current time, only a quarter of MAUDE records include them, greatly limiting the 
usefulness of this field.  However, nearly all MAUDE records are linked to a text description 
of the adverse event.  Thus, text mining has the potential to greatly expand the 
denominator of records associated with particular medical device problems.  It could also 
be used to analyze MAUDE treatment data, validate product codes or analyze sentiments 
expressed in the adverse event descriptions. 
This research demonstrated the potential feasibility within the group of ICD leads of 
enacting an early warning system of product problems based upon past product failures.  A 
natural extension is to apply this methodology to a different product type in order to begin 
gaining a sense of its potential broader applicability.  Certain limitations were encountered 
by exploring a medical device that had ‘only’ two recent Class I recalls.  Thus, it would make 
sense to select a medical device for this next exploration with a larger number of Class I 
recalls.  The recall database downloads do not include device product code.  However, an 
iterative search of the recall database informed by the list of products with the highest 
number of recalls cited in the FDA’s report. “Understanding barriers to medical device 




include a large number of Class I recalls since 2010, and thus would likely provide good 
targets for subsequent research: 
• non-wearable AEDs (product code MKJ, the group from which cohort 2 in this 
study was selected) 
• infusion pumps (product code FRN) 
• intravascular administration sets (product code FPA) 
• Continuous facility use ventilators (product code CBK) 
There are also several extensions that could be made to the current work.  This 
research assumed, but did not test, whether adverse event descriptions changed after a 
product recall was announced, instead censoring records received post recall.  Comparison 
of adverse event descriptions pre- and post-recall could be performed to determine 
whether knowledge of a recall influenced how adverse events were described.   
Detailed analysis of features derived from the adverse event text could also help 
determine whether the lead-specific predictions observed in this study reflect differences in 
the reporting of the Sprint Fidelis and Riata/Riata ST lead failure mechanisms.  For example, 
Ghazizadeh (168) explored term clustering near different automotive product recalls, and a 
similar evaluation might demonstrate important differences in the adverse event 
descriptions among recalled ICD leads.  Such a finding might even suggest approaches for 
incorporating into future models training information specific to other common ICD lead 
failures modes. (63, 257, 258) 
Finally, this approach focused on the MAUDE database.  It would be highly 




repositories, which might include other regulatory agency databases (e.g., EMEA, MHRA, 
IMC), product or warranty registries (e.g., National ICD Registry), institutional electronic 
records and social media. 
8.5 Summary 
The increased use of sophisticated medical devices combined with a dramatic rise in 
medical device problem reports, no increase in the regulators available to evaluate the 
reports, and the textual nature of the reports makes it imperative that computational 
approaches be developed to detect potential product problems earlier in time.  This study 
demonstrated the feasibility of using information garnered from past reports of known 
recalled products to train text classification models to predict serious product problems.  
Using standard disproportionality analysis techniques, text-mining derived predictions were 
shown to provide early indication of two high-profile ICD lead recalls months to years prior 
to their occurrence.  In addition, this approach also signaled that further scrutiny was 
merited for a related ICD lead 2.5 years earlier than the FDA’s mandate for additional 
surveillance of this lead.  With this study’s demonstration of the feasibility of an exciting 
approach to ICD lead safety monitoring, it is important to pursue the work necessary to 
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MEDWATCH FORM 3500 
 
This appendix shows the MedWatch Form 3500A used to collect mandatory 
reporting adverse event information from user facilities, importers, distributors and 
manufacturers.  Fields that are available in the publicly available version of the MAUDE 
database are highlighted in yellow.  The Voluntary reporting forms (MedWatch Form 3500 
and the consumer-friendly MedWatch Form 3500B) are similar, generally containing a 








Figure A.1: MedWatch Mandatory Reporting Form 3500A – Page 1. 







Figure A.2: MedWatch Mandatory Reporting Form 3500A – Page 2. 







Figure A.3: MedWatch Mandatory Reporting Form 3500A – Page 3. 






LITERATURE SEARCH RESULTS 
 
This appendix provides details of the citations summarized in Table 2.1, organized by 
search area: 
• Table B.1 MAUDE PubMed Citations:  Details the entire group (n=126) of MAUDE 
PubMed Literature Search citations.  This table includes the assigned Product Area; the 
type of cardiology or other product (Cardiology Product/ Other Note) referenced in the 
work; information (How MAUDE Used) pertaining to whether the citation primarily used 
the MAUDE database, combined the MAUDE database with other information, or simply 
referenced the MAUDE database to supplement other sources; and, if the work 
combined usage of the MAUDE database with other information, what additional 
sources (Combo Detail) were used.  Columns indicating whether the abstract or article 
was read (Abstract Read?, Article Read?), and if the citation referenced the use of Text 
(“text” or “narrative”) data (“Text” Related) are included.  This table is sorted by Product 
Area, Cardiology Product / Other Note and Title. 
• Table B.2 Medical Device Recalls PubMed Citations:  Details the entire group (n=112) of 
Medical Device and Safety Withdrawal citations.  This table includes the Product Area; 
Product; and a column indicating whether the citation was read (Article Read?).  This 
table is sorted by Product Area, Product and Title. 
• Table B.3 Data Mining Methods Used in SRS Databases PubMed Citations:  Details the 
group (n=103) of SRS database citations referencing both the use of a SRS database and 
“data mining” or “disproportionality analysis”.  This table shows the Database utilized in 
the study, the general Approach taken (DPA = disproportionality analysis; Overview; 
Text Mining); and the specific Methodology utilized (BCPNN = Bayesian confidence 
propagation neural network; BT = boosted trees; CHI = chi square test; DT = decision 
trees; EBGM = empirical Bayes geometric mean; FC = frequency counts; GAM = 
generalized additive model; GPS = gamma Poisson shrinker; IC = information 
component; kNN = k-nearest neighbors; LR = logistic regression; MARS = multivariate 
adaptive regression splines; ME = maximum entropy; NA = not applicable; NB = Naïve 
Bayes; NET = network analysis; OR = odds ratio; PRR = proportional reporting ratio; PHI = 
phi coefficient; RDA = regularized discriminant analysis; RF = random forests; RPCT = 
recursive partitioning classification trees; ROR = reporting odds ratio; RRR = relative 
reporting ratio; SB = stochastic boosting; SG = standardized gamma; SVD = singular value 
decomposition; SVM = support vector machines; URN = urn model).  Columns indicating 
whether the abstract or article was read (Abstract Read?, Article Read?), and Notes 




• Table B.4 Text Mining Methods Used in SRS Databases PubMed Citations:  Details the 
group (n=7) of SRS database citations referencing both the use of a SRS database and 
“text mining” or “text classification” or “natural language processing”.  Includes the 
Database utilized in the study and Notes about the citation.  This table is sorted by 





















































































































































Table B.4: Text Mining Methods Used in SRS Databases PubMed Citations. 
 
Title First Author Short Details Database Notes 
Automatic detection of adverse 
events to predict drug label 









Demonstrates that drug safety 
signals extracted from the 
Medicines and Healthcare 
Products Regulatory Agency label 
changes dataset can be used to 
predict (DPA) safety signals in 
other databases. 
Automatically Recognizing 
Medication and Adverse Event 
Information from Food and Drug 
Administration's Adverse Event 
Reporting System Narratives. 
Polepalli 
Ramesh, B 
JMIR Med Inform.  
2014 
FAERS Evaluates supervised machine 
learning approaches (Naïve Bayes, 
support vector machines and 
conditional random fields) to 
automatically identify medication 
and adverse drug information. 
Predicting adverse drug events 
from personal health messages. 
Chee BW AMIA Annu Symp 




Utilizing Naïve Bayes and support 
vector machines, explores the 
ability of health forum data to 
inform the decision of potential 
drug safety issues for further FDA 
scrutiny based on drugs having 
disproportionately more negative 
or adverse effect language 
discussions. 
Standardizing adverse drug 
event reporting data. 
Wang L J Biomed Semantics.  
2014 
FAERS Standardizes FAERS drug names 
to RxNorm codes using a NLP 
medication extraction tool, 
MedEx, and then aggregates 
drug-adverse event information, 
creating a publicly available 
normalized data source. 
Using statistical text 
classification to identify health 
information technology 
incidents. 
Chai KE J Am Med Inform 
Assoc.  2013 
MAUDE Examines the feasibility of using 
statistical text classification to 
identify HIT events within 
MAUDE. 
The contribution of the vaccine 
adverse event text mining 
system to the classification of 
possible Guillain-Barré syndrome 
reports. 
Botsis T Appl Clin Inform.  
2013 
VAERS Assesses the contribution of a 
developed vaccine adverse event 
text mining system to 
automatically classify reports 
finding that overall MedDRA 
performed better. 
Vaccine adverse event text 
mining system for extracting 
features from vaccine safety 
reports. 
Botsis T J Am Med Inform 
Assoc.  2012 
VAERS Develops a vaccine adverse event 
text mining system to 
automatically classify SRS reports. 
Text mining for the Vaccine 
Adverse Event Reporting 
System: medical text 
classification using informative 
feature selection. 
Botsis T J Am Med Inform 
Assoc.  2011 
VAERS Uses text mining to categorize 
H1N1 SRS vaccine records finding 
rule-based classifiers worked best 







MAUDE DATABASE VARIABLES 
 
This appendix provides a list of all data elements in the publicly available MAUDE 
downloadable zipped files.  Figure C.1 provides a summary with highlighting depicting linked 
fields and Tables C.1 – C.5 provide a complete list of variables in each files: 
• Figure C.1: Maude Files and Fields Summary 
• Table C.1: MAUDE Master (MDRFOI) File Data Elements 
• Table C.2: MAUDE Device File Data Elements 
• Table C.3: MAUDE Patient File Data Elements 
• Table C.4: MAUDE Text File Data Elements 
• Table C.5: MAUDE Device Problem File Data Elements 







Figure C.1: Summary of MAUDE Files and Fields. 
Added shading indicates file linking.  Information in parentheses indicates the MedWatch 








MAUDE Master File Data 
Element 








1 MDR Report Key 
(MDR_REPORT_KEY) 
  ID field 
2 Event Key (EVENT_KEY)   ID field 
3 Report Number     
4 Report Source Code 
(REPORT_SOURCE_CODE) 
 P = Voluntary report 
U = User Facility report 
D = Distributor report 
M = Manufacturer report 
 
5 Manufacturer Link Flag    
6 Number Devices in Event 
(NO_DEVICES_IN_EVENT) 
  Used to link data 
with Device data 
file 
(DEVICE_SEQ_NO) 
7 Number Patients in Event 
(NO_PTS_IN_EVENT) 
  Used to link data 
with Patient data 
file (PT_SEQ_NO) 
8 Date Received (DATE_RCVD)    
9 Adverse Event Flag 
(AE_FLAG) 
B1   
10 Product Problem Flag 
(PRODUCT_PROBLEM_FLAG) 
B1   
11 Date Report B4   
12 Date of Event 
(DATE_OF_EVENT) 
B3  Added in 2006 
13 Single Use/Reprocessor Flag D8  Added in 2006 

























300 OTHER CAREGIVERS  
301 DENTAL ASSISTANT 
302 HOME HEALTH AIDE 




306 PATIENT FAMILY 
MEMBER OR 
FRIEND 
307 PERSONAL CARE 
ASSISTANT 





















MAUDE Master File Data 
Element 

























500 RISK MANAGER 
600 ATTORNEY 
999 UNKNOWN 
NA NOT APPLICABLE 
NI NO INFORMATION 
UNK UNKNOWN 
 
15 Health Professional E2   
16 Initial Report to FDA E4 Y = Yes 
N = No 
U = Unknown 
* = No answer provided 
 
17 Distributor Name F3   
18 Distributor Address line 1 F3   
19 Distributor Address line 2 F3   
20 Distributor City F3   
21 Distributor State Code F3   
22 Distributor Zip Code F3   
23 Distributor Zip Code Ext F3   
24 Date Facility Aware F6   
25 Type of Report F7 I = Initial submission 
F = Follow-up 
X = Extra copy received 
O = Other information submitted 
Multiple Types 
separated by ‘;’ - 
up to 2 reported 
26 Report Date F8   
27 Report to FDA F11   
28 Date Report to FDA F11   
















606 CLINIC - WALK IN, 
OTHER 
607 DIALYSIS CENTER 
608 DRUG CLINIC 
609 IMAGING CENTER - 
MOBILE 
610 IMAGING CENTER - 
STATIONARY 
611 LABORATORY 
612 MOBILE HEALTH 
UNIT 
613 MRI CENTERS 
614 PSYCHIATRIC 












MAUDE Master File Data 
Element 








   502 CRITICAL CARE 
UNIT 








507 MATERNITY WARD 
- NURSERY 
508 OPERATING ROOM 
509 OUTPATIENT 
CLINIC/SURGERY 









602 BLOOD BANK 
603 BLOODMOBILE 
604 CATHETERIZAT’N 









700 LONG-TERM CARE 
FACILITY 
701 HOSPICE 





705 RETIREMENT HOME 
810 PATIENT'S HOME 
820 IN TRANSIT TO 
USER/MEDICAL 
FACILITY 








NA NOT APPLICABLE 
NI NO INFORMATION 
UNK UNKNOWN 
 
30 Report to Manufacturer F13   
31 Date Report to 
Manufacturer 
F13   
32 Manufacturer Name 
(MFR_NAME) 
F14   
33 Manufacturer Address line 
1 
F14   
34 Manufacturer Address line 
2 
F14   
35 Manufacturer City F14   
36 Manufacturer State Code F14   
37 Manufacturer Zip Code F14   
38 Manufacturer Zip Code Ext F14   
39 Manufacturer Country Code F14   
40 Manufacturer Postal Code F14   
41 Manufacturer Contact Title 
Name 
G1   
42 Manufacturer Contact First 
Name 








MAUDE Master File Data 
Element 








43 Manufacturer Contact Last 
Name 
G1   
44 Manufacturer Contact 
Street 1 
G1   
45 Manufacturer Contact 
Street 2 
G1   
46 Manufacturer Contact City G1   
47 Manufacturer Contact State 
Code 
G1   
48 Manufacturer Contact Zip 
Code 
G1   
49 Manufacturer Contact Zip 
Code Ext 
G1   
50 Manufacturer Contact 
Country Code  
G1   
51 Manufacturer Contact 
Postal Code  
G1   
52 Manufacturer Contact 
Phone No Area Code 
G1   
53 Manufacturer Contact 
Phone No Exchange 
G2   
54 Manufacturer Contact 
Phone No 
G2   
55 Manufacturer Contact 
Phone No Ext 
G2   
56 Manufacturer Contact 
Phone No Country Code  
G2   
57 Manufacturer Contact 
Phone No City Code  
G2   
58 Manufacturer Contact 
Phone No Local  
G2   
59 Manufacturer G1 Name G1   
60 Manufacturer G1 Street 1 G1   
61 Manufacturer G1 Street 2 G1   
62 Manufacturer G1 City G1   
63 Manufacturer G1 State 
Code 
G1   
64 Manufacturer G1 Zip Code G1   
65 Manufacturer G1 Zip Code 
Ext 
G1   
66 Manufacturer G1 Country 
Code  
G1   
67 Manufacturer G1 Postal 
Code  










MAUDE Master File Data 
Element 








68 Source Type 
(SOURCE_TYPE) 
G3 00 = Other 
01 = Foreign 
02 = Study 
03 = Literature 
04 = Consumer 
05 = Health Professional 
06 = User facility 
07 = Company representation 
08 = Distributor 
99 = Unknown 
* = Invalid data 
Multiple Source 
Types separated 
by ‘;’ - up to 2 
reported 
69 Date Manufacturer 
Received 
G4   
70 Device Date of Manufacture 
(DEVICE_DATE_MFG) 
H4   
71 Single Use Flag H5   
72 Remedial Action 
(REMEDIAL_ACTION) 
H7 RC = Recall 
RP = Repair 
RL = Replace 
RB = Relabeling 
OT = Other 
NO = Notification 
IN = Inspection 
PM = Patient Monitoring 
MA = Modification/Adjustment 
* = Invalid Data 
Multiple Remedial 
Actions separated 
by ‘;’ - no multiple 
actions reported 
 
Use to identify 
recalled products 
73 Previous Use Code H8   
74 Removal/Correction 
Number 
H9   
75 Event Type (EVENT_TYPE) H1 D = Death 
IN = Injury 
IL = Injury 
IJ = Injury 
M = Malfunction 
O = Other 
* = No answer provided 




















1 MDR Report Key 
(MDR_REPORT_KEY) 
  ID field 
2 Device Event Key 
(DEVICE_EVENT_KEY) 
  ID field 
3 Implant Flag D6  Added in 2006 
4 Date Removed Flag D7 U = Unknown 
A = Not available 
I = No information at this time 
M = Month and year provided only 
Y = Year provided only 
Added in 2006 
5 Device Sequence No 
(DEVICE_SEQ_NO) 
  Used to link data 




6 Date Received 
(DATE_RCVD_DEV) 
  If not provided in 
Master 
7 Brand Name (BRAND_NAME) D1   
8 Generic Name 
(GENERIC_NAME) 
D2   
9 Manufacturer Name 
(MFR_NAME_DEV) 
D3  If not provided in 
Master 
10 Manufacturer Address 1 D3   
11 Manufacturer Address 2 D3   
12 Manufacturer City D3   
13 Manufacturer State Code D3   
14 Manufacturer Zip Code D3    
15 Manufacturer Zip Code ext D3   
16 Manufacturer Country Code D3   
17 Manufacturer Postal Code D3   
18 Expiration Date of Device D4   
19 Model Number (MODEL_NO) D4   
20 Lot Number D4   
21 Catalog Number D4   
























0LP LAY USER/PATIENT 



























115 SPEECH THERAPIST 
116 DENTIST 
300 OTHER CAREGIVERS  
301 DENTAL ASSISTANT 







306 PATIENT FAMILY 
MEMBER OR 
FRIEND 
307 PERSONAL CARE 
ASSISTANT 

















500 RISK MANAGER 
600 ATTORNEY 
999 UNKNOWN 
NA NOT APPLICABLE 
NI NO INFORMATION 
UNK UNKNOWN 
 
24 Device Availability D10 Y = Yes 
N = No 
R = Device was returned to manufacturer 
* = No answer provided 
 
25 Date Returned to 
Manufacturer 
D10   





51668.htm#sti > foiclass.zip  
ID field 

















28 Device Evaluated by 
Manufacturer 
(DEV_EVAL_BY_MFR) 
H3 Y = Yes 
N = No 
R = Device not returned to manufacturer 
* = No answer provided 
 
29 Baseline Brand Name 
(BASE_BRAND_NAME) 
   
30 Baseline Generic Name 
(BASE_GENERIC_NAME) 
   
31 Baseline Model Number 
(BASE_MODEL_NO) 
   
32 Baseline Catalog Number    
33 Baseline Other ID Number    
34 Baseline device family    
35 Baseline shelf life contained 
in label 
 Y = Yes 
N = No 
A = Not applicable 
* = No answer provided 
 
36 Baseline shelf life in months    
37 Baseline PMA flag    
38 Baseline PMA no    
39 Baseline 510(k flag    
40 Baseline 510(k no    
41 Baseline preamendment    
42 Baseline transitional    
43 Baseline 510(k exempt flag    
44 Baseline date first marketed    
45 Baseline date ceased 
marketing 






Table C.3: MAUDE Patient File Data Elements. 
 






1 MDR Report Key 
(MDR_REPORT_KEY) 
  ID field 
2 Patient Sequence 
Number (PT_SEQ_NO) 
  Used to link data 
with Master data 
file 
(PT_SEQ_NO) 
3 Date Received   Use DATE_RCVD 
in Master data 






































Table C.4: MAUDE Text File Data Elements. 
 






1 MDR Report Key 
(MDR_REPORT_KEY) 
  ID field 
2 MDR Text Key 
(MDR_TEXT_KEY) 
  ID field 
3 Text Type Code 
(TEXT_TYPE_CODE) 
 D = MedWatch field B5 (Adverse event description) 
E = MedWatch field H3 (Manufacturer’s device 
evaluation or reason not evaluated) 
N = MedWatch field H10 (Additional adverse event 
narrative) 
 
4 Patient Sequence 
Number 
(PT_SEQ_NO) 
  Used to link data 
with Master data 
file 
(PT_SEQ_NO) 
5 Date Report 
(DATE_REPORT) 
   












Table C.5: MAUDE Device Problem File Data Elements. 
 






1 MDR Report Key 
(MDR_REPORT_KEY) 
  ID field 
2 Device Problem Code 
(DEVPROBCODE_1 – 
DEVPROBCODE_18) 











Table C.6: MAUDE Problem Code Descriptions File Data Elements. 
 






1 Device Problem Code 
(DEVICE_PROBLEM_CODE) 
F10   
2 Problem Description 
(DEVICE_PROBLEM_DESC) 







FDA’S MEDICAL DEVICE RECALLS DATABASE SEARCH RESULTS 
 
This appendix provides a list of product recalls obtained by searching the FDA’s 
database of recalled medical devices.  For products in which only the month and year of 
recall notification was provided, the 15th of the month was assumed, and if a notification 
date was not provided the Recall Date was assumed to be the Date Posted.  Products 
recalled through 2013 are listed in the following tables: 
• Table D.1 Cohort 1 (ICD Leads) Recalls Database Search Results:  Search terms ICD lead 
product codes LWS or MRM or NIK or NVY and (‘lead’ or ‘electrode’). 
• Table D.2 Cohort 2 (AED) Recalls Database Search Results:  Search terms AED product 
code MKJ and ‘automated external defibrillator’. 
• Table D.3 Cohort 3 (IAB) Recalls Database Search Results:  Search terms IAB product 
code DSP and ‘intra-aortic balloon’. 
• Table D.4 Cohort 4 (Cement MoM THR) Recalls Database Search Results:  Search terms 






































































































ICD LEAD STANDARDIZED PRODUCT IDENTIFIERS 
 
This appendix shows the MAUDE Cohort 1 ICD Lead model names and numbers 





Table E.1: ICD Lead Standardized Product Identifier Assignment by MAUDE Brand 





Included Brand Names Included Model Numbers 
BIOTRONIK AROX AROX 338021, 338022, 338023, 338025 
COROX OTW COROX OTW 346542, 346543, 354805, 354807, 
355148, 355149, 368345, 368346 




124217, 124218, 124 218, 124219, 
124235, 124236, 124237, 124 236, 
124 237, 124238, 124239, 124240, 
122005, 338148, 124325 




332231, 332232, 124574, 342390, 
342391, 342392, 342393, 342394, 
342395, 342396, 342397 
KENTROX 
STEROID 
KENTROX STEROID RV 
KENTROX STEROID RV-S 
KENTROX STEROID SL-S 
KENTROX STEROID SL 
KENTROX Z+ 
345988, 345989, 343080, 348090, 
348091, 347349, 347350, 347351, 
347352, 347353, 347354, A+ 




350053, 350054, 350055, 350056, 
363303, 351337, 351338, 351340, 
351333, 351334, 351353, 351354 
LINOX SMART LINOX SMART SD 
LINOX SMART S DX 
LINOX SMART TD 
LINOX SMART S 
LINOX SMART T 
LINOX SMART DF4 SD 
359065, 359066, 359067, 359068, 
365500, 365501, 359073, 359074, 
359075, 375012, 369818, 369819, 
369820, 359070, 359071, 359072 
LINOX SMART 
PROMRI 
LINOX SMART PROMRI S 
LINOX SMART PROMRI SD 
LINOX SMART PROMRI S DX 
LINOX SMART PROMRI DF4 SD 
377166, 377167, 377169, 377170, 
377171, 377211, 377212, 394102, 
394103, 394104 
LUMAX LUMAX 365608, 360346, 355366, 355367, 
360348, 381461 
SELOX SELOX 343081, 343082, 343083, 346366, 
346367, 346368, 346369 
SETROX SETROX 350973, 350974, 350975 
TILDA-R TILDA-R R45, R53, R60 
VIGILA 1 VIGILA 1 382901, 382907, 383938 
VIGILA 2 VIGILA 2 382930, 382935, 382940, 382946, 





Table E.1: ICD Lead Standardized Product Identifier Assignment by MAUDE Brand Name 





Included Brand Names Included Model Numbers 
BOSTON 
SCIENTIFIC 
ACUITY ACUITY 4554, 4555, 4556 
EASYTRAK EASYTRAK 4510, 4511, 4512, 4513, 4535, 
4536, 4537, 4538 
EASYTRAK 2 EASYTRAK 2 4515, 4517, 4518, 4520, 4542, 
4543, 4544 
EASYTRAK 3 EASYTRAK 3 4522, 4524, 4525, 4527, 4548, 
4549, 4550 
ENDOTAK ENDOTAK C, 60 and 70 Series 0044, 0060, 0062, 0064, 0065, 
0066, 0067, 0068, 0070, 0072, 







134, 135, 136, 144, 145, 146, 154, 
155, 156,  






RELIANCE G 4-SITE, 
RELIANCE G 4-FRONT, 
RELIANCE S, 
RELIANCE SG, 
RELIANCE SG 4-SITE, 
RELIANCE SG 4-FRONT 
160, 161, 162, 170, 171, 172, 173, 
180, 181, 182, 295, 296, 285, 286, 
658, 695, 696, 657, 692, 693, 282, 
283, 292, 293, 265, 266, 275, 276, 
265, 266, 275, 276, 127, 128, 137, 
138, 164, 165, 166, 167, 174, 175, 
176, 177, 184, 185, 186, 187, 147, 
148, 149, 157, 158, 159,  
ENDOTAK SQ ENDOTAK SQ 0047, 0048, 0049, 0063, 0085 
FINELINE FINELINE 4456, 4457, 4458, 44594479, 4480 
FLEXTEND FLEXTEND 4086, 4087, 4088 
FLEXTEND 2 FLEXTEND 2 4095, 4096, 4097 
INTERVENE INTERVENE 497-05, 497-19, 497-20, 497-22, 
497-23 
SELUTE SELUTE 4033, 4034, 4035, 4063, 4064, 4285 
TACHY LEAD 
EPI-PATCH 
TACHY LEAD EPI-PATCH 0040, 0041 
CAMERON 
HEALTH 





Table E.1: ICD Lead Standardized Product Identifier Assignment by MAUDE Brand Name 





Included Brand Names Included Model Numbers 
MEDTRONIC AESCULA AESCULA 1055T 
ATTAIN ATTAIN 2187, 4193, 4194, 4195, 4196, 
4296, 4298, 4396, 4398 
CAPSURE CAPSURE 4024, 4068, 4074, 4076, 4092, 
5424, 4568, 4574, 4592, 5033, 
5034, 5054, 5068, 5076, 5086, 




EPICARDIAL PATCH 6721 
SELECTSECURE SELECTSECURE 3830 
SPRINT SPRINT 6932, 6942, 6943, 6945 
SPRINT FIDELIS SPRINT FIDELIS 6930, 6931, 6948, 6949 
SPRINT 
QUATTRO 








SPRINT QUATTRO SECURE MRI 6935M, 6947M 
SUB-Q SUB-Q 6996 
SVC SVC 6933, 6937 
TRANSVENE TRANSVENE 6963, 6966, 6999, 6933, 6936, 
6939, 6943, 6937 
SORIN ANGEFLEX ANGEFLEX 4023 
ANGEPASS ANGEPASS 4041 
ISOLENE ISOLENE 2CR-5, 2CR-6, 2CT-6 
SITUS SITUS UW28D 
STELID II STELID II BTF26D 






Table E.1: ICD Lead Standardized Product Identifier Assignment by MAUDE Brand Name 





Included Brand Names Included Model Numbers 
ST JUDE 
MEDICAL 
DURATA DURATA 7120, 7121, 7122, 7130, 7131, 
7170, 7171, 7172, 7120Q, 7121Q, 
7122Q, 7170Q, 7171Q, 7172Q 
QUARTET QUARTET 1458 
QUICKFLEX QUICKFLEX 1156, 1158 
QUICKFLEX u QUICKFLEX u 1258 
QUICKSITE QUICKSITE 1056, 1058 
RIATA RIATA 1560, 1561, 1562, 1570, I1570, 
1571, 1572, 1580, 1581, 1582, 
1590, 1591, 1592 
RIATA ST RIATA ST 7000, 7001, 7002, 7010, 7011, 
7040, 7041, 7042 
RIATA ST OPTIM RIATA ST OPTIM 7020, 7021, 7022, 7030, 7031, 
7070, 70715 
SPL SPL SP01, SP02, SP03, SP04 
TENDRIL TENDRIL 1388, 1782, 1788, 1882, 1888 
TVL TVL SV01, SV02, SV03, RV02, RV06, 
RV07 
TVL-ADX TVL-ADX 1559 
  
                                                     
 
5 In 2008, St. Jude Medical submitted to the FDA a tradename request to rename 





SUPPLEMENTAL MACHINE LEARNING RESULTS 
 
This appendix shows additional comparisons between machine learning classifiers.  
With the exception of the complexity parameter, Tables and Figures F.1 – F.8 compare 
approaches using the same modeling feature combinations within class imbalance 
adjustment approach.  For the methods that incorporate a complexity parameter (decision 
trees and SVMs), the best complexity parameter for the method is utilized, rather than 
forcing use of the same, and thus potentially sub-optimal - complexity parameter across 
classifiers.  Tables and Figures F.9-F.11 compare models achieving the best performance 
metric (precision, recall, F1 score, and PRC area) for each class imbalance adjustment 
approach. 
• Table F.1 & Figure F.1: Classifier Comparison – No Class Imbalance Adjustment 
• Table F.2 & Figure F.2: Classifier Comparison – Cost Adjustment (Cost2) 
• Table F.3 & Figure F.3: Classifier Comparison – Under-Sampling 
• Table F.4 & Figure F.4: Classifier Comparison – Over-Sampling (SMOTE3) 
• Table F.5 & Figure F.5: Classifier Comparison – Hybrid (SMOTE3 + Under-Sampling) 
using Unigrams 
• Table F.6 & Figure F.6: Classifier Comparison – Hybrid (SMOTE3 + Under-Sampling) 
using Bigrams 
• Table F.7 & Figure F.7: Classifier Comparison – Hybrid (SMOTE5 + Under-Sampling) 
using Bigrams 
• Table F.8 & Figure F.8: Classifier Comparison – Hybrid (SMOTE3 + Under-Sampling) 
using Trigrams 
• Table F.9 & Figure F.9: Comparison of Best Unigram Models by Classifier and 
Performance Metric 
• Table F.10 & Figure F.10: Comparison of Best Bigram Models by Classifier and 
Performance Metric 
• Table F.11 & Figure F.11: Comparison of Best Trigram Models by Classifier and 








Parameter Precision Recall F1 PRC Area 
Run Time 
(Minutes) 
Naïve Bayes NA 0.792 0.822 0.807 0.848 0.2 
Decision Tree 0.1 0.875 0.922 0.897 0.875 17.2 
Linear SVM 0.05 0.853 0.924 0.887 0.911 15.7 













Parameter Precision Recall F1 PRC Area 
Run Time 
(Minutes) 
Naïve Bayes NA 0.388 0.804 0.524 0.506 0.9 
Decision Tree 0.1 0.58 0.708 0.637 0.551 32.3 
Linear SVM 0.05 0.605 0.709 0.653 0.67 2.9 














Parameter Precision Recall F1 PRC Area 
Run Time 
(Minutes) 
Naïve Bayes NA 0.792 0.822 0.807 0.848 0.2 
Decision Tree 0.1 0.83 0.902 0.864 0.818 3.7 
Linear SVM 0.05 0.845 0.903 0.873 0.903 0.4 














Parameter Precision Recall F1 PRC Area 
Run Time 
(Minutes) 
Naïve Bayes NA 0.711 0.879 0.786 0.716 1.2 
Decision Tree 0.1 0.880 0.898 0.889 0.893 42.8 
Linear SVM 0.05 0.801 0.839 0.819 0.856 28.2 














Parameter Precision Recall F1 PRC Area 
Run Time 
(Minutes) 
Naïve Bayes NA 0.760 0.822 0.790 0.751 0.5 
Decision Tree 0.1 0.875 0.922 0.897 0.875 17.2 
Linear SVM 0.05 0.853 0.924 0.887 0.911 15.7 










Table F.6: Classifier Comparison – Classifier Comparison – Hybrid (SMOTE3 + Under-




Parameter Precision Recall F1 PRC Area 
Run Time 
(Minutes) 
Naïve Bayes NA 0.810 0.839 0.824 0.792 2.5 
Decision Tree 0.1 0.881 0.924 0.902 0.875 107 
Linear SVM 0.05 0.881 0.946 0.912 0.931 159 





Figure F.6: Classifier Comparison – Classifier Comparison – Hybrid (SMOTE3 + Under-









Parameter Precision Recall F1 PRC Area 
Run Time 
(Minutes) 
Naïve Bayes NA 0.800 0.886 0.841 0.786 5.4 
Decision Tree 0.1 0.906 0.931 0.918 0.896 720 
Linear SVM 0.05 0.891 0.957 0.923 0.937 467.5 














Parameter Precision Recall F1 PRC Area 
Run Time 
(Minutes) 
Naïve Bayes NA 0.865 0.727 0.790 0.788 10.6 
Decision Tree 0.1 0.879 0.923 0.900 0.871 584.8 
Linear SVM 0.05 0.892 0.951 0.921 0.937 615.2 























Decision Tree (SMOTE5 + Under-
sampling) 
0.904  0.917 0.910 54.7 
Decision Tree (SMOTE5 + Cost2)  0.950   117.8 
 
Naïve Bayes (Under-sampling) 0.792  0.807 0.852 0.2 
Naïve Bayes (SMOTE5)  0.879   1.2 
 
Linear SVM (SMOTE5 + Under-
sampling) 
0.860  0.895 0.916 64.7 
Linear SVM (SMOTE4 + Cost3)  0.982   43.1 
 
Quadratic SVM (SMOTE3 + 
Under-sampling) 























Decision Tree (SMOTE5 + Under-
sampling) 
0.906 0.931 0.918 0.896 627.1 
 
Naïve Bayes (SMOTE2 +  
Under-sampling) 
0.828  0.841 0.803 1.7 
Naïve Bayes (SMOTE5)  0.888   7.5 
 
Linear SVM (SMOTE5 +  
Under-sampling) 
0.891  0.923 0.937 467.5 
Linear SVM (SMOTE5)  0.982   533.6 
 
Quadratic SVM (SMOTE3 + 
Under-sampling) 























Decision Tree (SMOTE5) 0.898 0.923 0.910 0.885 1377.4 
 
Naïve Bayes (SMOTE3 +  
Under-sampling) 
  0.790 0.788 10.6 
Naïve Bayes (SMOTE5) 0.925    17.2 
Naïve Bayes (SMOTE3)  0.736   14.5 
 
Linear SVM (SMOTE3 +  
Under-sampling) 
0.892 0.951 0.921 0.937 615.2 
 
Quadratic SVM Not Performed 
 
 
   
 








SUPPLEMENTAL SIGNAL DETECTION RESULTS 
 
This appendix presents the detailed tabular disproportionality results used to create 
the heat maps shown in Chapter 7 (Tables H.1-H.3).  In addition, results are included for all 
leads by cumulative quarter (Figures H.1-H.3 and Tables H.4-H.6), and for combined lead 
groups by individual (Figures H.4-H.6 and Tables H.7-H.9) and cumulative quarter (Figures 
H.7-H.9 and Tables H.10-H.12).  Results for all leads by individual quarter were also 
separately generated for the held-out test and are included in Figures H.10-H.11 and Tables 
H.13-H.15. 
All DPA measures refer to the one-sided lower confidence bound statistics.  EB05 
refers to the empirical Bayes geometric mean, BCPNN025 refers to the information 
component Bayesian confidence propagation neural network, and PRR025 refers to the 
proportional reporting ratio. 
Individual Quarter – Discrete Lead Results 
• Table G.1: Individual Quarter EB05 Results - Discrete Leads 
• Table G.2: Individual Quarter BCPNN025 Results - Discrete Leads 
• Table G.3: Individual Quarter PRR025 Results - Discrete Leads 
Cumulative Quarter – Discrete Lead Results 
• Figure G.1: Cumulative Quarter EB05 Heat Map - Discrete Leads 
• Table G.4: Cumulative Quarter EB05 Results - Discrete Leads 
• Figure G.2: Cumulative Quarter BCPNN025 Heat Map - Discrete Leads 
• Table G.5: Cumulative Quarter BCPNN025 Results - Discrete Leads 
• Figure G.3: Cumulative Quarter PRR025 Heat Map - Discrete Leads 
• Table G.6: Cumulative Quarter PRR025 Results - Discrete Leads 
Individual Quarter – Combined Lead Group Results 
• Figure G.4: Individual Quarter EB05 Heat Map - Combined Lead Groups 
• Table G.7: Individual Quarter EB05 Results - Combined Lead Groups 
• Figure G.5: Individual Quarter BCPNN025 Heat Map - Combined Lead Groups 
• Table G.8: Individual Quarter BCPNN025 Results - Combined Lead Groups 
• Figure G.6: Individual Quarter PRR025 Heat Map - Combined Lead Groups 





Cumulative Quarter – Combined Lead Group Results 
• Figure G.7: Cumulative Quarter EB05 Heat Map - Combined Lead Groups 
• Table G.10: Cumulative Quarter EB05 Results - Combined Lead Groups 
• Figure G.8: Cumulative Quarter BCPNN025 Heat Map - Combined Lead Groups 
• Table G.22: Cumulative Quarter BCPNN025 Results - Combined Lead Groups 
• Figure G.9: Cumulative Quarter PRR025 Heat Map - Combined Lead Groups 
• Table G.12: Cumulative Quarter PRR025 Results - Combined Lead Groups 
Individual Quarter – Discrete Lead Results – Held-Out Test Data 
• Table G.13: Individual Quarter EB05 Results - Discrete Leads, Held-Out Test Data 
• Figure G.10: Individual Quarter BCPNN025 Heat Map - Discrete Leads 
• Table G.14: Individual Quarter BCPNN025 Results - Discrete Leads, Held-Out Test Data 
• Figure G.11: Individual Quarter PRR025 Heat Map - Discrete Leads 





































































































































VIGILA 1                 
TVL-ADX 0.58 0.77 0.98 0.95 1.03 0.85 0.66 0.49 0.96 0.77  1.07  0.35 1.92 0.45 








0.80  1.11 0.85 1.00 0.94 0.93 1.05 1.19 1.18 1.70 1.05 1.76 1.83 1.93 1.24 
SPRINT 
QUATTRO 
0.80  0.86 0.79 0.97 0.62 0.71 0.97 0.96 1.26 1.41 1.05 1.69 1.04 1.93 1.02 
SPRINT 1.05 1.00 0.44 0.85 0.56 0.70 0.36 0.76 0.75 0.90 1.18 1.05 1.29 0.54 1.92 0.49 
SPL 0.58 0.55 0.41 0.67 0.81 0.32 0.44  0.68        
RIATA ST 
OPTIM 
                
LINOX 
SMART 
                
LINOX                 
KENTROX 
STEROID 
                
KENTROX             1.06 0.35   
KAINOX      0.45     0.49      
ISOLINE                 
ENDOTAK 
RELIANCE 
     0.20    0.22 0.06   0.04   
ENDOTAK 
ENDURANCE 
      0.14          
ENDOTAK 
DSP 
     0.07     0.17      
ENDOTAK  0.22      0.13   0.13      






            1.54 1.26 1.93 1.46 
RIATA  0.55 0.73 1.07 1.08 1.10 1.08 1.38 1.22 1.49 1.07 1.05 1.82 0.46 1.93 1.09 






































































































































VIGILA 1                 
TVL-ADX 0.50 0.72 0.51 0.35 0.83  0.31   0.45 0.44 0.37 0.34 0.27 0.54  








0.82 0.43 0.52 0.56 0.63 0.35 0.15 0.39 0.34 0.22 0.14 0.35 0.31 0.17 0.05 0.17 
SPRINT 
QUATTRO 
0.84 0.31 0.58 0.43 0.51 0.35 0.20  0.34  0.26  0.18 0.12 0.08 0.16 
SPRINT  0.41 0.29 0.50 0.41  0.24  0.38 0.26 0.18  0.14  0.09 0.33 
SPL  0.59 0.29         0.45 0.69 0.33  0.24 
RIATA ST 
OPTIM 
        0.67 0.58 0.74 0.80 0.77 0.92 0.72 0.96 
LINOX 
SMART 
                
LINOX    0.20 0.08 0.12 0.08 0.25 0.49  0.06    0.03 0.05 
KENTROX 
STEROID 
  0.25 0.20  0.27 0.23  0.31 0.11      0.29 
KENTROX 0.30  0.25       0.26       
KAINOX     0.27  0.31  0.48 0.19       
ISOLINE               0.24 0.37 
ENDOTAK 
RELIANCE 
   0.01 0.01 0.09    0.14   0.06   0.06 
ENDOTAK 
ENDURANCE 
                
ENDOTAK 
DSP 
                
ENDOTAK                 






1.15 1.19 1.11 1.32 1.15 1.03 1.06          
RIATA 1.25 1.40 1.40 1.41 1.29 0.35 0.60 1.32 1.42 1.14 1.21 1.29 1.20 1.62 1.49 2.20 





































































































































VIGILA 1             0.54    
TVL-ADX 0.67 1.56 0.52 1.42 0.97 0.84 1.16  1.13 0.50 1.09 0.49 0.59  1.25 0.42 








0.15 0.12 0.08 0.08 0.04 0.03 0.02 0.04 0.01 0.10 0.04 0.09 0.56  0.57  
SPRINT 
QUATTRO 
0.13 0.22  0.13 0.04  0.04 0.08 0.02 0.20 0.01      
SPRINT 0.11  0.10 0.19 0.08 0.16  0.11   0.19 0.37     
SPL 0.29 1.56   0.75 0.84  0.72 1.13 3.41 1.78 0.49  1.09 1.25 1.15 
RIATA ST 
OPTIM 
1.16 4.50 1.31 5.73 1.56 3.16 2.03 3.21 3.53 7.19 4.19 6.27 2.62 3.53 2.09 1.91 
LINOX 
SMART 
     0.60 0.04 0.14 0.05 0.29 0.30 0.23 0.30 0.18 0.25 0.09 
LINOX 0.03 0.06 0.05 0.34 0.39 0.39 0.09 0.17 0.46 0.55 0.85 0.72 0.65 0.39 0.18 0.16 
KENTROX 
STEROID 
   0.77     0.28 0.37 0.49    0.28  
KENTROX  0.69     0.31  0.60        
KAINOX      1.08           
ISOLINE 0.15 0.19 0.18 0.49   0.10 0.18 0.28 0.42 0.60    0.57  
ENDOTAK 
RELIANCE 
    0.00 0.01  0.02  0.04 0.02 0.05  0.01   
ENDOTAK 
ENDURANCE 
                
ENDOTAK 
DSP 
                
ENDOTAK                 






                
RIATA 1.83 5.87 2.67 6.94 3.52 6.72 3.10 5.78         






































































































































VIGILA 1                 
TVL-ADX -2.82 -1.79 -0.47 -0.90 -0.80 -0.67 -1.10 -1.85 -0.97 -1.93  -0.69  -2.96 -3.14 -3.20 








-1.77  -0.33 -1.01 -0.59 -0.51 -0.42 -0.38 -0.09 -0.50 0.34 -1.36 0.39 0.60 0.18 -0.06 
SPRINT 
QUATTRO 
-1.77  -1.18 -1.22 -0.99 -1.35 -1.17 -0.62 -0.97 -0.34 -0.17 -2.51 0.08 -0.40 -0.03 -0.63 
SPRINT -0.87 -0.90 -2.61 -1.01 -3.14 -1.23 -2.61 -0.91 -2.40 -1.36 -0.56 -1.39 -1.82 -1.95 -3.14 -2.38 
SPL -2.82 -2.84 -3.40 -2.24 -1.61 -3.29 -2.45  -3.34        
RIATA ST 
OPTIM 
                
LINOX 
SMART 
                
LINOX                 
KENTROX 
STEROID 
                
KENTROX             -2.86 -2.96   
KAINOX      -2.34     -2.86      
ISOLINE                 
ENDOTAK 
RELIANCE 
     -3.19    -3.63 -5.40   -6.19   
ENDOTAK 
ENDURANCE 
      -4.23          
ENDOTAK 
DSP 
     -5.18     -3.88      
ENDOTAK  -3.74      -4.29   -4.32      






            -0.34 -0.10 0.16 0.30 
RIATA  -2.84 -1.77 -0.52 -0.40 -0.11 -0.06 0.15 0.00 0.08 -0.65 -1.36 0.39 -2.06 -0.15 -0.44 





































































































































VIGILA 1                 
TVL-ADX -1.65 -1.12 -1.87 -3.20 -0.75  -3.36   -2.49 -2.52 -2.63 -3.45 -3.28 -1.64  








-0.51 -1.53 -1.23 -1.28 -0.89 -3.30 -3.61 -2.23 -2.71 -3.77 -3.39 -2.39 -2.14 -2.85 -4.59 -2.74 
SPRINT 
QUATTRO 
-0.64 -2.26 -1.15 -1.72 -1.25 -3.30 -3.70  -3.27  -3.02  -4.01 -3.61 -4.44 -2.92 
SPRINT  -2.40 -2.71 -2.24 -2.09  -3.51  -3.15 -3.58 -3.99  -4.34  -4.62 -1.89 
SPL  -1.55 -3.33         -2.46 -1.29 -3.16  -3.07 
RIATA ST 
OPTIM 
        -1.91 -1.09 -0.57 -0.64 -0.58 -0.43 -0.65 -0.34 
LINOX 
SMART 
                
LINOX    -3.66 -4.73 -4.37 -5.14 -3.12 -1.47  -5.24    -5.70 -4.94 
KENTROX 
STEROID 
  -2.65 -3.66  -3.44 -3.04  -3.39 -4.67      -2.47 
KENTROX -3.41  -2.86       -3.58       
KAINOX     -3.38  -3.36  -2.91 -3.96       
ISOLINE               -2.73 -1.97 
ENDOTAK 
RELIANCE 
   -7.59 -6.98 -4.70    -3.52   -5.71   -5.06 
ENDOTAK 
ENDURANCE 
                
ENDOTAK 
DSP 
                
ENDOTAK                 






0.07 0.12 0.06 0.29 0.16 -0.05 0.04          
RIATA 0.23 0.38 0.38 0.25 0.24 -3.30 -1.56 -0.13 -0.18 0.07 0.19 0.28 0.19 0.54 0.50 0.98 





































































































































VIGILA 1             -2.36    
TVL-ADX -1.29 -0.76 -1.90 -0.72 -1.11 -2.53 -0.82  -0.37 -2.39 -1.40 -2.38 -2.33  -0.31 -2.53 








-2.88 -3.22 -3.83 -3.79 -4.50 -5.00 -6.50 -4.63 -6.10 -3.89 -4.54 -4.29 -2.33  -2.62  
SPRINT 
QUATTRO 
-3.24 -2.41  -3.33 -3.97  -4.86 -3.97 -5.51 -3.22 -5.58      
SPRINT -3.70  -3.99 -2.79 -3.24 -3.08  -3.60   -3.46 -2.09     
SPL -3.16 -0.76   -1.79 -2.53  -1.49 -0.37 -0.47 0.05 -2.38  -0.25 -0.31 -0.38 
RIATA ST 
OPTIM 
0.00 1.25 0.11 1.03 0.37 1.03 0.83 1.06 1.46 2.05 1.76 1.56 1.20 1.37 0.86 0.74 
LINOX 
SMART 
     -2.06 -4.48 -3.26 -4.34 -2.64 -2.49 -3.82 -2.83 -2.79 -2.59 -4.75 
LINOX -6.46 -4.97 -5.37 -1.81 -1.72 -1.87 -3.15 -2.83 -1.71 -1.08 -1.15 -0.58 -1.03 -1.87 -3.03 -3.10 
KENTROX 
STEROID 
   -0.72     -3.17 -2.35 -2.75    -3.31  
KENTROX  -1.44     -2.90  -2.61        
KAINOX      -1.43           
ISOLINE -3.76 -3.07 -3.51 -1.40   -3.37 -3.05 -3.17 -2.26 -2.60    -2.62  
ENDOTAK 
RELIANCE 
    -9.07 -6.20  -6.16  -6.76 -5.96 -6.75  -6.52   
ENDOTAK 
ENDURANCE 
                
ENDOTAK 
DSP 
                
ENDOTAK                 






                
RIATA 0.77 2.33 1.31 2.44 1.72 2.55 1.56 2.22         






































































































































VIGILA 1                 
TVL-ADX   0.25 0.48 0.60 0.26 -0.11 -0.44 0.37   1.98     








  0.49 0.17 0.30 0.45 0.27 0.52 0.47 0.89 1.07  0.97 1.19 0.71 0.56 
SPRINT 
QUATTRO 
  0.41 0.09 0.59 -0.01 0.32 0.66 0.37 0.91 1.10  1.14 0.54 0.63 0.57 
SPRINT 0.66 0.60  0.17  0.41  0.03  0.84 1.06      
SPL     0.57            
RIATA ST 
OPTIM 
                
LINOX 
SMART 
                
LINOX                 
KENTROX 
STEROID 
                
KENTROX                 
KAINOX                 
ISOLINE                 
ENDOTAK 
RELIANCE 
                
ENDOTAK 
ENDURANCE 
                
ENDOTAK 
DSP 
                
ENDOTAK                 






            1.09 0.79 0.75 0.80 
RIATA   0.40 0.52 0.39 0.46 0.42 0.81 0.51 1.01 0.71  1.11  0.69 0.58 





































































































































VIGILA 1                 
TVL-ADX -0.38 0.44 0.46  0.42          -0.11  








-0.05 -0.83 -0.60 -0.50 -0.40   -1.36   -2.33 -1.06 -1.24 -2.08 -3.37 -2.18 
SPRINT 
QUATTRO 
0.13 -1.18 -0.41 -0.86 -0.60         -2.61  -2.08 
SPRINT     -0.39           -1.18 
SPL  0.43           0.32    
RIATA ST 
OPTIM 
         -0.49 -0.28 -0.02 -0.18 0.13 -0.27 0.22 
LINOX 
SMART 
                
LINOX         -1.08        
KENTROX 
STEROID 
  -1.50              
KENTROX                 
KAINOX                 
ISOLINE               -1.60 -0.86 
ENDOTAK 
RELIANCE 
         -2.47       
ENDOTAK 
ENDURANCE 
                
ENDOTAK 
DSP 
                
ENDOTAK                 






0.35 0.39 0.28 0.63 0.41 0.56 0.58          
RIATA 0.52 0.72 0.63 0.65 0.45  0.36 0.85 1.08 0.38 0.43 0.65 0.42 0.84 0.74 1.19 





































































































































VIGILA 1                 
TVL-ADX 0.70 1.90  1.99 1.35  1.22  1.80      0.81  








-2.19 -3.23 -2.92 -3.16 -3.46 -4.09 -4.92 -3.74 -4.77 -3.25 -3.59 -3.45     
SPRINT 
QUATTRO 
-2.28 -1.71  -2.43 -2.91   -2.93  -2.41       
SPRINT -2.64   -2.00        -1.42     
SPL  1.90       1.80 2.62 1.95   1.52 0.81 1.31 
RIATA ST 
OPTIM 
0.33 1.60 0.52 1.62 0.65 1.40 0.94 1.35 1.49 2.25 1.66 1.91 1.59 1.54 0.90 0.86 
LINOX 
SMART 
          -1.72   -2.02 -1.81  
LINOX    -1.20 -1.15 -1.26 -2.23 -2.01 -1.12 -0.61 -0.69 -0.22 -0.58 -1.28 -2.19 -2.26 
KENTROX 
STEROID 
   0.18             
KENTROX                 
KAINOX                 
ISOLINE    -0.54             
ENDOTAK 
RELIANCE 
     -4.80  -4.74   -4.63      
ENDOTAK 
ENDURANCE 
                
ENDOTAK 
DSP 
                
ENDOTAK                 






                
RIATA 0.94 2.23 1.40 2.30 1.73 2.42 1.64 2.17         










Figure G.1: Cumulative Quarter EB05 Heat Map - Discrete Leads. 
The Sprint Fidelis was recalled October 25,2007; the Riata/Riata ST November 28, 2011.  ICD 

































































































































TVL-ADX 1.36 1.79 1.79 1.73 1.73 1.84 1.85 1.86 1.88 1.93 1.59 1.76 1.81 1.83 1.82 1.80 




0.88 1.04 1.78 1.71 1.72 1.84 1.85 1.86 1.88 1.93 1.79 1.88 1.95 2.02 2.02 1.99 
SPRINT 
QUATTRO 
1.13 1.16 1.54 1.61 1.67 1.84 1.85 1.86 1.88 1.93 1.67 1.79 1.88 1.90 1.91 1.90 
SPRINT 1.83 2.02 1.53 1.58 1.63 1.83 1.85 1.86 1.88 1.93 1.36 1.64 1.65 1.66 1.66 1.65 
SPL 0.88 1.30 1.37 1.54 1.64 1.83 1.85 1.86 1.88 1.93 1.19 1.64 1.62 1.62 1.63 1.64 
RIATA ST 
OPTIM 
                
LINOX 
SMART 
                
LINOX                 
KENTROX 
STEROID 
                
KENTROX             0.07 0.34 1.10 0.27 
KAINOX      1.83 1.85 0.37 0.38 0.49 0.49 1.58 1.51 1.49 1.52 1.55 
ISOLINE                 
ENDOTAK 
RELIANCE 
     0.06 0.05 0.04 0.03 0.05 0.04 0.04 0.03 0.03 0.02 0.02 
ENDOTAK 
ENDURANCE 
      0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 
ENDOTAK 
DSP 
     0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 
ENDOTAK  0.01 0.00 0.01 0.01 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.02 0.02 0.02 0.02 






            1.58 1.65 1.78 1.89 
RIATA  0.46 1.42 1.65 1.70 1.84 1.85 1.86 1.88 1.93 1.87 1.94 2.05 2.07 2.05 2.02 



































































































































TVL-ADX 1.79 1.86 1.80 1.72 1.56 1.56 1.54 1.73 1.73 1.69 1.62 1.59 1.51 1.50 1.47 1.51 




1.83 1.86 1.78 1.67 1.44 1.43 1.39 1.62 1.59 1.55 1.41 1.36 1.24 1.13 0.95 0.79 
SPRINT 
QUATTRO 
1.82 1.86 1.79 1.68 1.42 1.42 1.38 1.60 1.57 1.53 1.44 1.39 1.24 1.14 1.04 0.91 
SPRINT 1.76 1.86 1.78 1.67 1.41 1.40 1.36 1.56 1.51 1.49 1.39 1.32 1.08 1.02 0.95 0.86 
SPL 1.78 1.86 1.79 1.71 1.51 1.50 1.47 1.59 1.55 1.54 1.49 1.47 1.31 1.32 1.30 1.30 
RIATA ST 
OPTIM 
        0.45 1.08 1.15 1.21 1.13 1.15 1.11 1.14 
LINOX 
SMART 
                
LINOX    0.07 0.07 0.09 0.08 0.13 0.24 0.17 0.15 0.11 0.09 0.08 0.07 0.07 
KENTROX 
STEROID 
  0.14 0.17 0.16 0.19 0.24 0.27 0.28 0.26 0.21 0.18 0.13 0.12 0.11 0.14 
KENTROX 1.74 0.19 0.27 0.28 0.28 0.28 0.28 0.36 0.39 0.42 0.35 0.35 0.51 0.37 0.21 0.23 
KAINOX 1.76 0.19 0.17 0.18 0.27 0.27 0.36 0.50 0.58 0.46 0.37 0.32 0.45 0.37 0.25 0.23 
ISOLINE               0.08 0.18 
ENDOTAK 
RELIANCE 
0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.02 0.02 0.02 
ENDOTAK 
ENDURANCE 
0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 
ENDOTAK 
DSP 
0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 
ENDOTAK 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.01 0.02 0.02 0.02 0.02 






1.83 1.86 1.79 1.70 1.54 1.54 1.52          
RIATA 1.88 1.86 1.83 1.82 1.77 1.76 1.75 2.07 2.10 2.02 1.92 1.89 1.82 1.83 1.81 1.86 










































































TVL-ADX 1.53 1.78 1.84 2.14 2.25 2.49 2.53 2.66 




0.67 0.36 0.33 0.28 0.26 0.23 0.21 0.20 
SPRINT 
QUATTRO 
0.82 0.74 0.69 0.66 0.64 0.59 0.56 0.51 
SPRINT 0.76 0.74 0.69 0.68 0.68 0.69 0.65 0.62 
SPL 1.32 1.54 1.58 1.80 1.86 2.07 2.05 2.19 
RIATA ST 
OPTIM 
1.18 1.42 1.48 1.70 1.78 1.96 2.04 2.16 
LINOX 
SMART 
     0.06 0.07 0.08 
LINOX 0.07 0.07 0.07 0.09 0.13 0.15 0.16 0.17 
KENTROX 
STEROID 
0.14 0.17 0.17 0.27 0.24 0.27 0.26 0.26 
KENTROX 0.19 0.34 0.34 0.49 0.49 0.49 0.53 0.52 
KAINOX 0.24 0.28 0.29 0.42 0.41 0.53 0.53 0.52 
ISOLINE 0.19 0.23 0.25 0.38 0.36 0.36 0.37 0.38 
ENDOTAK 
RELIANCE 
0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 
ENDOTAK 
ENDURANCE 
0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
ENDOTAK 
DSP 
0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 
ENDOTAK 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 






        
RIATA 1.88 2.22 2.30 2.64 2.78 3.07 3.11 3.26 








Figure G.2: Cumulative Quarter BCPNN025 Heat Map - Discrete Leads. 
The Sprint Fidelis was recalled October 25,2007; the Riata/Riata ST November 28, 2011.  ICD 


































































































































TVL-ADX -0.55 -0.09 0.46 0.47 0.51 0.48 0.38 0.37 0.36 0.41 0.48 0.60 0.66 0.68 0.66 0.64 




-1.60 -1.64 0.40 0.41 0.45 0.48 0.47 0.52 0.56 0.61 0.69 0.80 0.86 0.92 0.93 0.91 
SPRINT 
QUATTRO 
-0.97 -1.10 -0.22 0.01 0.18 0.16 0.18 0.29 0.31 0.41 0.53 0.64 0.74 0.77 0.79 0.79 
SPRINT 0.35 0.52 0.09 0.14 0.09 0.10 -0.01 0.05 0.02 0.11 0.24 0.32 0.40 0.44 0.43 0.40 
SPL -1.60 -1.02 -1.02 -0.66 -0.32 -0.34 -0.30 -0.30 -0.30 -0.26 -0.20 -0.11 -0.06 -0.04 -0.07 -0.09 
RIATA ST 
OPTIM 
                
LINOX 
SMART 
                
LINOX                 
KENTROX 
STEROID 
                
KENTROX             -3.30 -2.30 -2.32 -2.34 
KAINOX      -2.10 -2.18 -2.31 -2.35 -2.33 -1.74 -1.66 -1.62 -1.61 -1.63 -1.65 
ISOLINE                 
ENDOTAK 
RELIANCE 
     -3.75 -4.29 -4.91 -5.34 -4.46 -4.56 -5.00 -5.40 -5.37 -5.74 -6.00 
ENDOTAK 
ENDURANCE 
      -6.66 -6.80 -7.07 -7.09 -7.27 -7.24 -7.38 -7.46 -7.48 -7.51 
ENDOTAK 
DSP 
     -7.42 -7.62 -7.82 -7.99 -8.10 -6.90 -6.91 -6.98 -7.02 -7.06 -7.09 
ENDOTAK  -4.83 -5.59 -5.99 -6.22 -6.56 -6.93 -5.87 -6.04 -6.24 -5.62 -5.65 -5.69 -5.76 -5.80 -5.83 






            -0.67 0.11 0.55 0.76 
RIATA  -2.72 -0.92 0.14 0.36 0.53 0.58 0.65 0.65 0.71 0.78 0.88 0.95 0.96 0.96 0.94 


































































































































TVL-ADX 0.50 0.46 0.42 0.42 0.40 0.39 0.39 0.66 0.67 0.62 0.54 0.50 0.45 0.44 0.42 0.45 




0.75 0.62 0.52 0.49 0.37 0.37 0.33 0.59 0.57 0.51 0.36 0.33 0.24 0.10 -0.14 -0.40 
SPRINT 
QUATTRO 
0.68 0.56 0.46 0.40 0.26 0.26 0.24 0.50 0.49 0.42 0.32 0.28 0.21 0.08 -0.06 -0.23 
SPRINT 0.22 0.17 0.10 0.12 0.06 0.06 0.04 0.31 0.29 0.23 0.11 0.05 -0.06 -0.15 -0.27 -0.39 
SPL -0.21 -0.08 -0.10 -0.10 -0.17 -0.17 -0.18 0.07 0.08 0.03 -0.05 -0.01 0.07 0.10 0.07 0.09 
RIATA ST 
OPTIM 
        -2.24 -0.51 -0.04 0.02 0.06 0.09 0.05 0.09 
LINOX 
SMART 
                
LINOX    -3.66 -3.67 -3.46 -3.59 -2.95 -2.15 -2.61 -2.87 -3.25 -3.55 -3.72 -3.85 -3.86 
KENTROX 
STEROID 
  -2.63 -2.43 -2.63 -2.36 -2.09 -1.88 -1.89 -2.04 -2.35 -2.58 -2.71 -2.85 -3.01 -2.72 
KENTROX -1.87 -2.28 -1.88 -1.89 -1.95 -1.95 -1.96 -1.72 -1.71 -1.58 -1.73 -1.76 -1.88 -2.06 -2.24 -2.21 
KAINOX -1.74 -2.28 -2.43 -2.44 -2.08 -2.09 -1.79 -1.56 -1.39 -1.44 -1.64 -1.79 -1.90 -1.99 -2.12 -2.17 
ISOLINE               -3.27 -2.40 
ENDOTAK 
RELIANCE 
-6.40 -6.71 -7.01 -6.94 -6.76 -6.59 -6.61 -6.35 -6.35 -5.96 -6.06 -6.11 -6.07 -6.08 -6.14 -6.01 
ENDOTAK 
ENDURANCE 
-7.65 -7.74 -7.81 -7.83 -7.91 -7.91 -7.92 -7.66 -7.64 -7.70 -7.80 -7.84 -7.91 -7.93 -7.97 -7.93 
ENDOTAK 
DSP 
-7.23 -7.30 -7.35 -7.36 -7.43 -7.43 -7.44 -7.17 -7.15 -7.21 -7.30 -7.34 -7.40 -7.40 -7.44 -7.43 
ENDOTAK -5.97 -6.05 -6.11 -6.12 -6.19 -6.19 -6.20 -5.93 -5.92 -5.97 -6.06 -6.09 -6.15 -6.15 -6.17 -6.14 






0.75 0.71 0.62 0.62 0.56 0.56 0.55          
RIATA 0.87 0.85 0.83 0.83 0.77 0.77 0.76 1.03 1.05 0.99 0.91 0.89 0.83 0.84 0.82 0.86 










































































TVL-ADX 0.48 0.72 0.77 0.97 1.05 1.19 1.22 1.29 




-0.63 -1.51 -1.61 -1.84 -1.97 -2.15 -2.26 -2.36 
SPRINT 
QUATTRO 
-0.39 -0.51 -0.60 -0.67 -0.71 -0.83 -0.91 -1.02 
SPRINT -0.56 -0.54 -0.63 -0.67 -0.66 -0.65 -0.72 -0.78 
SPL 0.12 0.39 0.43 0.62 0.68 0.83 0.81 0.91 
RIATA ST 
OPTIM 
0.15 0.42 0.48 0.69 0.76 0.90 0.96 1.04 
LINOX 
SMART 
     -3.61 -3.60 -3.37 
LINOX -3.96 -3.84 -3.82 -3.41 -2.94 -2.73 -2.68 -2.60 
KENTROX 
STEROID 
-2.78 -2.62 -2.62 -2.06 -2.13 -2.04 -2.06 -2.06 
KENTROX -2.34 -1.74 -1.74 -1.60 -1.57 -1.51 -1.36 -1.36 
KAINOX -2.16 -1.98 -1.94 -1.83 -1.81 -1.38 -1.36 -1.36 
ISOLINE -2.32 -2.20 -2.12 -1.78 -1.79 -1.76 -1.72 -1.65 
ENDOTAK 
RELIANCE 
-6.05 -5.92 -6.21 -6.49 -6.67 -6.54 -6.78 -6.62 
ENDOTAK 
ENDURANCE 
-7.94 -7.77 -7.84 -7.92 -8.05 -8.10 -8.25 -8.32 
ENDOTAK 
DSP 
-7.43 -7.23 -7.27 -7.21 -7.28 -7.26 -7.38 -7.36 
ENDOTAK -6.13 -5.91 -5.90 -5.81 -5.80 -5.74 -5.78 -5.74 






        
RIATA 0.88 1.12 1.17 1.37 1.44 1.59 1.61 1.68 









Figure G.3: Cumulative Quarter PRR025 Heat Map - Discrete Leads. 
The Sprint Fidelis was recalled October 25,2007; the Riata/Riata ST November 28, 2011.  ICD 


































































































































TVL-ADX 1.42 1.38 0.99 0.91 0.88 0.78 0.65 0.61 0.58 0.62 0.66 0.75 0.79 0.80 0.78 0.76 




  1.10 0.92 0.82 0.78 0.71 0.72 0.72 0.76 0.81 0.89 0.93 0.97 0.97 0.95 
SPRINT 
QUATTRO 
1.39 0.69 0.81 0.70 0.74 0.63 0.59 0.63 0.61 0.67 0.73 0.81 0.87 0.87 0.86 0.85 
SPRINT 1.15 1.14 0.57 0.54 0.48 0.45 0.35 0.35 0.32 0.38 0.47 0.52 0.58 0.60 0.58 0.55 
SPL  1.33 0.49 0.57 0.65 0.58 0.54 0.54 0.51 0.54 0.59 0.66 0.70 0.72 0.70 0.68 
RIATA ST 
OPTIM 
                
LINOX 
SMART 
                
LINOX                 
KENTROX 
STEROID 
                
KENTROX                 
KAINOX           -0.05 0.03 0.07 0.08 0.06 0.04 
ISOLINE                 
ENDOTAK 
RELIANCE 
         -3.27 -3.36 -3.72 -4.06 -4.04 -4.34 -4.55 
ENDOTAK 
ENDURANCE 
                
ENDOTAK 
DSP 
                
ENDOTAK           -4.22 -4.25 -4.27 -4.32 -4.33 -4.34 






            0.86 0.76 0.85 0.88 
RIATA   1.01 0.95 0.81 0.80 0.79 0.83 0.81 0.86 0.89 0.98 1.02 1.01 0.99 0.96 


































































































































TVL-ADX 0.63 0.60 0.56 0.56 0.52 0.52 0.52 0.72 0.73 0.69 0.63 0.59 0.55 0.54 0.51 0.54 




0.78 0.65 0.54 0.51 0.40 0.40 0.37 0.59 0.58 0.52 0.39 0.35 0.28 0.16 -0.04 -0.25 
SPRINT 
QUATTRO 
0.73 0.62 0.52 0.46 0.34 0.34 0.32 0.53 0.51 0.46 0.38 0.34 0.28 0.17 0.06 -0.08 
SPRINT 0.40 0.36 0.30 0.31 0.26 0.26 0.25 0.45 0.42 0.37 0.28 0.23 0.14 0.06 -0.04 -0.15 
SPL 0.58 0.59 0.56 0.55 0.51 0.50 0.50 0.69 0.70 0.66 0.60 0.59 0.58 0.59 0.57 0.54 
RIATA ST 
OPTIM 
         -0.02 0.13 0.17 0.17 0.19 0.14 0.17 
LINOX 
SMART 
                
LINOX      -2.39 -2.50 -2.01 -1.43 -1.79 -1.99 -2.28 -2.49 -2.63 -2.72 -2.73 
KENTROX 
STEROID 
  -1.55 -1.45 -1.64 -1.43 -1.25 -1.10 -1.14 -1.28 -1.54 -1.72 -1.82 -1.93 -2.05 -1.84 
KENTROX -0.42 -1.12 -0.93 -0.93 -0.98 -0.98 -0.99 -0.80 -0.79 -0.72 -0.86 -0.88 -1.00 -1.18 -1.36 -1.33 
KAINOX -0.05 -1.12 -1.31 -1.31 -1.01 -1.01 -0.78 -0.59 -0.51 -0.64 -0.83 -0.97 -1.07 -1.16 -1.27 -1.33 
ISOLINE               -2.21 -1.51 
ENDOTAK 
RELIANCE 
-4.84 -5.06 -5.27 -5.21 -5.05 -4.92 -4.93 -4.84 -4.84 -4.53 -4.55 -4.56 -4.50 -4.49 -4.51 -4.40 
ENDOTAK 
ENDURANCE 
                
ENDOTAK 
DSP 
                
ENDOTAK -4.43 -4.47 -4.50 -4.50 -4.54 -4.54 -4.55 -4.37 -4.36 -4.39 -4.45 -4.47 -4.51 -4.50 -4.52 -4.49 






0.78 0.72 0.64 0.64 0.61 0.61 0.61          
RIATA 0.91 0.91 0.88 0.87 0.79 0.79 0.77 1.16 1.17 1.11 1.03 1.02 0.96 0.96 0.94 0.97 










































































TVL-ADX 0.55 0.72 0.76 0.90 0.95 1.05 1.07 1.12 




-0.45 -1.21 -1.30 -1.51 -1.60 -1.77 -1.84 -1.93 
SPRINT 
QUATTRO 
-0.21 -0.31 -0.38 -0.44 -0.47 -0.57 -0.62 -0.71 
SPRINT -0.29 -0.29 -0.37 -0.41 -0.40 -0.40 -0.45 -0.50 
SPL 0.55 0.73 0.76 0.90 0.91 1.02 0.99 1.05 
RIATA ST 
OPTIM 
0.21 0.40 0.44 0.59 0.63 0.74 0.77 0.83 
LINOX 
SMART 
      -2.58 -2.37 
LINOX -2.80 -2.71 -2.69 -2.40 -2.07 -1.92 -1.88 -1.83 
KENTROX 
STEROID 
-1.88 -1.78 -1.78 -1.37 -1.43 -1.37 -1.38 -1.38 
KENTROX -1.46 -1.00 -1.01 -0.91 -0.89 -0.86 -0.75 -0.76 
KAINOX -1.32 -1.19 -1.16 -1.10 -1.08 -0.76 -0.75 -0.76 
ISOLINE -1.47 -1.41 -1.36 -1.13 -1.14 -1.13 -1.10 -1.06 
ENDOTAK 
RELIANCE 
-4.40 -4.28 -4.50 -4.72 -4.87 -4.78 -4.95 -4.84 
ENDOTAK 
ENDURANCE 
        
ENDOTAK 
DSP 
        
ENDOTAK -4.48 -4.32 -4.31 -4.25 -4.24 -4.20 -4.23 -4.20 






        
RIATA 0.98 1.18 1.22 1.38 1.44 1.55 1.57 1.63 








Figure G.4: Individual Quarter EB05 Heat Map - Combined Lead Groups. 
The Sprint Fidelis was recalled October 25,2007; the Riata/Riata ST November 28, 2011.  
 
































































































































VIGILA Group                 




1.35  1.13 0.95 1.11 0.98 0.98 1.25 1.20 1.80 2.08 9.57 2.16 1.88 1.55 1.32 
SPRINT 1.20 0.90 0.35 0.80 0.38 0.66 0.29 0.72 0.61 1.51 1.28 0.96 1.51 1.42 0.43 0.42 
SPL 0.73 0.44 0.30 0.58 0.66 0.27 0.35  0.51        
LINOX Group                 
KENTROX 
Group 
            1.10 1.24   
KAINOX      0.40     0.38      
ISOLINE                 
ENDOTAK 
Group 
 0.08    0.06 0.02 0.03  0.08 0.05   0.08   
DURATA 
Group 






            1.79 1.59 1.42 1.44 




































































































































VIGILA Group                 




0.93 0.45 0.62 0.66 0.65 0.33 0.17 0.33 0.35 0.18 0.18 0.33 0.31 0.17 0.06 0.18 
SPRINT  0.41 0.28 0.89 0.44  0.22  0.35 0.31 0.18  0.14  0.09 0.34 
SPL  0.60 0.27         0.49 0.70 0.33  0.27 
LINOX Group    0.11 0.08 0.08 0.06 0.23 0.48  0.06    0.03 0.05 
KENTROX 
Group 
0.32  0.30 0.11  0.17 0.21  0.29 0.16      0.30 
KAINOX     0.31  0.28  0.45 0.21       
ISOLINE               0.24 0.38 
ENDOTAK 
Group 
   0.00 0.01 0.06    0.15   0.07   0.06 
DURATA 
Group 




1.15 1.19 1.11 1.35 1.15 1.00 1.06          
































































































































VIGILA Group             0.42    




0.16 0.14 0.06 0.09 0.05 0.03 0.06 0.05 0.02 0.08 0.04 0.03 0.14 0.05 0.01 0.05 
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Figure G.5: Individual Quarter BCPNN025 Heat Map – Combined Lead Groups. 
The Sprint Fidelis was recalled October 25,2007; the Riata/Riata ST November 28, 2011. 
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Figure G.6: Individual Quarter PRR025 Heat Map – Combined Lead Groups. 
The Sprint Fidelis was recalled October 25,2007; the Riata/Riata ST November 28, 2011. 
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Figure G.7: Cumulative Quarter EB05 Heat Map - Combined Lead Groups. 
The Sprint Fidelis was recalled October 25,2007; the Riata/Riata ST November 28, 2011.  
The Vigila lead group had no Class I recall predictions and is not included in this Figure. 
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Figure G.8: Cumulative Quarter BCPNN025 Heat Map – Combined Lead Groups. 
The Sprint Fidelis was recalled October 25,2007; the Riata/Riata ST November 28, 2011.  
The Vigila lead group had no Class I recall predictions and is not included in this Figure. 
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Figure G.9: Cumulative Quarter PRR025 Heat Map – Combined Lead Groups. 
The Sprint Fidelis was recalled October 25,2007; the Riata/Riata ST November 28, 2011.  
The Vigila lead group had no Class I recall predictions and is not included in this Figure. 
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Figure G.10: Individual Quarter BCPNN025 Heat Map - Discrete Leads, Held-Out Test Data. 
The Sprint Fidelis was recalled October 25,2007; the Riata/Riata ST November 28, 2011.  ICD 
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-0.95 -0.83 -0.34 -1.37 0.14 0.40 0.29 0.68 0.78 0.40 0.95 -1.13 -0.85 0.50 0.63 -0.37 
LINOX 
SMART 
      -3.29 -3.51  -2.89 -2.21  -3.35 -2.45 -3.43  
LINOX   -4.19 -1.67 -2.00 -2.59 -4.67 -2.60 -3.73 -2.30 -1.28 -1.25 -2.55 -2.22 -4.35 -3.02 
KENTROX 
STEROID 
   -1.37     -2.69      -2.85  
KENTROX  -1.41     -2.80          
KAINOX                 
ISOLINE   -3.15 -1.59   -2.84  -2.62 -2.38 -2.59    -2.64  
ENDOTAK 
RELIANCE 
       -6.48  -5.19 -6.49   -6.35   
ENDOTAK                 






                
RIATA 0.51 1.87 1.08 2.09 1.41 2.11 1.40 1.75         









Figure G.11: Individual Quarter PRR025 Heat Map - Discrete Leads, Held-Out Test Data. 
The Sprint Fidelis was recalled October 25,2007; the Riata/Riata ST November 28, 2011.  ICD 






































































































































VIGILA 1                 
TVL-ADX   0.25  0.32 0.45   0.22        








  0.27 0.20 0.32 0.43 0.35 0.62 0.25 0.84 1.24  0.44 1.01 0.82 0.48 
SPRINT 
QUATTRO 
       0.62   0.94   0.19 0.76  
SPRINT    0.18             
SPL                 
RIATA ST 
OPTIM 
                
LINOX 
SMART 
                
LINOX                 
KENTROX 
STEROID 
                
KENTROX                 
KAINOX                 
ISOLINE                 
ENDOTAK 
RELIANCE 
                
ENDOTAK                 






             0.52 0.74 0.41 
RIATA    0.19 -0.15 0.20 0.21 0.78 0.28 0.79   0.86  0.71 0.35 






































































































































VIGILA 1                 
TVL-ADX  0.47  0.49             








-1.48 -0.56  -0.61         -1.83  -2.46 -1.48 
SPRINT 
QUATTRO 
 -0.42 0.61              
SPRINT               -1.18  
SPL            0.27     
RIATA ST 
OPTIM 
        -0.51 -0.19 0.10 -0.29 -0.17 -0.17 0.66  
LINOX 
SMART 
                
LINOX        -1.40         
KENTROX 
STEROID 
                
KENTROX                 
KAINOX                 
ISOLINE                 
ENDOTAK 
RELIANCE 
                
ENDOTAK                 






0.19 -0.08 0.18 0.23 -0.73 -0.01          0.19 
RIATA 0.74 0.60 0.53 0.53   0.45 0.75 0.34 0.25 0.53 0.17 0.62 0.53 1.09 0.74 






































































































































VIGILA 1                 
TVL-ADX                 








-2.44 -3.67 -3.40 -3.37 -3.00 -4.15  -3.67   -3.57      
SPRINT 
QUATTRO 
-1.48 -1.89  -1.80             
SPRINT                 
SPL         1.73        
RIATA ST 
OPTIM 
0.11 0.83 1.15  1.07 1.38 0.85 1.46 1.52 2.31 1.32  0.45 1.35 1.06 0.21 
LINOX 
SMART 
                
LINOX    -0.90 -1.27      -0.55 -0.49  -1.50   
KENTROX 
STEROID 
                
KENTROX                 
KAINOX                 
ISOLINE                 
ENDOTAK 
RELIANCE 
                
ENDOTAK                 






                
RIATA 0.85 2.13 1.31 2.27 1.54 2.26 1.60 1.90         
RIATA ST 0.18 1.62 0.97 1.92 1.10 1.75 1.09 1.47         
 
